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 Large extremity injuries that involve damage to both muscle and bone pose a 
significant challenge in the clinic. Even with gold standard treatment, covering the 
exposed bony defect with a vascularized muscle flap, these injuries often do not recover 
to full function, affecting patients' quality of life and their contributions to society. 
Patients recovering from large extremity wounds suffer from pain and mobility issues 
years after limb salvage, and some patients ultimately opt for late stage amputation. Thus, 
there is a need for tissue engineering strategies to facilitate functional recovery of large 
composite defects of the limb. 
 Despite this pressing need, few tissue engineering strategies exist and have been 
tested in composite defects preclinically, limiting the number of translatable treatment 
options. The overall goal of this dissertation is to examine the regenerative potential of 
engineered matrix constructs and stem cells on composite bone & muscle defects.  To 
accomplish this goal, we first established a volumetric muscle loss model in the 
quadriceps and a composite muscle and bone injury model in the quadriceps and femur of 
the rat, designed to allow for functional measurements of tissue function. We found that a 
large VML in the quadriceps caused sufficient damage that an autograft within the defect 
space was not able to significantly recover muscle function. In the composite injury 
model, the addition of the muscle injury on top of the segmental bone defect compounded 
functional deficits and attenuated rhBMP-2 mediated bone regeneration. In the 
characterization of these models, we found that the VML in the quadriceps defect was 
complicated by multi-muscle and vessel/nerve damage and that early revascularization 
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was delayed in the composite injury group compared to the bone injury only group. To 
address these issues, we designed a separate VML model that is more suited for testing 
for muscle regeneration within a single, planar muscle, the biceps femoris, and further 
tested a vascular treatment, microvascular constructs with or without myoblasts, within 
this VML model. We found that though this treatment allowed for an early vascular 
response, the microvascular constructs treatment did not lead to a full recovery of the 
muscle. Third, we tested the effects of this vascular treatment in the composite injury 
model, either surrounding the bone or within the muscle defect. We found that the 
microvascular constructs surrounding the bone resulted in an early revascularization of 
the limb but led to decreased bone regeneration. Microvascular constructs with 
myoblasts, on the other hand, were implanted into the muscle and demonstrated a small 
increase in both bone and muscle regeneration despite a lack of increased vascularization. 
Taken together, these results suggest that while vascularization may play a role in 
regenerating tissues, the full recovery of complex limb injuries likely depend on other 
cellular and biochemical factors as well. 
 The studies presented here move the field of composite injuries forward by 
presenting new platforms on which to test therapeutics and measure functional outcomes. 
This work has led to some insights into the revascularization of large defects, and by 
analyzing the effects of vascular treatment on these complex injuries, we have 
demonstrated a potential therapeutic that may warrant further research. Overall, this work 
will aid in the development of tissue engineering treatments to facilitate the full 





CHAPTER 1  Specific Aims 
 Approximately 82% of all fractures in current US armed conflicts are open 
fractures, in which a soft tissue injury is sustained along with the bone fracture [1].  The 
clinical gold standard for treating such injuries with large defects in the bone and muscle  
involves using muscular flaps to cover the bone [2]. Despite this treatment approach, the 
percentage of complications remains high, and patients often do not regain normal 
function of their extremity [3, 4]. Though multi-tissue injuries remain a complex clinical 
problem, few animal models exist in which to test possible treatments, limiting 
assessments of tissue engineering strategies [5-9]. 
 Due to a substantial amount of tissue damage and debridement treatment in 
composite injuries, a large volume of cells and extracellular matrix (ECM) proteins that 
are necessary for tissue healing are removed from the body. The replacement of cells and 
structural proteins within the defect space may aid in regeneration by facilitating the re-
population of the defect space. In the replacement of large volumes of tissue, nutrient 
transfer necessitates a vascular supply to maintain the viability of delivered cells. The 
objective of this project is to examine the regenerative potential of engineered 
matrix constructs and stem cells on composite bone & muscle defects. We 
hypothesize that stem cells delivered on engineered matrix constructs into the muscle 
defect will aid in muscle regeneration and promote bone healing, ultimately resulting in 
superior functional limb recovery. This objective will be accomplished through the 
following specific aims: 
  
Aim 1: Characterize a volumetric muscle loss model and bone & muscle composite 
injury model in the rat. There is a need for animal models that recapitulate extremity 
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injuries seen in the clinic that involve damage to multiple muscle groups and tissues. Our 
hypothesis was that a large volumetric muscle loss in the quadriceps will result in 
decreased muscle function and that a composite bone and muscle injury will result in a 
compounded functional deficit in the bone, muscle, and limb function. To develop the 
volumetric muscle loss (VML) model in quadriceps, we used an 8-millimeter diameter 
biopsy punch to create a full-thickness defect in the antero-medial quadriceps muscle. For 
the composite injury model, we added this VML defect to our well-characterized 
critically sized segmental bone defect in the rat femur [10]. Functional outcome measures 
included measurements of muscle torque production, longitudinal bone volume 
measurements, bone mechanical testing, and gait measurements to quantify full limb 
recovery. Further characterization of the model examined defect revascularization, 
analyzed via Micro-Computed Tomography (Micro-CT) Angiography, as a possible 
source for the compounded functional deficits seen in the composite defect. 
  
Aim 2:  Develop a single-muscle VML model to evaluate therapeutic strategies.  
While the quadriceps VML recapitulated the complexity of  traumatic battlefield injuries, 
the model was very complex, involving injury of four separate muscles as well as blood 
vessels and nerves. This complexity may preclude any therapeutics that may regenerative 
potential for muscle. A single-muscle VML model with uniform alignment of muscle 
fibers would be a simpler test bed for evaluation of muscle regeneration strategies. In 
considering a therapeutic to test in this sizeable VML model, a vascular supply is very 
important in providing adequate perfusion to aid in graft survival and integration [11]. 
Microvascular constructs, consisting of microvessels isolated from adipose tissue 
suspended in a collagen gel, have been shown to form vascular networks in vitro that 
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inosculate with host vasculature in vivo. Furthermore, the addition of myoblasts, adult 
muscle stem cells, facilitated microvascular construct growth in vitro through a paracrine 
effect, suggesting that microvascular constructs with myoblasts may aid in both vascular 
response as well as provide muscle stem cells to the defect site. Our hypothesis was that 
a volumetric muscle loss in the biceps femoris muscle will result in very little muscle 
regeneration when untreated and enhanced muscle regeneration when treated with 
autograft, and that microvessel treatment with or without myoblasts of the biceps femoris 
defect will result in increased revascularization and muscle regeneration. Outcome 
measures included muscle force measurements, micro-CT angiography, histology, and 
biochemical assays to determine creatine kinase and citrate synthase activity as well as 
fat and actin/myosin content to identify the type of tissue formed in the defect space. 
  
Aim 3:  Assess the effects of  microvascular construct treatment on the early 
revascularization and long-term regeneration of bone and muscle tissues in the 
composite injury model.  Early vascularization response was diminished in limbs with 
the composite bone and muscle defects. Combined with literature evidence of poor 
vascularity impeding bone healing, the impaired bone regeneration may indeed be a 
result of poor early vascularization due to volumetric muscle loss. Thus, for this aim, we 
treated the composite defect with a microvascular construct to determine if a vascular 
treatment will aid in bone and/or muscle healing. Our hypothesis was that microvascular 
constructs implanted into composite injuries will aid in revascularization and 
regeneration of both tissues.  Early revascularization of the defect areas were analyzed 
through Micro-CT angiography. Functional outcome measures included measurements of 
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muscle torque production, longitudinal bone volume measurements, and bone mechanical 
testing to quantify full limb recovery. 
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CHAPTER 2  Literature Review1 
2.1 Traumatic Injuries to the Extremities 
2.1.1 Volumetric Muscle Loss 
 Up to 88% of combat wounds in previous US armed conflicts involve extremity 
injuries, and in Operation Iraqi Freedom/Operation Enduring Freedom, 53% (or 1881 
cases) of extremity wounds involved large, traumatic soft tissue injuries [1]. Tissue 
trauma in the civilian population often involve high impact accidents in which a energy is 
absorbed by soft tissue. Common causes of injury include vehicular impacts, industrial 
accidents, and high-energy sports [12]. Studies have shown that these injuries that 
involve extensive loss of muscle tissue, or volumetric muscle loss (VML), often result in 
a decrease in muscle performance that is difficult to recover [13]. 
 Soft tissue trauma often results in edema and inflammation, leading to 
compromised vascular supply, hypoxia, and soft tissue necrosis at the site [12]. Soft 
tissue injuries can result in a multitude of complications. Acutely, a common 
complication is compartment syndrome, in which edema or hematoma within the muscle 
leads to an increase in tissue pressure and, in severe cases, progressive ischemia [14]. In 
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cases of blunt skeletal trauma, ectopic calcification may occur in injured muscle, and 
muscular infections may develop [14]. One multi-center study found trauma to be the 
number one cause of necrotizing soft-tissue infections, which are associated with high 
mortality rates, chronic pain, and limitations in physical function [15, 16]. 
2.1.1.1 Gold Standard Treatments 
 There is currently no sufficient clinical treatment for VML and its resulting 
functional deficits. There is no universal consensus on how to manage orthopedic soft 
tissue injuries. Initial analysis of the soft tissue trauma involves assessing the viability of 
the extremity, often by screening for vascular injury [17]. Thorough irrigation of the 
injured areas and debridement of devitalized soft tissues aid in reducing chances of 
infection [18]. Early soft tissue coverage with the use of muscle or fasciocutaneous flaps 
is the gold standard treatment for large, traumatic extremity injuries [19]. These soft-
tissue flaps provide vascularization and offer protection of the underlying exposed tissue 
[17].  
 Despite careful actions by reconstructive surgeons to salvage the limb, long-term 
outcomes for patients that suffer from severe soft tissue trauma are grim. Patients that 
underwent fasciotomy to relieve compartment syndrome after soft tissue injury suffer 
from pain (50%) and report problems with physical activities (37%) seven to ten years 
after treatment [20, 21]. Patients that received radical debridement after a severe crush 
injury were more likely to suffer from motor disability [22]. In a study that compared 
limb function after excision of a muscle sarcoma, larger muscle excisions resulted in 
lower functional scores compared to partial muscle excisions [23]. These results indicate 
that patients with large VML injuries are likely to experience severe functional deficits 
that are unlikely to recover over time, despite current treatments. 
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2.1.2 Open Fractures/Composite Injuries 
 It is estimated that 185,000 persons undergo an amputation of an upper or lower 
limb every year, commonly caused by severe traumatic injury to the extremity [24].  In 
the civilian population, composite bone and muscle defects often result from motor 
vehicle and motorcycle accidents, falls, or crush injuries. The Lower Extremity 
Assessment Project (LEAP) study was conducted to study the variables in the civilian 
patient population that sustain traumatic injuries in the below-the-knee lower limb. 601 
patients were enrolled, and their treatment and recovery were followed for 44 months 
[25]. From this large study, fractures caused by high-energy trauma, often involving 
damage to the bone and muscle, were found to have a high prevalence of complications, 
most notably wound infection and nonunion of fractures. 
 In current US armed conflicts, extremity wounds are prevalent due to the increase 
in use of improvised explosive devices and individual vehicular body armor, which 
protects the body but leaves the extremities prone to injury. Extremity injuries  utilized 
the most resources out of any other  types of wounds for injury treatment [1]. Out of 1333 
soldiers in the study, 54% sustained an extremity injury, which averaged 17.9 inpatient 
days and utilized more than $42 million in resources [26]. Of the extremity wounds from 
the conflicts, one study found that 53% were penetrating soft-tissue wounds, and 26% 
were fractures. A large percentage (82%) of these fractures comprised of open fractures, 
in which a concomitant soft tissue injury was sustained alongside a bone injury [1]. 15% 
of all military amputations occur at least 12 weeks post-injury, mostly due to 
complications in the treatment of open fractures that included soft tissue injury requiring 
flap coverage [27, 28]. 
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2.1.2.1 Gold Standard Treatments 
 Orthopedic surgeons often have a hard decision between limb salvage and 
amputation when a patient with a traumatic limb injury is admitted. Many factors play a 
big role in making such a decision, such as vascular status, contamination of the injury, 
and long-bone instability. Though limb salvage is often preferred by patients and could 
result in full recovery of function in the limb, multiple operations are usually required. 
One study indicated recovery time for limb salvage to be about 13 months compared to 
only 6 months for patients that opted for amputation [29]. From the LEAP study, patients 
that underwent reconstruction to salvage a limb had higher chances of re-hospitalization, 
osteomyelitis, and more surgeries than patients that elected to amputate the limb [30]. A 
recent study comparing outcomes of amputation versus limb salvage in military lower-
extremity trauma found that patients with an amputation had better functional and 
psychological scores compared to those that underwent limb salvage [31]. Additionally, it 
was found that patients in the LEAP study that underwent late amputation (at least 3 
months post-injury) exhibited a higher level of disability compared to patients that 
underwent earlier amputations [32, 33]. Thus, a decision to salvage the limb may lead to 
severe consequences. 
 The gold clinical standard for treating open fractures consists of muscular flaps 
used to cover the bone and occupy empty space in order to reduce chances of infection 
[34]. Additionally, the soft tissue flaps provide a vascular supply, cells, and  growth 
factors that may aid in the repair of the bone defect or fracture [35]. Use of the muscle 
flap is known to be vital in treating lower extremity composite injuries and has been 
shown to increase bone union rate [36]; however, the percentage of complications remain 
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high [2], with one 15-year study reporting 58% nonunion and 11% amputation of open 
tibial fractures [3]. Another study of 115 wounded soldiers reported 40% infections 
complications, resulting in a significantly lower rate of soldiers returning to duty [37]. In 
addition, patients often do not regain normal function of their extremity [4]. Though 
upper extremity replantation resulted in better outcomes than an upper extremity 
amputation and prosthetic, one study showed that the replantation group only had a 50% 
rate of a good or excellent functional outcome [38]. Only 23% of the patients in the 
LEAP study reported to be pain-free 7 years after the initial treatment [39]. This 
persistence of pain after traumatic musculoskeletal injury is confirmed by another study 
that reviewed 4388 cases, in which patients reported pain up to 84 months post-injury 
[40]. Without full functional recovery and pain associated with the extremity for years 
after the treatments, some patients elect to amputate the limb even after the many 
surgeries required for limb salvage. This clearly necessitates strategies in the limb 
salvage realm that aids in functional recovery in addition to the survival of the limb. 
2.2 Animal Injury Models 
2.2.1 Volumetric Muscle Loss 
 Historically, skeletal muscle was thought to have a high regenerative potential due 
to early experiments in which a minced skeletal muscle replaced in its bed was able to 
regenerate within 4 weeks. These studies were often performed on mice and using 
smaller muscles such as the extensor digitorum longus [41]. This does not emulate the 
clinical situation in which patients with damage to large muscles often have difficulties 
regaining function of that muscle. Thus, recent studies in the field have focused on 
establishing larger VML injuries that are difficult to regenerate and functionally heal. 
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While various groups have examined muscle regeneration after a chemical, burn, or 
freezing injury as well as muscle loss from the abdominal wall or latissimus dorsi, the 
focus here will specifically be on models that create a VML in which a large portion of 
muscle is resected from an extremity.  
 Various VML injuries have recently been characterized in rodent models. 
Specifically, in the mouse, models have been developed in which sections of the tibialis 
anterior (TA) are removed (ranging from 4 milligrams to 30 milligrams of muscle). In 
this TA VML models, the untreated injured leg could only produce about half the force 
that an intact leg could produce [42, 43]. At 6 to 10 weeks post-injury, untreated injured 
muscle had a smaller cross-section and larger amounts of connective tissue compared to 
an uninjured muscle, which indicated possible atrophy of muscle and scarring instead of 
regeneration. Similarly, a VML model in the quadriceps of a mouse, in which a 4 x 3 
millimeter portion of the tensor fasciae latae muscle was removed, exhibited a reduction 
in muscle size and contained connective and adipose tissue instead of muscle fibers [44]. 
In the rat, removal of 20% (weight) of the TA resulted in a reduction in muscle force 
production in the injured leg to 2/3 of the contralateral control muscle at 4 months post-
injury [45]. In contrast, removal of 10% (weight) of the TA resulted in a reduction of 
muscle force in the injured leg to 3/4 of the contralateral control muscle at 4 weeks post-
injury, indicating that there is a correlation between the size of VML and functional 
outcome [46]. Removal of 300 milligrams of the gastrocnemius muscle in the rat resulted 
in reduction of the muscle force produced by about 20% [47]. In all rodent models of 
VML injury, untreated injuries resulted in excess connective tissue around muscle fibers 
as measured by Masson's Trichrome staining, indicating fibrosis and scar formation. Few 
VML models exist in larger animals. Canine and lepine models have been used to test 
various constructs, which will be discussed in section 2.3.1. 
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 The development of VML models is a relatively new field; most of the 
aforementioned models were published in the past 5 years. In general, the VML injury is 
characterized by a large loss of muscle function (30-50% of contralateral control) with a 
relatively smaller loss of muscle size (10-20%). Masson's trichrome is often used to 
determine the amount of fibrosis or scarring in the muscle. Inflammatory infiltrate is 
often present between muscle fibers, at least at the earlier time points (2 weeks, 4 weeks 
post-injury). In severe cases, adipose tissue is present between the muscle fibers. This 
intermuscular adipose tissue is usually associated with glucose dysregulation and lower 
levels of muscle strength, and the presence of this fat may be an indication of reduced 
physical activity after injury [48, 49]. 
 Important distinctions to note are the position and size of these VML injuries. 
Most of these models involve damage to 1 or 2 muscles, and the largest VML injury 
involved the resection of a 300 milligram piece of muscle. These injuries do not involve a 
full-thickness defect in which the underlying bone is revealed. Clinically, many 
complications arise when soft tissue trauma results in exposed bone that could then 
increases chances of infection. Additionally, while most of the models indicate a loss of 
size in the injured muscle, few showed a complete lack of regeneration in the center of 
the defect. 
2.2.2 Composite Bone & Muscle Injuries 
 Of the few composite injury preclinical models that have been established, the 
main focus appears to be the investigation of crosstalk between the healing responses of 
bone and muscle. These models reveal clues about the mechanisms by which the two 
tissues interact. 
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 Augat et al. incorporated soft tissue blunt-impact trauma with a closed tibial 
fracture model in rats in order to study the influence of muscle injury in revascularization 
during fracture healing [50] [51]. A large area of the periosteum covered in osteoid as 
early as day 3 in the tibial fracture only group while very little periosteal bone formation 
was seen in the composite injury group, indicating an early difference in bone healing. 
Laser Doppler flowmetry showed a similar initial delay in blood flow in the bone from 
the composite injury group. However, this difference in bone healing did not persist 
beyond day 3; by days 14 and 28, the two groups no longer showed differences in blood 
flow and bone strength. This study showed that a closed fracture with blunt muscle 
trauma may cause a slight delay in healing, but it may not be as severe as open fractures 
seen in the clinic. 
 Landry et al. included an anterior tibialis muscle resection with their tibial 
periosteum defect in the rat in order to study the inflammatory and cellular response in 
periosteally mediated bone healing [52] [53]. For the tibial defect, a jeweler’s burr was 
used to create a 0.5 millimeter deep periosteal defect in which the medullary cavity was 
not exposed. For the muscle defect, 10% of the anterior tibialis adjacent to the bone 
defect was resected. A composite group included both the tibial and muscle defects. The 
osteoblast concentration in the inner periosteal layer was increased in the composite 
injury group as compared to the single-tissue bone and muscle injury groups, but the 
callus formation did not show a significant difference between the composite injury and 
the bone injury groups. Early cellular response in the composite model was different as 
well, despite no permanent change in healing response. 
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 Though these studies showed little difference in bone healing between the 
composite injury and bone-only injury groups, the muscle injuries in these studies may 
not have been severe enough to influence bone healing. Utvag et al. tested a nailed tibial 
osteotomy rat model with three levels of soft tissue damage: a control group with intact 
muscle, a moderate muscle injury group with a muscle crush injury, and a severe muscle 
injury group with resection of muscles within the anterolateral compartment [54]. At 4 
weeks post-injury, the muscle resection group resulted in a significantly lower maximum 
three-point bending load and a significantly lower callus cross-sectional area as compared 
to the control group. Surprisingly, the muscle crush injury group did not differ 
significantly from the control group in these two parameters. It is important to point out 
that the fibular nerve was also resected, making the animal non-weight bearing. This may 
add an additional layer of complexity to the model, as this creates an additional nerve 
tissue defect, and the lack of weight bearing reduces the mechanical stresses that 
normally guide bone remodeling and homeostasis. 
 The close anatomical relationship of bones and skeletal muscle lends credence to 
the idea that muscle contributes to bone healing as a source of blood vessels, growth 
factors, and progenitor cells. Through careful observation of callus formation after tibial 
fractures in rats, rabbits, and sheep, Stein et al. noted that the callus forms between the 
fracture and the intact muscle bed adjacent to it [55]. This adjacent muscle acts almost as 
a “secondary periosteum” that can provide osteoprogenitors, especially when the 
periosteum itself, normally a good source of osteogenic cells, is damaged [56]. The 
importance of healthy muscle tissue in bone healing suggests that muscle regeneration in 
a composite model may aid in bone regeneration as well. 
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 In contrast to most composite injury models that were developed mainly to 
investigate tissue interactions and regeneration, a study by Pfeifer et al. investigated the 
systemic inflammatory response that may result from polytrauma. Mice were injected 
with bone fragments, given a soft tissue injury, or both insults were applied. After 6 
hours, systemic inflammatory responses were analyzed, and the composite injury resulted 
in significantly higher levels of interleukin-6 and interleukin-10 in the blood compared to 
any single insult [57]. While much research focuses on regenerating tissues, it is 
important to note that systemic inflammatory effects caused by large traumatic injuries 
may also play a role in the healing of these injuries. 
2.3 Current Tissue Engineering Strategies Tested in Pre-Clinical Injury Models 
2.3.1 Treatments for Volumetric Muscle Loss 
 As the VML field is relatively new, the strategies tested in VML models are 
currently limited. These strategies can be roughly divided into 2 groups: acellular or 
devitalized scaffolds (i.e. decellularized extracellular matrix, or ECM), and cell delivery 
with or without a carrier scaffold. The field of muscle regeneration, which extends past 
the VML models developed in the last few years, warrants a brief review as well. 
2.3.1.1 Decellularized or devitalized scaffolds 
 Various decellularized or devitalized tissues have been examined as a possible 
therapeutic for VML injuries. Specifically, research groups have tested decellularized 
skeletal muscle ECM  [47, 58, 59] and porcine small intestine submucosa (SIS-ECM) 
[44, 60, 61] with some success in functional restoration. 
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 The structure of the skeletal muscle extracellular matrix is linked closely to the 
function of muscle, specifically in force transmission across the muscle fibers [62]. Thus, 
it is not unreasonable to postulate that the decellularized ECM of skeletal muscle may aid 
in muscle regeneration and functional restoration. Ideally, decellularized skeletal  muscle 
ECM could be advantageous over other decellularized matrices by providing a muscle-
specific blueprint that could guide the movement of endogenous cells. However, the 
decellularization of skeletal muscle tissue involves a protocol of various chemical 
treatments in order to remove or devitalize cells, which also alters the specific structures 
of the skeletal muscle ECM [63, 64]. Although the implantation of decellularized skeletal 
muscle ECM resulted in a slight improvement in muscle force (approximately 10% closer 
to the contralateral uninjured controls), studies have shown that endogenous cells do not 
migrate into the center of the ECM, and few, if any, muscle fibers are generated within 
the implanted matrices [47, 59]. Instead, the implanted scaffolds are remodeled within the 
body into fibrotic scar tissue that no longer resembles the ordered structure of skeletal 
muscle ECM. These results show that even with a structural scaffold that can guide 
cellular growth and conduct forces across the defect space, fibrosis still dominates the 
healing process with little or no regeneration of muscle fibers. 
 SIS-ECM has been tested as a therapeutic scaffold in a mouse quadriceps VML 
model [44], two different canine models involving VML in the quadriceps [60, 61], and 
notably, humans in the clinic [65, 66]. While SIS-ECM is a xenogeneic biologic scaffold 
due to its porcine origins, it has been found to suppress human T-cell activation in vitro, 
and the cytokine response to this material induced a Th-2 immune response instead of the 
Th-1 cell-mediated rejection response [67, 68]. In addition to acting as a scaffold, SIS-
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ECM has been shown to be degraded by peripheral blood monocytes and drive the 
invading macrophages down the immunomodulatory and tissue remodeling pathway [69, 
70]. In the mouse, the SIS-ECM promotes cellular infiltration, though the scaffold itself 
still remains at 28 days [44]. Results from the canine model are mixed; while the SIS-
ECM resulted in an improvement in muscle function when implanted in the distal 
gastrocnemius musculotendinous junction, the scaffold caused a strong fibrotic response 
in the quadriceps [60, 61]. Humans who exhibited a minimum of 25% loss of muscle 
mass and muscle function were implanted with the SIS-ECM, and 6 months after surgery, 
3 out of 5 human subjects showed improved functional outcomes as measured by balance 
and hop tests [65, 66]. These mixed results warrant further investigations into the full 
potential of the SIS-ECM in the treatment of VML.  
2.3.1.2 Cell delivery 
 Various combinations of cell types and carriers have been tested for their 
therapeutic benefit in muscle regeneration in VML models. In VML models, a portion of 
adult stem cells are removed from the vicinity of the defect due to the amount of muscle 
tissue that is resected, which mimics the clinical situation. Cell therapies aim to replace 
these adult stem cells and their roles in muscle regeneration. 
 Cells in phosphate-buffered saline (PBS) injected locally to a small VML model 
has been shown to increase skeletal muscle regeneration in the region. Human peripheral 
blood-derived  CD133+ cells and human adipose-derived regenerative cells were injected 
into the rat tibialis anterior, in which a wedge-shaped defect (6 x 4 x 5 millimeters) was 
removed [71, 72]. Both cell types demonstrate functional muscle regeneration even as 
early as 1 week post-injury. The cell-treated group resulted in tissue that included 
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myofibers with diameters of around 125 µm. However, an injection of PBS in the defect 
(negative control) resulted in small diameter myofibers (75 µm) at 4 weeks, indicating 
that the negative control still exhibited muscle regeneration and myofiber formation. 
Further research into cell delivery without a biomaterial by this group included bone-
marrow-derived mesenchymal stem cells (MSCs) that were delivered in PBS via 
injection to the injury site. A strong magnet was then placed in proximity to the injury 
site for ten minutes. The magnetically localized cells resulted in a higher number of 
capillaries at the defect site as well as increased muscle strength and myofiber diameter 
compared to cells that were not localized by the magnet [46]. All these cell therapies 
demonstrate the great potential that cell delivery could have on muscle regeneration. 
 Porcine bladder acellular matrices (BAM) have been examined as a carrier for 
muscle progenitor cells (MPCs) for delivery into and for the therapy of VML injuries. 
This strategy was first tested in a latissimus dorsi (LD) model in which approximately 
half the muscle was removed. The MPCs were seeded onto the BAM scaffold and pre-
cultured in a perfusion bioreactor that stretched the construct cyclically for 7 days in vitro 
to form a tissue-engineered muscle repair construct (TE-MR). At 2 months post-injury, 
the group treated TE-MR exhibited higher muscle force than the empty defect or scaffold 
alone when the LD was removed and tested ex vivo [73].  Histological analyses showed 
signs of myofiber, vessel, and neurovascular formations in the TE-MR, though the 
majority of the TE-MR still comprised of connective tissue. Further studies into TE-MR 
and the pre-conditioning of the construct showed that a second seeding of MPCs onto the 
construct after in vitro pre-conditioning in differentiation media incrementally improved 
functional regeneration in the LD model [74]. The implantation of the TE-MR into the rat 
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TA VML model resulted in higher muscle function compared to untreated or scaffold 
only control at 4 weeks, with very little functional recovery across time (up to 12 weeks) 
[75]. Though this strategy delivered a different type of cell (MPCs) compared to previous 
strategies, the cells again demonstrated potential in aiding muscle regeneration in VML 
models. 
 Given the nature of adult muscle progenitors and their propensity to differentiate 
into muscle cells, various groups have attempted to deliver these cells on different 
materials. Human muscle progenitor cells were delivered on fibrin microthreads and 
shown to reduce scar formation and improve muscle function compared to an untreated 
TA VML defect in a murine model at 90 days post-injury [43]. Freshly isolated satellite 
cells (or MPCs) were embedded in a hyaluronic acid-photoinitiator complex, delivered 
directly to the site of injury, then photopolymerized into a hydrogel. The stem cell treated 
group resulted in an improvement in muscle function as compared to an untreated defect 
[42]. Rat myoblasts that were cultured to attach to engineered bone anchors were 
implanted into a rat TA VML and demonstrated functional recovery by 28 days after 
injury [76]. Signs of small myofibers in histology suggested that the injury is healing 
despite some fibrotic tissue in the defect site. 
 Further evidence that a cellular component may be needed in the healing of 
muscle defects was shown in two separate studies. When human MSCs were delivered 
into a VML model in the gastrocnemius muscle of the rat on a decellularized muscle 
ECM,  the resulting functional recovery at 42 days post-injury was higher in the ECM-
MSC group compared to the ECM only group [77]. This study found a marked effect of a 
cellular component on muscle regeneration that an acellular therapy did not provide. In 
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another study, muscle grafts that were either left vital (with live cells) or devitalized (with 
cells mostly removed as measured by nucleic acid content) were implanted into a rat TA 
model. The vital graft resulted in higher muscle function as compared to the devitalized 
graft and the empty untreated control [58]. These studies, as well as the studies involving 
the TE-MR compared to the BAM scaffold alone, emphasizes the need for a live 
biological component, in addition to a space-filling scaffold, for improved muscle 
functional regeneration. 
2.3.1.3 Therapies for other muscle injuries 
 While tissue engineering constructs have been tested in VML models in the recent 
years, the field of muscle regeneration extends far back and includes a wide array of 
strategies for repair of muscle injuries that do not involve volumetric muscle loss. 
Though these other muscle injuries may be smaller in size and different in healing 
response, the strategies tested for these muscle injuries could lead to insights into muscle 
regeneration that could be applied to VML. 
 Literature into tissue engineering strategies for skeletal muscle injuries again 
confirms the potential of cell therapy for tissue repair [78]. Studies have shown that 
muscle injury activates and/or recruits a host of different cell types in the body, including 
satellite cells [79], bone marrow derived myogenic progenitors [80], inflammatory cells 
such as neutrophils and macrophages [81-83], and fibro/adipogenic progenitors [84]. 
Other unorthodox cells can also cultured down the myogenic lineage, including neural 
stem cells, hematopoietic cells, mesenchymal stem cells, mesangioblasts, endothelial 
progenitor cells, and adipose-derived stem cells [85]. Thus, there seems to be no 
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limitation in which types of cells can contribute to muscle regeneration, though the 
relative regenerative potentials of these cell types may differ. 
 More recently, studies have focused on the importance of vascularization for 
survival of grafts in skeletal muscle. Pre-vascularized grafts constructed of a tri-culture of 
myoblasts, embryonic fibroblasts, and endothelial cells seeded in polymer scaffolds were 
shown to improve vascularization, perfusion, and survival of muscle tissue when 
implanted in vivo subcutaneously, intramuscularly, and as a graft for an abdominal wall 
defect [86]. A longer culturing period (3 weeks in vitro) that yielded more organized 
vessels and muscle fibers within the construct exhibited enhanced perfusion and 
transition of satellite cells to mature fibers compared to constructs with shorter culturing 
periods (1 day to 2 weeks in vitro) [87]. These studies highlight the importance of 
vascularization for the survival of cells within the construct, and the maturation of 
satellite cells within these vascularized constructs suggest that there may be an effect of 
the vascular elements on the myogenic differentiation of muscle progenitor cells. This 
speculation is further supported by a study in which a vascular endothelial growth factor 
(VEGF) coated collagen matrix was applied in a soft tissue trauma model and resulted in 
restoration of muscle force and an increase in muscle fiber count [88]. Other studies in 
which VEGF and insulin-like growth factor-1 (IGF-1) were delivered in an alginate 
hydrogel in addition to cultured myoblasts, resulting in increased muscle mass and 
contractile function after hind limb ischemia [89] and myotoxin damage to the TA of 
mice [90]. These studies present convincing evidence emphasizing the need for sufficient 
vasculature for muscular grafts and regeneration. 
2.3.1.4 Limitations 
 While various strategies have been tested in VML injuries, no single treatment 
has been able to allow for complete functional recovery (back to the strength of an 
uninjured or contralateral limb) or full recovery of the muscle with little or no fibrosis. 
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Many treatments allow for partial recovery of function; however, deposition of collagen 
and scar formation may also contribute to function without functional cells. Additionally, 
the exact nature and mechanisms behind many of these strategies are not well understood. 
A prime example of this is evident in SIS-ECM studies. While the potential of SIS-ECM 
is convincingly demonstrated, its use in larger animals and in humans results in highly 
variable functional outcomes. All treatments are subject to further investigation in order 
to more fully understand the mechanisms behind their regenerative potentials. 
2.3.2 Treatments for Composite Injury Models 
 Composite models have been used to test the advantageous effects of muscular 
flap treatment in pre-clinical models.  In a series of canine studies, Richards et al. 
examined blood flow characteristics in a model of devascularized tibial cortex covered on 
the anterior side with either a local muscle flap or vascularized skin [91, 92].  At 31 days 
post-injury, the rates of blood flow and osteotomy union were both significantly greater 
in the muscle flap coverage group as compared to the vascularized skin coverage group. 
Further study showed that the muscle flap group had increased intracortical blood flow, 
which correlated with greater cortical porosity, a measure of bone turnover. In a similar 
study in mice, Harry et al. investigated the effect of different soft tissue coverage for 
open tibial fractures [93]. An inert polymer insert was used for selective tissue exclusion 
either directly between the bone and the anterior skin/fascia or between the bone and the 
posterior muscle. At 4 weeks post-injury, the group with muscle coverage 
(fasciocutaneous separation) was histomorphometrically similar to the fracture control 
group and performed as well in a four-point bending test.  The group with 
fasciocutuaneous coverage (muscle exclusion) demonstrated an impaired healing 
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response, with a significantly lower load to failure, bone mineral content, bone mineral 
density, and bone volume compared to the fracture control and muscle coverage groups. 
All of these pre-clinical studies validate the gold standard treatment of muscular flap 
coverage for bone regeneration, though no specific mechanisms were elucidated. 
 Very few composite models have been used for studying additional tissue 
engineering strategies for treating composite defects. One study tested the use of a 
biological factor for the treatment of a composite tissue defect. Hamrick et al. treated 
mice given a composite bone and muscle defect with recombinant myostatin propeptide, 
which effectively inhibits active myostatin [94]. The composite defect consisted of a 
fibula osteotomy as well as laceration of the lateral compartment muscles. The mice were 
then treated with myostatin propeptide injections at 20mg/kg at days 0, 5, and 10 post-
injury. At 15 days, safranin-O stained histological sections showed an increase in fracture 
callus in the propeptide-treated group as compared to a saline-treated control group. 
Masson’s trichrome staining on the muscle injury site showed less fibrosis in the 
propeptide treated group. Micro-CT analyses also showed a significantly higher bridging 
rate and fracture callus bone volume in the treated group. These results indicate that the 
myostatin propeptide can be used in a composite defect to benefit both muscle and bone 
regeneration. 
2.4 Motivations for Research 
 Traumatic injuries to the extremities often result in composite wounds in which 
bone and muscle tissues are compromised. Composite wounds are more difficult to heal 
and result in more complications, such as infections and bone nonunion, than single 
tissue injuries. The main clinical response to composite wounds is to decide between limb 
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salvage or, if the injury involves a large amount of necrotic tissue or lack of vascular 
perfusion, amputation of the limb. Though amputation often reduces limb function, 
especially in the upper extremities, limb salvage has its disadvantages as well. Not only 
does limb salvage require multiple surgeries and subsequent painful recoveries, patients 
often experience more complications and do not regain full function, leading to a 
secondary, late amputation that results in a worse disability than an early amputation and 
prosthetic. Thus, neither limb salvage nor amputation consistently results in full 
functional recovery of the limb. 
 With tissue engineering strategies applied to large composite injuries of the limb 
for the purpose of restoring limb function, it may be possible to increase the rate of 
success for limb salvage as well as increase the chance of healing severe extremity 
injuries. Additionally, composite bone & muscle injury pre-clinical models allow us to 
study the interactions between the two tissues during healing, which may lead to valuable 
insights for the tissue engineering field. Thus, the main motivations behind this proposal 
are to test therapeutic options for treating severe musculoskeletal injuries as well as 
to gain insights to how the muscle and bone tissues interact during healing of a 
large, complex injury. 
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 Severe injuries to the extremities often result in muscle trauma and, in some 
cases, significant volumetric muscle loss (VML). These injuries continue to be 
challenging to treat, with few available clinical options, a high rate of complications, and 
often persistent loss of limb function. To facilitate the testing of regenerative strategies 
for skeletal muscle, we developed a novel quadriceps VML model in the rat, specifically 
addressing functional recovery of the limb. Our outcome measures included muscle 
contractility measurements to assess muscle function and gait analysis for evaluation of 
overall limb function. We also investigated treatment with muscle autografts, whole or 
minced, to promote regeneration of the defect area.  Our defect model resulted in a loss of 
muscle function, with injured legs generating less than 55% of muscle strength from the 
contralateral uninjured control legs, even at 4 weeks post-injury. The autograft treatments 
did not result in significant recovery of muscle function. Measures of static and dynamic 
gait were significantly decreased in the untreated, empty defect group, indicating a 
decrease in limb function. Histological sections of the affected muscles showed extensive 
fibrosis, suggesting that this scarring of the muscle may be in part the cause of the loss of 
muscle function in this VML model. Taken together, these data are consistent with 
clinical findings of reduced muscle function in large VML injuries. This new model with 
quantitative functional outcome measures offers a platform on which to evaluate 
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treatment strategies designed to regenerate muscle tissue volume and restore limb 
function. 
3.2 Introduction 
Extremity injuries comprise the majority of combat wounds in recent US 
conflicts, 53% of which are penetrating soft-tissue wounds involving extensive damage to 
the muscle, also known as volumetric muscle loss (VML) [1]. Sixty-four percent of all 
soldiers found unfit for duty are soldiers with extremity injuries, accounting for the 
majority of the $170 million in projected disability costs [26]. 12% of civilian patients 
that had lower extremity trauma experienced VML, and these subsequent treatments 
resulted in a mean cost of $65,735 [96, 97]. Despite the high prevalence and societal cost 
of VML injuries to the extremities, no tissue engineering treatments are currently 
available. 
Coverage of VML wounds with autogenic muscle flaps is known to be critical in 
reducing early complications to the healing of soft tissue defects and is the current 
clinical gold standard [98, 99]. Muscle flap type is a significant predictor of short-term 
complications [100, 101], and muscle coverage aids bone regeneration by increasing 
bone blood flow [91, 92]. Other treatment options include the use of sophisticated 
bracing that allows for physical therapy, but no tissue engineering strategies are available 
in the clinic thus far [13]. 
The current treatment options do not take into account structural restoration of 
muscle, and this is evident in the fact that large muscular defects often lead to persistent 
functional deficits. High-energy trauma to soft tissues were significantly correlated with 
poor physical Sickness Impact Profile (SIP) scores—a measure of self-reported physical 
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limitations [102]. Thirty percent of patients with extensive soft tissue injury reported 
problems with motility and chronic pain 7-10 years post-injury [20, 21]. An increasing 
number of VML patients requested late amputations due to functional deficits of the limb 
[103]. This persistence of functional deficits highlights the need for functional tissue 
engineering of VML injuries as well as animal models to quantitatively evaluate 
regenerative strategies. 
Various preclinical VML models have recently been developed to test tissue 
engineering strategies, as detailed in the literature review. The associated studies have 
used a variety of outcome measures; however, standardized and consistent techniques are 
not established. As we move forward in refining rat VML models, we seek to increase the 
relevance to clinical outcomes, in which functional biomechanical testing is critical. 
Further, many of these models utilize relatively small VML defects in a single muscle – 
an injury that may heal without an intervention. In order to further tissue engineering 
research in VML and to facilitate the translational aspect of these regenerative strategies, 
there is a need for preclinical models that mimic the complexity and severity of VML 
injuries observed in the clinic where there is a significant volume of muscle affected 
including injury to multiple muscles. 
 Accordingly, our objective was to develop a severe skeletal muscle defect 
model in the rat incorporating quantitative analysis of muscle regeneration and 
restoration of limb function.  We hypothesized that a full thickness defect through the 
quadriceps would result in a significant loss of muscle strength and limb function. We 
further used our model to quantitatively evaluate treatment with muscle autograft, a 
strategy that has previously been tested in mouse models and shown to improve muscle 
regeneration by 4 weeks post-injury [41]. Thus, we hypothesized that an autograft, 
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whether whole or morselized, will significantly increase muscle functional capacity and 
result in tissue regeneration. We present a very challenging muscle defect rat model that 
can be used by the scientific community for two important purposes: 1) to further 
understanding of VML with quantitative measures of the healing process, and 2) to 
evaluate the success of different muscle regeneration strategies. 
3.3 Materials/Methods 
Surgical Procedure 
All surgical procedures were conducted in accordance with guidelines set by the 
Georgia Tech IACUC (protocol #09039 & #12075). 13-week-old female Sprague-
Dawley rats (Charles River) were randomly assigned to three treatment groups: empty 
untreated defect (n=12), whole autograft (n=12), and morselized autograft (n=12). For all 
groups, the muscular injury was performed on the left leg while the right leg served as a 
non-surgical contralateral control. Muscle defects were created in the quadriceps femoris 
as previously described [104]. Briefly, the full-thickness muscular defect comprised of an 
8-mm diameter biopsy punch through the medial anterior portion of the quadriceps, 
affecting parts of all four muscles (Figure 1A, top). In the whole autograft group, the 
biopsied muscle (Figure 1B, bottom) was placed back into the defect. In the morselized 
autograft group, biopsied muscle graft was cut into cubes 2 mm in length. All animals 
were divided into 2 groups: 2-week (n=6 per group) and 4-week (n=6 per group). 
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Figure 1: Methods for Creating and Analysis of the Quadriceps VML Model. A. 
Representative images showing the muscle defect surgery (top) and excised 8-mm 
diameter muscle (bottom). B. Representative diagram of the top-down view of muscle 
strength measurements. C. Representative diagram of the side view of muscle strength 
measurements. D. Timeline of longitudinal in vivo (MRI, Catwalk) and ex vivo (muscle 




 Gait analysis was performed on all animals pre-surgery (baseline) and at 2 weeks 
post-injury. Only the 4-week recovery group animals were measured at 4 weeks (Figure 
1D). Using the CatWalk 7.1 system (Noldus Information Technology, The Netherlands), 
quantitative gait measurements were collected. The CatWalk system has previously been 
validated for assessment of functional limb recovery after sciatic nerve injury [105-107] 
and spinal cord contusion [108]. For each data collection, three uninterrupted runs per rat 
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were conducted when possible. Runs that traversed at least half the walkway length were 
analyzed. 
Magnetic Resonance Imaging (MRI) 
 Three additional animals received empty muscle defects and underwent MR 
imaging at days 2, 4, 7, and 14 post-injury (Figure 1D); no autograft-treated animals 
underwent MR imaging. MRI has been shown to be useful in characterizing hematoma or 
edema formation after muscle injuries [109-111]. Images were taken in a 7-tesla MRI 
system (Pharmascan 7T, Bruker Corp.) and processed in ParaVision 5.1 (BrukerBioSpin, 
Bruker Corp.). A radiofrequency coil (Doty CP Litzcage coil, 60-mm inner coil diameter) 
was used for transmitting and receiving signal.T1-weighted images (axial) were taken 
using a FLASH sequence (TR/TE: 379.5/6.0ms) with 1mm slice thickness. T2-weighted 
images (axial) were taken using a RARE sequence (TR/TE: 3435.3/52.2ms, rare factor: 6, 
flip angle: 30 degrees) with 1mm slice thickness. Thirty slices were taken of each leg. 
 Images were analyzed using ImageJ v1.45 (National Institutes of Health). The 
volume of interest was determined by using well-defined anatomical structures visible in 
the T1-weighted images (Figure 2A). VOIs were overlaid on corresponding T2-weighted 
images (Figure 2B). For uninjured quadriceps femoris muscles, the mean and standard 
deviation of T2-weighted voxel intensities were used to calculate a threshold value (mean 
+ 2*SD). T2-weighted images of injured muscle were then thresholded (Figure 2B), and 
voxels with intensities above the threshold indicated hematoma or edema. The volume 
(V) of hematoma or edema was determined using the trapezoidal interpolation: 
, where h is the distance between axial sections and A1 and A2 are 
areas with edema/hematoma of consecutive images. 
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Measurements of Peak Isometric Contraction Torque about the Knee 
 At respective recovery time points, 2-week and 4-week rats underwent peak 
isometric strength measurements, a terminal procedure, to assess the functional capacity 
of the quadriceps (Figure 1D). An in vivo system similar to those used extensively  to 
assess lower leg muscle function was custom fabricated for assessing torque production 
about the knee [112, 113] . Briefly, a nerve cuff was used to stimulate the femoral nerve 
as a force transducer was used to measure maximal isometric torque production about the 
knee. Rat movement was restrained (Figure 1B), and the rat ankle was attached to a force 
transducer (Figure 1C). The nerve was stimulated with progressively increasing voltages 
to determine the maximum torque. 
 To assess the fatigability of the quadriceps femoris muscles, the muscle group 
was subjected to the standard Burke fatigue protocol [114]. This entailed isometric 
muscle stimulation with a train consisting of 13 pulses at 25-ms intervals; the train was 
repeated every second for 2 minutes. The endurance index was calculated as the torque 
produced at the 1 minute into the protocol divided by the highest torque produced during 
the protocol. The highest torque was used because varying degrees of potentiation 
occurred among animals during the first few contractions. Calculation of the endurance 
index in this manner yielded more reliable values. 
Histology 
 Directly following the measurements of muscle functional capacity, rats were 
euthanized and underwent perfusion fixation with 10% neutral-buffered formalin (EMD 
Chemicals, Gibbstown, NJ). The mass of the excised quadriceps was recorded, and the 
muscle was additionally submersion-fixated in 10% neutral-buffered formalin for 48 
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hours. Paraffin-processed samples were cut into 5-μm sections using a Microm 
Microtome (Thermo Scientific, Germany). Hematoxylin and eosin (H&E) staining and  
Masson’s trichrome staining were performed on these sections. 
Statistical Analyses 
 All data are presented as mean + standard error of the mean. Peak isometric 
muscle torque and muscle mass were analyzed by a two-way ANOVA (3 treatment 
groups x 2 time points). Independent t-tests with Bonferroni correction were used to 
identify within-group differences of recovery time points. 
3.4 Results 
Characterization of early VML with Magnetic Resonance Imaging 
Magnetic resonance images were taken at days 2, 4, 7, and 14 post-injury to 
characterize the muscle injury at early time points. Within the first week of injury, the 
total muscle volume, quantified by axial T1-weighted images, showed no significant 
difference between the injured left leg and the contralateral control right leg (Figure 2C). 
Axial T2-weighted images, in which fluid exhibits increased signal intensity, clearly 
showed edema/hematoma in the left quadriceps at days 2 and 4 (Figure 2E/F/G/H). This 
fluid volume was quantified and comprised the majority of the muscle volume at day 2 
post-injury (Figure 2D). This steadily decreased from day 2 to day 14 (Figure 2D). 
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Figure 2: MRI Visualization of the Extent of Muscle Injury. A. Representative 
selection of region of interest using T1-weighted image. B. Representative superposition 
of ROI on thresholded T2-weighted image. Dark pixels indicate pixels with intensities 
above threshold. C. Total muscle volume, measured using axial T1-weighted MRI 
images. D. Percentage of the left leg muscle that was inflamed, as determined by edema 
in the quadriceps area visualized by T2-weighted images. E-H. Representative T2-
weighted images at days 2 (E), 4 (F), 7 (G), and 14 (H) days are shown, with inflamed 
areas indicated by white arrows. *p<0.05, n=3, ANOVA with Bonferroni correction. 
 
Measurements of Muscle Functional Capacity 
 A representative measurement of muscle isometric tetanic torque about the knee 
is shown in Figure 3A. In all treatment groups, the maximum tetanic torque about the 
knee from the injured leg was significantly less than the contralateral uninjured leg 
strength (Figure 3B). A two-way ANOVA on the ratio of injured muscle torque to that of 
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uninjured muscle showed no significant differences between treatment groups or time 
points; there was no significant recovery of muscle strength in any autograft-treated 
group from 2 to 4 weeks post-injury (Figure 3C). 
 
Figure 3: Quantitative Measures of Muscle Function. A. Representative graph of 
tetanic muscle torque measurement for empty defect (dotted), morselized autograft 
(dash), whole autograft (dash-dot-dash), and unoperated control (solid) groups. B. 
Maximum isometric tetanic torque of the quadriceps muscle in the injured left leg (I) and 
contralateral control right leg (C). C. Muscle torque expressed as a ratio of the injured leg 
to contralateral control (I/C). *p<0.05, n=6 per group per time point. 
 
 Muscle fatigue measurements showed no significant changes in fatigue 
characteristics between these treatment groups (Figure 4). Endurance indices for 2-week 
fatigue measurements were 0.37 + 0.08, 0.28 + 0.13, 0.34 + 0.08, and 0.26 + 0.11 for 
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empty, morselized autograft, whole autograft groups, and contralateral controls 
respectively while 4-week endurance indices were 0.32 + 0.08, 0.31 + 0.08, 0.38 + 0.04, 
and 0.29 + 0.08.  
 
Figure 4: Quantitative Measures of Muscle Fatigue. A. Representative raw fatigue 
measurements for empty defect (dotted), morselized autograft (dashes), whole autograft 
(dash-dot-dash), and unoperated control (solid) groups. B. Muscle fatigue measured at 4 
weeks post injury. C. Endurance index expressed as a ratio of torque produced at one 
minute into the fatigue protocol to maximum torque produced in protocol. 
 
Muscle Mass Measurements 
 Injured muscle from all treatment groups lost a significant amount of muscle 
mass; the injured muscle had 70-90% of the muscle mass of contralateral controls (Figure 
5A). Muscle mass data of injured muscles normalized to contralateral control muscles 
showed no significant change in muscle mass between the two time points in any 
treatment groups (Figure 5B). There was no significant difference in muscle mass 
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between the empty defect group and the treatment groups. Histological cross-sections of 
muscle tissue at 4 weeks post-injury qualitatively confirmed that injured muscles were 
similar in size and slightly smaller than a control muscle (Figure 5C). Muscle mass 
measurements were found to significantly correlate with muscle strength measurements 
(Figure 6) with a correlation coefficient of 0.52. 
 
Figure 5: Muscle Mass and Representative Cross-Sectional Images of Muscle. A. 
Post-mortem muscle mass of the quadriceps muscle from the injured left leg (I) and 
contralateral control right leg (C). B. Post-mortem muscle mass expressed as a ratio of 
the injured leg to contralateral control (I/C). C. Representative H&E stained transverse 
(cross-sections) images of muscles from all treatment groups and control. *p<0.05, n=6 





Figure 6: Correlations between Measurements. Measured parameters for each 
individual sample were plotted in order to determine significant correlations between 
parameters. Significant correlations were found between static and dynamic gait 
parameters at 2 weeks (A) and 4 weeks (B), injured leg maximal isometric torque with 2-
week print area (C) and duty cycle (D), injured leg maximal isometric torque with injured 
leg mass (E), and injured leg maximal isometric torque with 4-week duty cycle (F). 
Linear regressions are shown with coefficients of determination. p<0.05 indicates a 
significant non-zero slope, n=36. 
 
Measurements of Limb Functionality 
 Hind paw print area was measured to quantitatively determine limb function in 
each treatment group. The empty defect group showed a significant decrease in print area 
ratio (injured to uninjured) compared to baseline control while autograft-treated groups 
did not show a significant change (Figure 7A). The duty cycle—measurement of the time 
a paw is contact with the ground as compared to the stride duration—also decreased 
significantly at 2 and 4 weeks post-injury compared to baseline control (Figure 7B). The 
whole autograft treated group had a decreased duty cycle at 2 weeks post-injury, 
compared to the baseline measurements from the same group. Paw print area and duty 
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cycle ratios were found to significantly correlate at weeks 2 and 4, with correlation 
coefficients of 0.74 and 0.70 respectively (Figure 6). 2-week print area and duty cycle 
ratios and 4-week duty cycle ratios were also found to significantly correlate with the 
injured leg isometric maximal tetanic torque (Figure 6C, D, F). 
 
Figure 7: Quantitative Measures of Gait and Limb Recovery. A. Print area, a static 
gait parameter, at baseline (measured prior to surgery), 2 weeks, and 4 weeks post injury. 
Representative paw prints are shown on the right. B.  Duty cycle, a dynamic gait 
parameter that measures the time a paw is in contact with the ground as compared to 
stride duration. *p<0.05, n=12 at 2 weeks, n=6 at 4 weeks. 
 
Muscle histology 
 Transverse histological sections were taken from all groups and all time points 
(Figure 8). Sections stained with H&E showed regenerating muscle fibers with centrally-
located nuclei at both time points in all groups. However, sections stained with Masson’s 
trichrome showed extensive fibrotic tissue formation (indicated by blue staining of 
collagen) near or surrounding the regenerating muscle fibers. At 4 weeks, the morselized 
autograft treated group had dispersed fibrotic tissues in small spaces between muscle 
cells (stained in blue), compared to the large sections of fibrosis seen in the untreated and 




Figure 8: Fibrosis and regenerating fibers, visualized in histology. Fibrosis can be 
seen in Masson’s Trichrome stained sections (collagen fibers stain blue). Regenerating 
muscle fibers, in which nuclei are centrally located, can be seen in H&E stained sections 
(indicated by black arrows). Images were taken at 10x magnification, scale bars: 100μm. 
3.5 Discussion 
This is, to our knowledge, the first rat model of above-the-knee volumetric 
skeletal muscle loss. Our model was quantitatively characterized by early analysis of 
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edema and hematoma in the injured muscle using MRI, peak isometric torque produced 
by the quadriceps femoris, and functional limb analysis as determined by gait. Given the 
thorough analyses of functional biomechanical outcomes, our model presents a useful 
platform in which tissue engineering and regenerative medicine strategies can be tested 
and quantitatively analyzed for efficacy in muscle regeneration. 
Our results showed a large decrease in muscle functional capacity, as 
hypothesized; however, this decrease in muscle function is not wholly explained by the 
relatively smaller decrease in muscle mass. One possible explanation is illustrated by 
Masson’s trichrome staining, which showed a large area of blue-stained collagen fibers, 
indicative of fibrosis of the muscle. Presumably, much of the injured muscle tissue was 
replaced by fibrotic scar tissue resulting in decreased tissue quality. This non-functional 
scar tissue in the muscle may account for part of the large functional deficit we see in our 
model.  
Peripheral nerve damage is a likely co-morbidity in our large VML injury. This 
possible nerve damage further complicates the model and may contribute to the lack of 
muscle recovery. Denervated muscle flaps have been shown to result in muscle atrophy 
[115-117]. Our model did not exhibit extensive atrophy, suggesting that although 
peripheral nerve damage may occur, it does not account for the majority of the functional 
deficit. Nevertheless, reinnervation of motor nerves may enhance muscle regeneration 
and function [118] and should be taken into account when developing a treatment 
strategy for VML. 
Clinically, thin muscle flaps that cover large muscle defects are not always 
effective for functional tissue engineering; thus, we examined the regenerative potential 
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of autografts, which consist of a higher amount of tissue than a muscle flap.  Contrary to 
our hypothesis that this treatment would improve muscle regeneration and function, our 
VML model showed little to no improvement with autograft treatment. These results 
seemingly contradict previous literature; the mouse extensor digitorum longus and the rat 
triceps surae muscles that had been excised, minced, then placed back into its muscle bed 
regenerated within 2 weeks with little fibrosis [41] [119]. However, our data showed no 
significant improvement in muscle function between any treatment groups at any 
recovery time point. A key difference between the morselized autograft in our model and 
the minced murine muscle is size. While smaller muscles were able to regenerate with 
minimal scarring, the larger quadriceps muscle did not reach the same regenerative 
potential. This is further illustrated in the clinic, where thin muscle flaps are used to cover 
VML injuries, providing only a small amount of tissue for regeneration with and often 
resulting in functional deficit. 
Another distinct possibility for the lack of functional recovery of the muscle with 
autograft treatment is related to the muscle extracellular matrix (ECM). In recent years, 
an increasing number of studies have demonstrated the importance of the ECM in muscle 
function [62, 120]. The muscle autografts used in our experiments were not specifically 
aligned with the muscle fibers within the injury bed, and our VML encompasses parts of 
all four muscles of the quadriceps, further complicating the orientation of our autograft 
treatment. This juxtaposition of randomly aligned graft ECM on the muscle ECM may 
have yielded inefficient functional recovery of the muscle. This lack of recovery with 
misaligned ECM and the importance of muscle ECM on muscle function suggest that 
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tissue engineering strategies that incorporate structure alignment may result in a more 
organized tissue and thus a higher chance of functional recovery. 
Vascular reconstruction, which is widely used clinically to maintain vascular 
perfusion in a muscle flap, was not performed in our autograft treatment. The success of 
muscle flap treatments in the clinic rely heavily on blood supply to the flap. This, again, 
alludes to the inversely proportional relationship between VML size and the regenerative 
potential of the muscle. Research investigating muscle flap treatment of open fractures 
shows that muscle flaps that are constructed too large suffer from ischemia-induced 
necrosis [121-123]. Additionally, vascularized muscle flaps that have reconstructed nerve 
connections served as better wound coverage than disconnected flaps, suggesting that 
vascularization and nerves play a role in survival of the graft [118]. The autografts used 
in our model may have necrosed from lack of intact vessels, leading to an inflammatory 
environment that may have deterred any healing response from stem cells or extracellular 
matrix proteins in the autograft. This suggests that regenerative approaches that facilitate 
vascular growth may increase the survival rate of implanted or migrated endogenous cells 
in the center of the VML defect. 
As mentioned before, our minced and whole autograft treatments of the VML 
defect illustrated the importance of  differences in mass and nutrient transfer that arise 
from the size scale of the muscle defect and the animal model . While minced and whole 
autografts did not result in functional regeneration in our rat quadriceps defect model, 
another group has demonstrated some success of this therapy in the tibialis anterior 
muscle of the rat, in which a smaller, single-muscle VML was created [124]. 
Additionally, while ECM treatment has had moderate success in regenerating muscles in 
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rodent models, the same treatment used in the dog gastrocnemius muscle resulted in little 
recovery in the muscle function after 3 months [60, 61]. This, again, highlights the need 
for a large, challenging regenerative environment in preclinical models to maximize 
translational potential of therapies. 
 Various tissue engineering strategies have been tested in preclinical models of 
VML that have shown promising effects on muscle regeneration. Small intestinal 
submucosa extracellular matrices (SIS-ECM) have been tested in a mouse quadriceps 
VML, and host skeletal muscle cells infiltrated the ECM, indicating possible muscle 
regeneration though no muscle function was tested [44]. Other groups have decellularized 
the rat gastrocnemius muscle and then recellularized this ECM with mesenchymal stem 
cells (MSCs). When implanted in a rat gastrocnemius defect, this treatment showed 
significant functional recovery compared to ECM or injury alone [47, 77]. Other 
promising interventions have used muscle-derived stem cells or satellite cells seeded on 
fibrin microthreads or  hyaluoronic acid hydrogel respectively; both studies showed 
functional recovery when implanted in a mouse tibialis anterior muscle VML model [42, 
43]. These regenerative strategies clearly have potential for the functional healing; 
however, the VML used to test these treatments were relatively small. Given the size 
considerations of VML models, it would be beneficial to test strategies such as these in 
our challenging VML in order to rigorously filter preclinical treatments prior to 
investigating their potential in even larger animal models or humans. 
 In conclusion, we have successfully established a novel model of VML in the 
quadriceps femoris of a rat with quantitative functional outcome metrics. Contrary to our 
hypothesis, neither minced nor whole autografts resulted in any significant recovery of 
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muscle function. This is consistent with clinical outcomes, in which autogenic muscle 
flap treatments of VML injuries often result in functional deficits. While this VML in the 
quadriceps represents well the major clinical challenges of VML injuries, the possible 
nerve and vessel damage in this VML model may hinder any tissue engineering strategies 
that may indeed facilitate muscle regeneration but does not actively support nerve or 
vessel repair. This is a major limitation to this model that will be addressed in the next 
chapter of this dissertation. 
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 Extremity injuries involving large bone defects with concomitant severe muscle 
damage are a significant clinical challenge often requiring multiple treatment procedures 
and possible amputation.  Even if limb salvage is achieved, patients are typically left with 
severe short and long-term disabilities. Current pre-clinical animal models do not 
adequately mimic the severity, complexity, and loss of limb function characteristic of 
these composite injuries. The objectives of this study were to establish a composite injury 
model that combines a critically-sized segmental bone defect with an adjacent volumetric 
muscle loss injury and then use this model to quantitatively assess rhBMP-2 mediated 
tissue regeneration and restoration of limb function. Surgeries were performed on rats in 
three experimental groups: muscle injury (8 mm diameter full-thickness defect in the 
quadriceps), bone injury (8 mm non-healing defect in the femur), or composite injury 
combining the bone and muscle defects. Bone defects were treated with 2μg of rhBMP-2 
delivered in pre-gelled alginate injected into a cylindrical perforated nanofiber mesh. 
Bone regeneration was quantitatively assessed using CT, and limb function was 
assessed using gait analysis and muscle strength measurements. At 12 weeks post-
surgery, treated bone defects without volumetric muscle loss were consistently bridged.  
In contrast, the volume and mechanical strength of regenerated bone were attenuated by 
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45% and 58%, respectively, in the identically treated composite injury group. At the same 
time point, normalized muscle strength was reduced by  51% in the composite injury 
group compared to either single injury group. At two weeks, gait function was impaired 
in all injury groups compared to baseline with the composite injury group displaying the 
greatest functional deficit. We conclude that sustained delivery of rhBMP-2 at a dose 
sufficient to induce bridging of large segmental bone defects failed to promote 
regeneration when challenged with concomitant muscle injury. This model provides a 
platform with which to assess bone and muscle interactions during repair and to 
rigorously test the efficacy of tissue engineering approaches to promote healing in 
multiple tissues. Such interventions may minimize complications and the number of 
surgical procedures in limb salvage operations, ultimately improving the clinical 
outcome. 
4.2 Introduction 
 There is growing appreciation of the profound interactions between skeletal 
muscle and bone during development, daily function, and healing subsequent to traumatic 
injury.  Clinical studies have reported that composite injuries consisting of both bone 
fracture and muscle injury significantly complicate fracture healing, often resulting in 
delayed healing, non-union, infection, re-hospitalization, and additional surgeries [125-
129]. Coverage of an open fracture with a muscle flap is the clinical gold standard for 
intervention and has been shown to improve fracture healing, suggesting that muscle 
somehow contributes to the bone repair process [54, 130, 131]. Medical advances have 
made limb salvage common after these severe injuries; however, patients are often left 
with substantial short-term and long-term disabilities [102, 129]. Though long term 
function at 2 and 7 years post-injury is approximately equivalent in amputation and limb 
salvage patients (based on the sickness impact profile scoring system), amputees are at 
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lower risk for further complications or additional surgeries [102, 129]. Additionally, 
functional disabilities, pain, neurologic dysfunction, and infection can result in delayed 
amputations at reported rates of 4-15% in limb salvage cases involving severe bone 
(grade III) and soft tissue injury (crush or volumetric muscle loss) [132-134]. Though 
limb salvage techniques have improved, there are substantial advancements still to be 
made in limb reconstruction and rehabilitation leading to the restoration of normal 
function. Highlighting this need, composite extremity injuries are the leading battlefield 
injury faced by returning servicemen [1, 132, 135]. To date, clinical composite injury 
studies have been mainly observational in nature without offering clear insight into the 
mechanisms involved.   
 Potential roles for muscle in bone healing include acting as a source for 
vascularization, progenitor cells, osteogenic myokines, and also biomechanical stimuli 
[136, 137].  Studies have shown that muscle surrounding a bone defect contributes to re-
establishing the blood supply, a step which is critical to ensure successful bone healing 
[138-140].  Additionally, muscle cells secrete numerous osteogenic factors (including 
IGF-1, FGF-2, and TGF-) under basal conditions, with increased secretion in 
regenerating muscle [137, 141, 142].  The periosteum, a cellular membrane that separates 
bone and muscle tissues, expresses receptors for these growth factors suggesting a 
mechanism of tissue cross talk [137]. These growth factors have also been implicated in 
the recruitment and differentiation of osteogenic progenitor cells.  Muscle progenitor 
cells have also demonstrated a capability to differentiate into osteogenic cell lineages 
[143, 144].  A recent study tracked these muscle progenitor cells after an open bone 
fracture and showed incorporation of these cells in regenerated bone [145]. These studies 
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have demonstrated potential mechanisms of interaction between bone and muscle during 
regeneration.  
 There are currently few models of composite bone-muscle injury in the literature 
and no models that can be used to assess multi-tissue engineering strategies. The few 
models in the literature have all been performed in the lower limb and combine a 
naturally healing fracture or osteotomy with varying degrees of muscle injury (laceration, 
crush, or resection) [54, 146-148]. Models with severe muscle injury (resection) typically 
displayed delayed bone healing, while models with less severe muscle injuries commonly 
displayed no effect on bone healing. A recent consensus recommendation published by 
experts in the fracture field pointed to the thin soft tissue coverage of the tibia as a reason 
that it may not be an ideal location to investigate the relation of soft tissue to bone repair 
[149]. Instead, the femur was recommended due to thick muscle coverage. In addition, a 
fracture model has limited utility for the investigation of tissue engineered bone 
constructs, which are typically assessed in critically sized, non-healing defects. To 
effectively develop and evaluate tissue engineered constructs for multi-tissue limb 
reconstruction, a more challenging pre-clinical model of traumatic injury is needed as are 
quantitative functional outcome measures. 
 In this study, our objective was to develop a composite injury model 
consisting of a critically sized segmental bone defect in the femur and an adjacent 
volumetric muscle injury in the quadriceps. An established tissue engineered 
recombinant human bone morphogenetic protein-2 (rhBMP-2) delivery system was tested 
for the treatment of the bone defect [10, 150, 151]. This system had previously been 
shown to provide sustained delivery of rhBMP-2 at a dose sufficient to induce bridging of 
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a bone defect in a single tissue injury model [10, 150, 151]. It was hypothesized that 
animals with a composite injury would have attenuated tissue regeneration and impaired 
limb function despite rhBMP-2 treatment. Additionally, in order to gain insight into the 
mechanisms by which muscle and bone interact during regeneration, we further tested 
whether muscle cells/ECM in the form of an autograft or early revascularization of the 
limb may play a role in the healing of the bone. 
4.3 Materials/Methods 
Surgical Procedure for Creation of the Composite Defect 
 Thirteen week old female Sprague-Dawley rats (Charles River Labs, Wilmington, 
MA) were used for this study. Animals were placed in one of three injury groups: bone 
defect only (n=5), muscle defect only (n=8), or composite bone and muscle defect (n=5). 
Unilateral bone defects were surgically created in the femora of rats, as previously 
described [10, 151, 152]. Briefly, an anterior incision was made along the length of the 
femur and the muscle was then separated using blunt dissection. A modular fixation plate 
was affixed to the femur using miniature screws (JI Morris Co., Part No. P0090CE250). 
A full-thickness segmental defect, 8 mm in length, was created in the diaphysis using a 
miniature oscillating saw. A perforated nanofiber mesh tube made of polycaprolactone 
(PCL) was then placed over the native bone ends surrounding the defect, and 150 μl 
alginate hydrogel containing 2.0 μg rhBMP-2 was then injected into the defect space 
[10]. This dose had previously been shown to consistently induce bridging of the bone 
defect [150]. Non-treated controls were not used in this study as previous studies have 
demonstrated that in the absence of rhBMP-2, the defect contains very little bone 
formation [150, 152]. Muscle defects were created through the full thickness of the 
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quadriceps down to the femur using an 8 mm diameter biopsy punch (Figure 9A). The 
defect encompassed regions of the rectus femoris, vastus lateralis, vastus medialis, and 
vastus intermedius. The muscle defect was untreated in this study and left empty. In 
composite injury animals, the bone defect was made first, then, once the incised muscles 
had been closed with 4-0 suture, the muscle defect was created. Animals were given 
buprenorphine post-surgery to manage pain (0.03 mg/kg 3x daily for the first 48 hours, 
then 0.01 mg/kg 3x for the next 24 hours). All procedures were approved by the Georgia 
Institute of Technology Institutional Animal Care and Use Committee (protocol 
#A09039). 
 
Figure 9: Representative Methods Images. Panel A shows schematics illustrations of 
the anatomical injury location including a cross section through the quadriceps (top) and 
a side view of the hindlimb (bottom). Panel B shows images from the muscle defect only 
surgery (top) and the composite bone and muscle defect surgery (bottom). Panel C shows 
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representative images of the muscle strength-measuring apparatus (top) and positioning 
of a rat limb in the apparatus (bottom). The animal was secured at the hips and the knee 
by a strap, and then the ankle was fastened to a force transducer. VM – Vastus Medialis; 
RF – Rectus Femoris; VI – Vastus Intermedius; VL – Vastus Lateralis 
 
Functional Gait Analysis 
 Hind limb function was assessed after injury using the CatWalk system (CatWalk 
7.1, Noldus Inc., Leesburg, VA) at baseline (1 week prior to surgery) and at 2, 4, 8, and 
12 weeks post-injury.  The system consisted of an illuminated platform, an enclosed 
walkway and a digital camera mounted below the platform. The rats were placed at the 
open end of the track and allowed to ambulate freely to the other end. Illuminated paw 
prints were recorded and paw print area and duty cycle were assessed for each group. 
Paw print area is a static parameter that measures the area of contact that the paw makes 
with the glass walkway during the stance phase. Duty cycle is a dynamic parameter 
indicative of limb use during ambulation, and is represented as the ratio of the stance 
duration to the sum of the stance and swing duration (stride duration). 
Muscle Isometric Tetanic Torque Assessment 
 Isometric tetanic torque production about the knee by the knee extensor muscles 
was measured at 12 weeks post-surgery using a custom built apparatus based on a 
previous design used for assessment of lower leg muscle function (Figure 9B) [113]. All 
measurements were made under isoflurane anesthesia during a terminal procedure 
immediately prior to euthanasia. A 2-cm long incision was made through the skin 
exposing the femoral triangle in the upper thigh. The posterior branch of the femoral 
nerve was carefully isolated and a nerve cuff was positioned surrounding that branch.  
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The rat was then carefully secured to the platform of the apparatus. The animal was 
positioned so that the knee angle was at 90
o
 and the ankle was secured to a force 
transducer (Isometric Transducer Model No. 60-2996, Harvard Apparatus). The knee 
extensor muscles were stimulated using a stimulator (GRASS S11 Stimulator, Grass 
Technologies) and the nerve cuff implanted on the femoral nerve. Stimulator pulse 
duration, frequency, and train duration were set to 0.5 ms, 175 Hz, and 500 ms, 
respectively; these settings elicited maximal isometric tetanic torque as determined in a 
pilot study. Measurements of injured muscles were normalized to contralateral intact 
muscle for each animal. A fatigue protocol was run using 60 Hz stimulation for 330 ms 
every second for two minutes. Fatigue was calculated as the ratio of the force produced at 
the end of the two minute protocol compared to the highest force, which typically 
occurred in the first few seconds of the protocol.  
Faxitron X-Ray Analysis 
 Digital radiographs (Faxitron MX-20 Digital; Faxitron X-ray Corp.) of the defect 
region in the femur were performed at an exposure time of 15 s and a voltage of 25 kV. 
Animals received X-ray imaging at 2, 4, 8 and 12 weeks post-surgery. Blinded analysis 
of bridging rates at 12 weeks was performed by three researchers.  
MicroCT Analysis 
 MicroCT scans (VivaCT 40, Scanco Medical) were performed at 38.0 μm voxel 
size at a voltage of 55 kVp and a current of 109 μA. Scans were taken at 4 and 12 weeks 
post-surgery. Bone tissue was segmented by application of a global threshold 
corresponding to 386 mg hydroxyapatite/cm
3
 (roughly 50% of the native cortical bone 
density), and a low-pass Gaussian filter (sigma = 1.2, support=1) was used to suppress 
 52 
noise. Samples were contoured and evaluated over 141 slices taken from a central region 
within the defect in order to normalize between samples without including cortical bone. 
Ex-vivo analysis over the entirety of the defect region was also performed and showed the 
same differences among the groups as the in vivo data at 12 weeks. 
Biomechanical Analysis 
 Animals were euthanized by CO2 inhalation 12 weeks post-surgery. This time 
point was chosen based on previous publications demonstrating that bone apposition 
reaches a plateau by this time [150]. Torsional testing was performed on extracted 
femurs. The femurs were cleaned of soft tissue and the ends potted in mounting blocks 
using Wood's metal (Alfa Aesar, Wood Hill, MA). After removal of the fixation plate, 
the specimens were tested (ELF 3200, Bose ElectroForce Systems Group, Minnetonka, 
MN) at a rotational rate of 3° per second. Maximum torque was measured at the failure 
point from the torque-rotation data. Torsional stiffness was calculated by fitting a straight 
line to the linear portion of the curve before failure.  
Histology 
 Histological analysis was performed at 12 weeks post-surgery on 
extracted quadriceps muscles and femurs. Samples were perfusion fixed then immersion 
fixed for 48 h at 4 °C with 10% neutral buffered formalin. Following paraffin processing, 
5 μm-thick cross-sections were cut and stained with hematoxylin and eosin (H&E), 0.5% 
Safranin-O (for bone),or Masson’s Trichrome (for muscle). Bright-field images were 
obtained with the Axio Observer.Z1 microscope (Carl Zeiss, Thornwood, NY). Images 
were taken at 4x and 10x magnification using the AxioVision software (Carl Zeiss, 
Thornwood, NY).  
 53 
Surgical Procedure and Analyses for Testing Muscle Autografts in the Composite Defect 
 Thirteen week old female Sprague-Dawley rats (Charles River Labs, Wilmington, 
MA) were used for this study. The composite bone and muscle defect was applied to all 
animals as previously described, with 2.0 μg rhBMP-2 delivered in RGD-functionalized 
2% alginate injected into a PCL perforated nanofiber mesh tube. Animals were placed in 
one of three muscle treatment groups: empty quadriceps defect (n=8), whole autograft 
(n=7), and morselized autograft (n=8). The autografts were applied as previously 
described in Section 3.1.3. Longitudinal micro-CT measurements and faxitron x-ray 
images were taken at 4, 8, and 12 weeks post-injury. At 12 weeks post-injury, muscle 
force measurements were performed as previously described. 
Surgical Procedure and Analyses for Determining Revascularization of the Limb 
 Thirteen week old female Sprague-Dawley rats (Charles River Labs, Wilmington, 
MA) were used for this study. The animals were placed in one of two injury groups: 
composite bone and muscle defect, or bone defect alone. All animals received 2.0 μg 
rhBMP-2 delivered in RGD-functionalized 2% alginate injected into a PCL perforated 
nanofiber mesh tube for the treatment of the bone. For evaluation of early 
revascularization, animals were euthanized at day 3 (n=3-6), 7 (n=7), and 14 (n=9) post-
injury. 
µCT Angiography 
 For all samples in the study determining revascularization of the limb post-
composite defect, congrast agent-enhanced micro-CT angiography was performed 
terminally at the designated time points (day 3, 7, or 14).  The technique has been 
previously described in detail [153-155]. Briefly, 0.9% salt solution (physiological saline) 
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containing 0.4% papaverine hydrochloride (Sigma-Aldrich) was perfused through the 
vasculature to clear the blood vessels. The vasculature was then perfusion fixed with 10% 
neutral buffered formalin, rinsed with physiological saline, and injected with lead 
chromate-based radioopaque contrast agent (2 parts microfil MV-22: 1 part diluent, Flow 
Tech). Samples were stored at 4°C overnight to allow for polymerization of the contrast 
agent. Hind limbs from the hip to the knee were excised. For day 3 and day 7 samples, 
the assumption was made that minimal bone was formed by that point, and limbs were 
scanned immediately. For day 14 samples, the samples were immersed in decalcification 
solution (Cal-Ex II, Fisher Scientific) for a period of 2-3 weeks under gentle agitation 
with solution changes every 1-3 days. 
 Excised samples were oriented with the femur along the z-axis for micro-CT 
scanning (vivaCT 40, Scanco Medical). Two sets of scans and volumes of interest (VOIs) 
were used to analyze within the bone defect only or within the thigh (including both 
muscle and bone). Scans were performed at 21µm voxel size for vessels within the bone 
defect region and 38µm voxel size for vessels within the thigh (muscle and bone). All 
scans were performed with an applied electroc potential of 55 kVp and a current of 109 
µA. The VOI analyzing the bone region consisted of a cylindrical volume 5mm in 
diameter that spanned the center 7mm of the bone defect. A global threshold was applied 
for segmentation of vasculature, and a Gaussian low-pass filter was used to suppress 
noise (σ = 0.8, support = 1). 
Statistical Analysis 
 All data are presented as mean +/- standard error of the mean (SEM). Differences 
between multiple groups were assessed by analysis of variance (ANOVA) or for analyses 
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with only two groups a student t-test or Mann-Whitney test were used. A Tukey post hoc 
comparison was performed on the muscle and bone regeneration data, while the gait data 
was assessed with a Boneferroni post hoc test with pairwise comparisons within groups 
across time points or within time points across groups. A p-value less than 0.05 was 
considered significant. GraphPad Prism 5 (GraphPad Software, Inc., La Jolla, CA) was 
used to perform the statistical analysis. One sample was removed from the control bone 
defect group as an outlier. Bone volume, stiffness, and failure strength from this sample 
were over two standard deviations from the mean for the group (and from historical 
values for over 20 samples) [150]. 
4.4 Results 
Bone Regeneration 
 Faxitron X-ray radiographs were taken at 2, 4, 8, and 12 weeks post-surgery and 
illustrated the progression of bone formation in each group (Figure 10). Blinded analysis 
of bridging rates showed that the defect was bridged at 12 weeks in all animals with bone 
only defects while only three of six animals in the composite group showed bridging of 
the defect. 
 
Figure 10: Femur Radiographs. Representative radiographs of the femurs from bone 
defect and composite defect animals at time points 2, 4, 8, and 12 weeks. 
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 MicroCT quantification of bone formation was performed at 4 and 12 weeks 
post-surgery (Figure 11A-B).  At week 4, there were no significant differences between 
the groups though there was a trend for attenuated bone formation in the composite injury 
group. Animals in both groups had a significant increase in bone formation in the defect 
region between 4 and 12 weeks. By week 12, the composite injury animals had 45% less 
bone volume formed in the defect region as compared to animals in the bone injury-only 
group, a significantly lower value.  
 The degree of functional restoration in the regenerated bone tissue was measured 
using torsional testing to failure (Figure 11C). The composite injury group had 
significantly lower failure torque (59% lower) and stiffness (87% lower) as compared to 
the bone from animals in the bone-only injury group. 
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Figure 11: Bone Regeneration. Panel A shows representative CT reconstructions at 12 
weeks from the defect regions of bone defect and composite defect animals. Quantitative 
measurements of mineral volume in the defect region are presented in panel B. 
Mechanical data showing failure strength and stiffness acquired from torsional testing to 
failure are presented in panel C. * p<0.05; **  p<0.05 using a Mann-Whitney test, n=5-8. 
 
 Histological assessment of bone quality and composition was performed using 
H&E and Safranin-O staining (Figure 12). Bone injury animals showed areas of bone 
formation and endochondral ossification with larger well defined pockets of alginate 
when present. Composite injury animals showed some bone formation, though 
endochondral ossification was not observed. Alginate was present throughout the bone 
defect region in smaller pockets integrated within the regenerated bone. 
 
Figure 12: Bone Histology. Representative H&E and Safranin-O images are presented 
from within the bone defect region. Bone injury animals showed pockets of hypertrophic 
chondrocytes indicative of endochondral ossification from Saf-O staining and few larger 
isolated pockets of alginate. Composite injury animals had smaller pockets of alginate 
dispersed throughout the defect region as identified in both Saf-O (glossy light pink) and 




 Muscle regeneration was assessed histologically using H&E and Masson’s 
Trichrome staining. Masson’s Trichrome stain from the composite injury group showed 
fibrosis surrounding individual muscle fibers and fat nodules, indicating poorly 
regenerated muscle (Figure 13B). Animals from the muscle injury only group showed a 
band of fibrosis through the central region while fibrosis was not apparent in the bone 
only injury group. Animals in all three groups primarily showed peripherally located 
nuclei in muscle fibers throughout the H&E stained tissue cross sections, indicating that 
most muscle fibers were mature and not regenerating 12 weeks post-injury (Figure 13A). 
 
 
Figure 13: Muscle Histology. Panel A shows representative H&E images from 
quadriceps muscle sections taken from control, bone injury, muscle injury or composite 
injury animals. Most muscle fibers showed peripherally located nuclei indicating mature 
fibers and minimal muscle regeneration at this time point. Panel B shows representative 
Masson’s trichrome images from sections adjacent to the images in Panel A. Blue 
staining shows fibrosis and the black arrows point to lipid deposits. Both fibrosis and 
lipid deposits were observed in the composite injury animals indicating poorly 
regenerated muscle. All images shown were from 12 weeks post-surgery. 
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 Muscle function was assessed by measuring isometric torque produced around the 
knee, which is a direct measure of quadriceps strength (Figure 14A). Representative 
force-time tracings during femoral nerve stimulation are presented. All groups showed a 
significant decrease in muscle strength as compared to the contralateral control limb, 12 
weeks post-injury. Strength in the injured limbs was 38 %, 38 %, and 18 % of the 
contralateral control in the bone only defect group, muscle only group, and composite 
group respectively. Normalizing the strength of the injured limb by that of the 
contralateral control limb showed that animals with a composite injury had a significantly 
greater deficit in muscle strength as compared to animals with a single tissue injury (51% 
greater deficit). Fatigue waveforms showed normal profiles with a peak in force produced 
shortly after initial stimulation then slowly dropping off (Figure 14B). Compared to 
contralateral controls, muscle fatigue was significantly decreased in animals with muscle 
only injuries, but not the bone only or composite injury groups.  
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Figure 14: Muscle Functional Capacity. Panel A presents peak torque data from 
animals in all groups at 12 weeks post-surgery including: peak isometric torque (left) in 
injured and contralateral non-operated control limb. Normalized torque (center) as the 
ratio of the peak torque in the injured limb compared to the peak torque in the 
contralateral non-operated limb, and representative torque curves (right). Panel B shows 
representative fatigue curves (right) and muscle fatigue data (left) Muscle fatigue was 
measured for each animal as the ratio of the minimum peak torque compared to the 
maximum peak torque for each limb. Panel C shows the wet muscle mass from the 
quadriceps immediately after euthanasia. Mass (left) and normalized mass are presented 
(right). * - p<0.05, n=5-8 
 
 Mass of the knee extensor muscle group was measured immediately after 
euthanizing the animals. All three groups showed a significant reduction in muscle mass 
in the injured limb as compared to the contralateral control limb (Figure 14C). 
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Normalized muscle mass (ratio of the mass of the injured limb to that of the contralateral 
control limb) in the composite injury animals was significantly lower compared to the 
muscle injury group but not the bone injury.  
Limb Function 
 Limb function was quantitatively evaluated by measuring two gait parameters: 
paw print area and duty cycle (Figure 15). All groups, including bone injury, muscle 
injury, and composite injury, showed a significant deficit in paw print area at two weeks 
post-surgery compared to baseline values.  The print area deficit observed at 2 weeks was 
significantly worse in composite injury animals compared to the single tissue injury 
animals.  The composite injury animals showed a steady recovery in print area between 2 
and 12 weeks, reaching a comparable level to the deficit observed in the single tissue 
injury animals. Similarly, the composite injury animals had a deficit in duty cycle at 2 
weeks compared to baseline values and compared to single tissue injury animals at the 




Figure 15: Limb Function. Measurements of gait were made using the Noldus Catwalk 
system. Print area and duty cycle (ratio of the stance duration to the sum of the stance and 
swing duration) at 2 week intervals from animals in all groups are presented in panel A. 
Data is presented as the ratio of the injured limb to the contralateral non-injured control 
limb. Panel B shows representative paw prints, corresponding to the paw print area from 
the injured limb of animals 2 weeks post-surgery.* - p<0.05 between groups within time 
point, ** - p<0.05 between time points within group, *** - p<0.05 compared to baseline 
within group and within time point between groups, n=5-8 
 
Treatment with Muscle Autografts 
 To determine if the removal of a large amount of cells/ECM is the main reason 
behind the attenuated bone regeneration, muscle autografts (whole or morselized) were 
implanted into the quadriceps defect and compared to the empty defect. Longitudinal 
faxitron images showed no significant differences between the three treatment groups 
(empty, whole, and morselized autograft) (Figure 16A), and µCT quantification of 
mineral volume confirmed this finding (Figure 16B). 12-week analysis of muscle 
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strengths showed significantly decreased muscle strengths in the injured legs compared to 
the uninjured contralateral controls Figure 17A). No significant differences were found in 
normalized muscle forces between the three treatment groups (Figure 17B). Wet muscle 
mass was also lower in the injured legs compared to uninjured controls, with no 
differences in the normalized data between the three treatment groups (Figure 17C,D). 
 
Figure 16: Bone Volume after Treatment with Muscle Autografts. Bone regeneration 
was monitored at 4, 8, and 12 weeks post-surgery. Panel A shows no visual differences 
between the three treatment groups at any time point. Panel B confirms this finding with 
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µCT analysis of mineral volume in the defect region. No differences were found between 
the three treatment groups at any time point. Empty n=8; morselized n=8; whole n=7. 
 
 
Figure 17: Muscle Regeneration after Treatment with Muscle Autografts. Maximal 
isometric force of the quadriceps was measured at 12 weeks post-injury in a terminal 
procedure. Panel A shows the maximal force produced by each leg in each group while 
panel B shows the same data with the left (injured) leg force normalized to the right 
(contralateral uninjured control) leg force. Panel C shows the wet muscle mass from the 
quadriceps immediately after euthanasia. Panel D shows the same muscle mass data with 
the left leg normalized to the right. In Panels B and D, the dotted red line indicates the 
level of muscle recovery from the initial composite injury study (from Figure 14) for 
comparison. * p<0.001 between the indicated groups; empty n=8, morselized n=8, whole 
n=7. 
 
Early Revascularization of the Composite Defect 
 Early revascularization of the defect areas was analyzed using µCT angiography 
at days 3, 7, and 14 days post-injury. Because this analysis method is terminal, these 
measurements are not longitudinal and represent results from different animals at 
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different time points. The bone injury group had a higher thigh vascular volume early on 
at days 3 and 7 compared to contralateral control whereas the composite group was not 
significantly different from control.  By day 14, vascular volume in both injury groups 
had increased from day 7 and were both significantly greater than the contralateral 
control leg (Figure 18A). Representative images of the vasculature in the thigh (within 
the defect area) show this difference is mainly from the surrounding muscle rather than in 
the bone defect itself (Figure 18B). 
 By examining the number of voxels within each diameter bin, we can determine 
the vessel size profile in either the thigh or the bone (Figure 19). At days 3 and 7, we see 
that the bone defect only group has more voxel counts in smaller diameter bins in the 
thigh compared to the composite groups, though there are no significant differences 
between the two groups. At day 7, there seems to be more smaller sized vessels 
(<400µm) in the bone defect group (not significant). Representative images of the vessels 
within the bone defect in both groups clearly shows that vessels do not grow through the 
PCL nanofiber mesh, as there is a clear empty space where the mesh resides (Figure 20). 
However, at distinct points in the mesh, vessels are seen to cross the mesh and link the 
bone defect region to the surrounding muscle. These points likely correspond to the 1-
mm macropores present on the mesh. 
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Figure 18: Early revascularization of the Thigh within the Defect Areas. µCT 
angiography analysis showed that the bone only group had a significantly higher leg 
(thigh) vascular volume compared to contralateral uninjured control while the composite 
group was not significantly different from control (Panel A). Panel B shows 
representative images of the vasculature. Heat map represents vessel diameter. * p<0.05 
between Bone and Control. ** p<0.01 between Bone and Control. ** p<0.001 between 




Figure 19: Vessel Diameter Distribution at Days 3, 7, and 14. Vessel diameter 
distributions at day 3 were similar between the two groups in the thigh and bone defect 
regions. However, by day 7, the bone injury group had more small blood vessels in both 
thigh and bone defect area  as compared to the composite injury group. At 14 days, the 
composite injury group did not have any blood vessels within the bone defect area with 
diameters greater than 450 microns whereas the bone injury group had vessels up to 700 





Figure 20: Representative Vessel Images within the Bone Defect Area at Day 14. 
The location of the mesh is shown by the red concentric circles in the axial view of both 
injury groups. Insets show vessels crossing the mesh itself at very specific points, which 
correspond to the 1-mm macropores present on the mesh, as seen in the surgical image 
(top right). Heat  map represents vessel diameter. 
4.5 Discussion 
 Traumatic injuries that create large bone defects often include damage to the 
surrounding soft tissues. Modern clinical techniques have improved the rates of success 
in limb salvage; however, patients still require repeated hospitalizations for multiple 
surgeries and complications during the healing process, such as non-union or infection, 
are common [126, 127, 129].  Even when limb salvage is successful, patients are often 
left with large functional deficits. The complexity, severity, and loss of limb function 
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associated with these injuries are not represented by current pre-clinical animal models 
limiting the utility of these models to test the efficacy of tissue engineered interventions.  
In this study, we developed a challenging rat model of composite bone and muscle injury 
by combining a critically sized segmental bone defect model with an adjacent volumetric 
muscle defect. We then tested the efficacy of a hybrid rhBMP-2 delivery system to 
regenerate bone and restore limb function.  
 Pre-clinical animal models of composite injury have previously been limited to 
lower limb tibial fractures and thus have lacked the capability to assess tissue engineering 
interventions for multi-tissue limb reconstruction. In this study, we incorporated a well-
established, larger than critically sized, segmental bone defect in the femur of a rat. The 8 
mm defect used in this model is 60% larger than the necessary critical size, 5 mm, and 
provides a more challenging regenerative environment; smaller defects could also be 
combined with an adjacent volumetric muscle injury, and would provide valuable 
information on the relative importance of defect size (surface area in contact between the 
bone and muscle) and insight into potential mechanisms of interaction. We have 
previously demonstrated the efficacy of a sustained release, hybrid rhBMP-2 delivery 
system, showing consistent bridging of the bone defect with doses of rhBMP-2 as low as 
1.0 g [150]. This system previously outperformed the clinical gold standard for rhBMP-
2 delivery, absorbable collagen sponge. Furthermore, the dose used was at the low end of 
doses commonly reported in similar rat models, which typically range from 2 g to 20 g 
[10, 150-152, 156-160]. Consistent with previously published data, the current study 
showed that the hybrid rhBMP-2 delivery system promoted consistent bone bridging in 
the bone-only injury model [150]. At 12 weeks, animals in the composite injury group 
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had significantly attenuated rhBMP-2 mediated bone regeneration compared to the bone 
injury only group, both in terms of mineralized matrix volume and mechanical strength. 
In this new composite injury model, which utilizes a segmental bone defect, it was 
demonstrated that a healing dose of rhBMP-2 sufficient to bridge a large bone defect, 
failed to promote regeneration when challenged with a concomitant volumetric muscle 
injury. 
 The surrounding soft tissue may be expected to play a larger role in the healing of 
a femoral segmental bone defect compared to the previously used tibial fracture. This 
may simply be due to the relative distance of the defect region to the muscle as opposed 
to the periosteum. Fractures primarily heal through endochondral bone repair, a process 
largely directed by the periosteum [161-164]. The contribution of muscle derived cells to 
fracture healing was recently demonstrated by tracking muscle derived cells (MyoD-
Cre
+
) [145]. After a closed fracture very few muscle derived cells were present in the 
fracture callus, however, after an open fracture with the adjacent periosteum denuded, 
there was a substantial population of muscle derived cells in the callus, fracture gap and 
pericortical bone [145]. This study speculated that the periosteum is sufficient for fracture 
healing, and when present, other sources for osteoprogenitor cells are not necessary. In 
critically sized segmental defects, the periosteum is not sufficient to direct healing and 
the natural healing progression will instead cap off the cortical bone ends. During 
rhBMP-2 mediated healing of segmental defects the relative contribution of various cell 
sources is unknown; however, new models, like the one presented in this study, will 
provide tools to address these gaps in the current understanding of bone regeneration. 
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 The deleterious effects of concomitant muscle injury on bone regeneration may be 
attributable to numerous potential mechanisms which have not yet been fully elucidated. 
One potential mechanism may be a diminished blood supply, which has been shown to be 
a risk factor for successful healing of a bone defect[165]. The large volumetric muscle 
defect was from a highly vascularized region of tissue.  Beyond, simply a loss in normal 
blood supply, there may be hyperemia through the collateral network immediately 
following the bone defect injury. This altered blood supply (whether normal or 
hyperemic)in the muscle defect animals may produce changes in nutrient and waste 
exchange, inflammation, circulating stem cell recruitment, and ultimately 
revascularization of the defect. Another potential mechanism may be that the loss of 
muscle volume removes a source for resident muscle stem cells and myokines (including 
IGF-1, FGF-2, or TGF-) which may contribute locally to bone regeneration. While these 
factors and cells are key components to muscle regeneration they have also been shown 
to have osteogenic capabilities [137, 142-144].There is also an increasing body of 
literature that suggests that muscle may act systemically on other organs, potentially 
through neural feedback or endocrine type mechanisms[166, 167]. Studies on injury, 
hindlimb unloading, and paralysis implicate both systemic and local roles for muscle in 
bone homeostasis, though the exact mechanisms are still unclear[166, 168, 169]. 
Restoration of a vascular supply, muscle derived stem cells, or growth factors all may be 
targets for tissue engineering interventions of composite injuries. An improved 
understanding of the mechanisms and timing of bone, muscle, and vasculature 
interactions involved in tissue regeneration will be valuable to inform the development of 
multi-tissue interventions. 
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 Composite injury animals had impaired muscle regeneration in addition to the 
impaired bone regeneration. These animals showed decreased muscle mass and impaired 
muscle function compared to single tissue injury animals. The decrease in mass may be 
attributable to a loss in volume from the defect as well as potential muscle atrophy. In the 
bone defect only animals there is a significant decrease in muscle mass potentially as a 
result of decreased limb function or the presence and volume of the fixation plate. The 
decreased muscle mass may account for some of the decreased function; however, in all 
three groups, the relative proportion of muscle mass lost was less than the relative 
decrease in muscle strength. This suggests that there is also a loss of functional capacity 
which may be due to poor muscle structure. Histology of muscle from the composite 
injury animals showed poorly regenerated tissue with fibrosis and lipid deposits. The 
local fibrotic response in the muscle tissue can result in increased local concentrations of 
fibrotic factors, such as TGF-, tissue inhibitor of matrix metalloproteinase (TIMP), and 
chemokine ligand 17 [47, 170]. These factors may reach the bone defect region and could 
direct a fibrotic response instead of bone regeneration [170]. Additionally, the impaired 
muscle function may have an effect on the bone regeneration as muscle atrophy and 
wasting are both associated with negative changes in bone structure and osteoporosis 
[166, 171, 172].  The bone defect itself, however, is largely stress shielded by fixation 
hardware, precluding a direct mechanical loading effect. 
 Composite injury animals showed functional gait deficits in injured limbs 
compared with single tissue injury animals at 2 weeks. By 4 weeks, composite injury 
animals had deficits that were comparable to single tissue injury deficits. These 
functional deficits could have a direct effect on limb usage and ultimately tissue 
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regeneration. A limitation of this technique is that these measurements assess functional 
gait ability (i.e. how well the animal can walk) at a given time but are not necessarily 
indicative of daily limb usage. It is, however, a quantitative functional metric with clear 
clinical relevance. No established model has yet proven to be an effective predictor for 
clinical translation of multi-tissue interventional strategies; however, this composite 
injury model provides a challenging regenerative environment, rigorous and quantitative 
analytical methods, and clinically relevant functional deficits. This model, therefore, has 
unique potential to discriminate between new technologies. 
  There is currently no accepted standard for treatment of composite injuries, 
though debridement of necrotic tissue, prevention of infection, muscle flap coverage, and 
bone grafting are most common [130, 173, 174]. While initial assessment of healing 
using a muscle autograft will be important, additional strategies could utilize novel 
grafting materials such as decellularized muscle tissue, which could be combined with 
controlled spatiotemporal growth factor delivery or progenitor cell delivery. A key 
component to the long term clinical treatment of composite injuries is rehabilitation and 
physical loading (physical therapy); however, this is often neglected in animal models. 
Recently, we demonstrated that properly applied mechanical loading to a bone defect 
could stimulate vascular remodeling and enhance bone regeneration [153, 175]. The 
muscle atrophy and functional deficits observed in this study suggest that a properly 
timed intervention providing physical stimulus to the injured limb may have an effect on 
revascularization and tissue regeneration.   
 In order to further characterize the regenerative cross-talk between the muscle and 
the bone, cells/ECM was analyzed to determine its role in the healing of this model. We 
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delivered an autograft, either whole or morselized, into the quadriceps defect site in the 
composite defect. Previously, it has been shown the morselized autograft could aid in the 
healing of the VML, possibly due to the cells, ECM, and factors present in the graft [41, 
124]. However, in our quadriceps VML model, the morselized autograft did not 
significantly influence the functional outcome [176]. Similarly, our treatment of the 
quadriceps in the composite model did not result in a functional improvement at 12 
weeks post-injury. Because the autograft was delivered immediately into the defect space 
after isolation, it was not possible to characterize the types of cells and ECM present in 
the autograft. This limitation in the autograft treatment prevents a detailed scrutiny of 
what may or may not be present in the graft that could aid in the healing of the defect. 
Though the presence of adult muscle stem cells has been demonstrated to aid in muscle 
regeneration [177, 178], it is difficult to assess exactly how many stem cells were present 
in the autograft and if they survived the transplantation. Additionally, because 
microsurgery was not performed to ensure perfusion of the autograft tissue, it is possible 
that this graft was not viable after implantation.  While the autograft tissue may contain 
multipotent progenitors that could aid in healing as previously shown [179], damaged and 
devitalized muscle tissue is usually debrided in order to prevent infection and minimize 
ectopic bone formation in the traumatized muscle [180, 181]. Leaving dying tissue in the 
body may result in a heightened inflammatory response by the body that may preclude 
any positive regenerative effects that the autograft may have [182, 183]. Thus, our 
autograft treatment may have not had a therapeutic effect and therefore did not positively 
influence the bone healing. 
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 Our investigation into the early revascularization of the defect space yielded 
interesting results that may have implications in the treatment of composite defects. 
Vascularity is known to play a large role in bone repair [184], and vascularized muscle 
flap coverage is often used in the clinic to cover bony defects in order to reduce infection 
rates as well as provide a vascular supply for bone healing [185-188]. Our early 
revascularization data support these claims that vascularization from the muscle is 
important for vascularization of the bone by demonstrating the lack of larger blood 
vessels within the bone defect region in the composite injury group that had reduced 
vasculature from the surrounding muscle. Our results suggest that if we can provide early 
revascularization within the composite defect, we can improve bone regeneration. This 
specific strategy will be investigated in Chapter 5 of this dissertation. 
 This pre-clinical model uniquely combined a segmental bone defect with a 
volumetric muscle injury. The results showed that the increased challenge of concomitant 
muscle injury impaired rhBMP-2 mediated bone regeneration. Impaired limb and muscle 
function were also found, which are similar to clinical observations after severe 
composite tissue injury. We used this model to investigate some possible causes for the 
attenuated bone healing and found that early revascularization may play a role. This 
composite injury animal model provides a platform with which to analyze the 
mechanistic relationship of regeneration between tissues as well as test the efficacy of 
tissue engineering approaches to promote healing in multiple tissues. Such interventions 
may minimize complications and the number of surgical procedures needed for limb 
salvage operations, ultimately improving clinical outcomes. 
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CHAPTER 5  Aim 2: Development and Characterization of the 
Hamstrings VML Model 
5.1 Abstract 
 Volumetric muscle loss injuries are a challenge to treat in the clinic; treatment 
options are limited, and pain and disability are reported a decade after injury. We have 
previously established a VML in the quadriceps of a rat in which a large portion of 
muscle was resected; however, possible nerve or vessel damage and damage to four 
distinct muscles complicate this model and may deter tissue engineering strategies. For 
this study, we aimed to develop a large VML model (>100mg muscle damage) that can 
be used to test therapeutics for their muscle regenerative potential quickly and efficiently. 
We created a 12-mm full-thickness defect in the biceps femoris of a rat and left the defect 
empty (negative control) or treated with an aligned autograft (positive control). We 
tracked muscle regeneration with muscle function, biochemical assays of enzymatic 
activity, and histology up to 8 weeks. Histologically, the negative and positive controls 
differed greatly in appearance, with a very thin fibrotic tissue forming in the empty defect 
and a thick tissue with myofibers in the autograft-treated defect. However, muscle force 
did not show a significant difference in function between the two groups, highlighting 
limitations of muscle function based on the chosen muscle of interest. Micro-CT 
angiography showed significant differences in vascular response between the negative 
and positive controls for muscle regeneration. This model serves as a platform for testing 
tissue engineering strategies and provides insights about the different healing responses 
of varying degrees of muscle regeneration. 
5.2 Introduction 
  Penetrating soft-tissue wounds, the most prevalent of combat extremity injuries, 
often involve extensive loss of skeletal muscle, also known as volumetric muscle loss 
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(VML). These large injuries are first irrigated and debrided to remove necrotic tissues 
and reduce infections, after which a muscle flap can be used to cover the wound in order 
to increase blood flow in the region as well as to reduce the likelihood of further 
infections [17]. Even with treatment of the wound, VML injuries are associated with poor 
long-term outcomes, including motor disability and pain [22, 102]. In light of poor 
functional outcomes, the field of tissue engineering of VML in preclinical models has 
come to fruition in the last decade. 
 Various VML models have been developed within the last half decade in order to 
test different therapeutics [43-46, 72]. While these strategies have contributed some 
success to the healing of muscle, the muscle defects themselves tend to be small (10-20% 
of whole muscle weight) and are not a full-thickness defect that further complicates the 
healing response. In order to capture the severity of clinical VML, our lab has previously 
developed a VML model in the quadriceps of the rat in which an autograft treatment does 
not contribute to functional recovery [176]. This model recapitulates complications in the 
clinic in which muscle flaps, the gold standard treatment for large defects in the muscle, 
may necrotize and require a second reconstructive surgery. 
 Though our quadriceps VML is a large defect that emulates clinical VML 
challenges and can be consistently produced, this model has limitations in its use as a 
tissue engineering test bed. First, the severity and size of the defect and hematomas in the 
days after the surgery suggest that major damage was done to nerves or vasculature in 
this model. While this may emulate the damage seen in the clinic, these injuries add a 
level of complexity to the healing of the defect. Tissue engineering strategies that have 
potential to regenerate muscle may not be able to overcome these other injuries to 
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nervous and vascular tissues. A second limitation lies in the fact that this injury is a full-
thickness injury that spans all four muscles in the quadriceps. Each of these four muscles 
are aligned differently, which makes the creation of a structured construct more 
challenging. Additionally, the quadriceps muscle itself folds in on itself during healing, 
and the defect space itself is hard to discern within a week after injury. 
 Because of these complications in our quadriceps VML model for testing tissue 
engineering strategies, our objective was to develop a simpler VML model that can be 
used to test therapeutics for their muscle regenerative potential quickly and 
efficiently. To do this, we decided to set the following design criteria. First, the muscle 
defect must not damage any major nerves or vessels so that the model will not be 
complicated by injury to these other tissues. Second, the muscle defect should ideally be 
a full-thickness defect created in one muscle in which the myofibers are approximately 
parallel. We posit that this will allow for ease of alignment should the therapeutic aim to 
reproduce muscle structure. Third, the empty defect should allow for minimal muscle 
regeneration while the autograft-treated defect should result in some muscle regeneration. 
This would allow for the empty defect to serve as a negative control for muscle 
regeneration and the autograft-treated defect to serve as a positive control. 
 The muscle we decided to choose for this VML model was the biceps femoris, a 
muscle group that spans from the hip to the tibia in the rat. The biceps femoris is a 
muscle that is part of the hamstrings, which also includes the semitendinosus and 
semimembranosus muscles and serves as a knee flexor. This muscle meets the first 
criterion, where we can confirm that the nearby major nerve (tibial nerve) is not damaged 
upon defect formation. Additionally, we did not note a high rate of hematoma formation 
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when the defect was created. This muscle meets the second criterion in that the defect 
would be in one muscle, and the muscle fibers are mostly parallel despite their fanning 
out from the hip inserts to the tibial insert that spans the entire length of the tibia. The 
muscle is distinctly separate from the surrounding muscles, and a full-thickness defect 
can be created in the biceps femoris easily. Additionally, the biceps femoris offer the 
advantage of being superficial, allowing the creation of the defect with very little damage 
to any other muscles. The biceps femoris is also a thin muscle, ranging from 1 to 5 
millimeters thickness, depending on the location of the tissue. This reduces the 
complexity of the defect, and flatter constructs can be tested in this model prior to scaling 
the construct into a more three-dimensional structure, which has its own challenges such 
as perfusion for survival at the construct center.  
 It remains to be seen whether the biceps femoris will satisfy the third criterion, in 
which the empty defect and autograft-treated defect could serve as the negative and 
positive controls respectively. Thus, the question in this study is to determine the muscle 
regeneration in empty and autograft-treated biceps femoris VML. The hypothesis is that 
the empty treated biceps femoris will result in minimal muscle regeneration while the 
autograft-treated biceps femoris would result in regenerated muscle with little fibrosis. 
5.3 Materials/Methods 
Surgical Procedure 
 Bilateral surgeries were performed on 13-week female Sprague-Dawley rats. To 
create the defect, a plastic spatula was inserted between the biceps femoris and the deeper 
hamstrings muscles after blunt dissection, carefully avoiding the sciatic nerve. A 12-mm 
biopsy punch was used to create a full-thickness muscle defect with the plastic spatula 
serving as a firm base for the biopsy punch and to protect underlying tissue. The defect 
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was either left empty (with 4 suture markers placed near the defect margins) or treated 
with an autograft (with the cut tissue attached back on the defect with 8 sutures). Animals 
were euthanized at 2, 4, 6, and 8 weeks post-injury. 
Muscle Force Measurements 
 A custom muscle force apparatus was used to measure the hamstrings force in 
vivo at 2 and 4 weeks post-injury. All measurements were made under isoflurane 
anesthesia during a terminal procedure immediately prior to euthanasia. A 1-cm long 
incision was made through the skin exposing the anterior biceps femoris and gluteus 
maximus. The tibial branch of the sciatic nerve was carefully isolated, and a nerve cuff 
was placed securely on this nerve branch. The knee was stabilized with a needle passed 
through the distal femur, anchoring it to a cork board platform onto which the animal was 
securely fixed for the duration of these tests.  The animal was placed in a prone position, 
and the knee and base of the tail were securely anchored into the cork board with needles. 
The ankle was secured to a force transducer (Isometric Transducer Model No. 60-2996, 
Harvard Apparatus) using a suture. A nerve cuff implanted on the tibial branch of the 
sciatic nerve allowed electrical stimulation and subsequent contraction of the hamstrings 
muscle with the use a stimulator (GRASS S11 Stimulator, Grass Technologies). 
Stimulator pulse duration, frequency, and train duration were set to 0.5 ms, 200 Hz, and 
500 ms, respectively; these settings elicited maximal isometric tetanic force as 
determined in a pilot study. Hamstrings muscle torque was determined by multiplying the 
maximal isometric tetanic force by the moment arm length. 
Micro-CT Angiography 
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 At 2 and 4 weeks post-injury, contrast agent-enhanced micro-CT angiography 
was performed terminally on animals from both groups (n=6).  The technique has been 
previously described in detail [153-155]. Briefly, 0.9% salt solution (physiological saline) 
containing 0.4% papaverine hydrochloride (Sigma-Aldrich) was perfused through the 
vasculature to clear the blood vessels. The vasculature was then perfusion fixed with 10% 
neutral buffered formalin, rinsed with physiological saline, and injected with lead 
chromate-based radioopaque contrast agent (2 parts microfil MV-22: 1 part diluent, Flow 
Tech). Samples were stored at 4°C overnight to allow for polymerization of the contrast 
agent. The biceps femoris was excised, and the defect region (marked with sutures) was 
isolated. For contralateral control legs, a 12-mm biopsy punch was used to remove a 
similarly-sized piece of uninjured muscle. 
 Excised samples were further fixed for 48 hours then stored in PBS. Samples 
were scanned in the micro-CT (vivaCT 40, Scanco Medical) with a resolution of 21µm 
voxel size. All scans were performed with an applied electroc potential of 55 kVp and a 
current of 109 µA. The VOI consisted of a cylindrical volume 14.7mm in diameter that 
spanned the full thickness of the biceps femoris. A global threshold was applied for 
segmentation of vasculature, and a Gaussian low-pass filter was used to suppress noise (σ 
= 0.8, support = 1). 
Muscle Homogenization 
 At 2, 4, 6, and 8 weeks, animals were euthanized (n=6 per time point per group), 
and the defect area was harvested using a 12-mm biopsy punch as during the initial 
surgery. The harvested tissue was immediately weighed, flash-frozen in liquid nitrogen, 
and stored at -80°C until homogenization. 
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 For homogenization, tissues were removed from -80°C, cut with a razor blade 
into small pieces, then manually homogenized with a tissue grinder (Duall
TM
 tissue 
grinders, Kimble-Chase Kontes). Samples were homogenized in 100mM potassium 
phosphate buffer (pH 7.4) at a ratio of 400µL of buffer for every 50mg of tissue. The 
homogenate was then separated into 5 equal volumes for analysis of creatine kinase 
activity, citrate synthase activity, and quantification of myosin/actin, triglycerides (fat), 
and hydroxyproline (collagen) content. Homogenates were frozen and stored at -80°C. 
Creatine Kinase (CK) Activity 
 The activity of creatine kinase, a metabolic enzyme that is specifically present in 
tissues with high consumption of energy such as skeletal muscle, was measured to 
determine the extent of skeletal muscle regeneration. A creatine kinase activity assay kit 
was used (Cat# MAK116, Sigma-Aldrich). Homogenate samples were centrifuged at 
10,000 x g for 15 minutes, and the cleared supernatant was used for the assay. For each 
assay, reagent consisting of 100 µL assay buffer, 10 µL substrate solution, and 1 µL of 
enzyme mix were used with 10 µL of sample. Blank (110 µL of water) and calibrator 
(100 µL water with 10 µL calibrator) wells were used per plate. Samples were mixed 
with the assay reagent in a UV-96-well plate and incubated at 37°C for 20 minutes. After 
20 minutes, the initial absorbance was read at 340nm. The plate was further incubated at 
37°C for an additional 20 minutes after which a final absorbance measure was read at 
340nm.  
Citrate Synthase Activity 
 Muscle homogenates were freeze-thawed 3 times and diluted (1:7) in 100mM Tris 
buffer (pH 8.0) prior to running the assay. 5.18µL of the diluted sample was added to the 
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143.59 µL of 100mM Tris buffer, 20.5 µL 1.0mM 5,5'-dithio-bis(2-nitrobenzoic acid) 
(DTNB) in 100mM Tris buffer, and 10.25 µL 3mM acetyl CoA in 100mM Tris buffer. 
The assay reaction was started by adding 20.5 µL of 5mM oxaloacetic acid in 100mM 
Tris buffer. Solutions were warmed up to 30°C prior to the assay, and the assay was 
carried out at 30°C. The spectrophotometer (BioTek PowerWave XS) was programmed 
to delay for 2 minutes prior to running a kinetic program to take OD readings at 412nm 
every 15 seconds for 3 minutes. The CS activity was calculated using the following 
equation: 
 
where ΔA/min is the change in absorbance, Vrxn is the volume of the assay reaction 





is the light path length (0.552cm for 0.2mL in a 96-well plate), Vsample is the volume of 
the sample used in the assay, Vbuffer is the volume of homogenizing buffer, wtmuscle is the 
weight of the homogenized muscle in g, and δ is the density of muscle (1.06g/mL). 
MHC/Actin Quantification 
 Samples were centrifuged at 5,000 x g for 15 minutes, and the supernatant was 
removed. The pellets were resuspended in 400µL of 100mM potassium chloride and 
20mM imidazole (pH 7.0). 10µg of the sample was run in a NuPAGE 4-12% Bis-Tris 
precast gel (Life Technologies), and the gels were dyed in a Coomassie Blue solution for 
1 hour. Gels were destained overnight and imaged with Bio-Rad Gel Doc XR. 
Histology 
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 Transverse muscle sections taken approximately from the middle of the muscle 
defect were stained with H&E and Masson's trichrome for morphological analysis. 
Representative histology was performed at 2, 4, 6, and 8 weeks post-injury. 
Statistics 
 As none of the measurements were longitudinal (i.e. made from the same animal 
across time), the independent samples were tested for statistically significant differences 
with two-way ANOVAs (time x treatment) with consequent pair-wise comparisons using 
the Šídák method. 
5.4 Results 
Enzyme Activities 
 Creatine kinase (CK) and citrate synthase (CS) activities were determined as a 
measure of metabolic activity. While creatine kinase is an enzyme that is predominantly 
present in skeletal muscle, citrate synthase is an important enzyme within the citric acid 
cycle and is present within all cells, though activity will be higher in tissues with higher 
metabolic activity. Creatine kinase activity was measured to be at a consistent level for 
control right legs, and both injured groups (autograft-treated and empty) resulted in a 
significant decrease of CK activity (Figure 21). On the other hand, citrate synthase 
activity was significantly lower in both injured groups only at 2 weeks post-injury. At 4, 
6, and 8  weeks post-injury, the autograft-treated group had a significantly higher citrate 
synthase activity compared to the empty defect group and comparable CS activity as the 
uninjured control group.  
 85 
 
Figure 21: Enzyme Activities of Defect Tissue after Biceps Femoris VML. Creatine 
kinase activity of the defect area was consistent among the right leg controls, and the 
autograft-treated and empty defect groups had significant lower CK activity than the right 
leg controls. Citrate synthase activity was also consistent among the right leg controls. 
Both the empty defect and  autograft-treated group had significantly lower CS activities 
compared to uninjured controls at 2 weeks post-injury. The autograft-treated group had 
an increased CS activity from 4 weeks post-injury onwards, with significantly higher CS 
activity compared to empty defects. *p<0.05, n=6 for autograft-treated and empty groups, 
n=12 for contralateral controls. 
 
Muscle Functional Outcome 
 At 2 and 4 weeks post-injury, the hamstrings muscle maximal tetanic torque was 
significantly lower in the injured groups (both empty and autograft-treated) as compared 
to the contralateral control muscles (Figure 22A). Examining the spread of the data, the 
range of the measured muscle forces from the injured groups spanned about 100 to 150 
gram-force (Figure 22B). The uninjured hamstrings muscle produced an average of 250 
gram-force. Representative torque curves of the hamstrings functional testing show 
tetanic stimulation was achieved (Figure 22C & D). 
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Figure 22: Hamstrings Muscle Function. Panel A shows hamstrings torque in the 
empty and autograft-treated groups were significantly lower than the torque produced by 
the uninjured contralateral control at 2 weeks post-injury. Panel B shows the spread of 
the muscle force data (same data as Panel A). Panels C and D show representative torque 
curves at 2 and 4 weeks post-injury respectively. p<0.05, n=5-6 per injured group per 
time point, n=21 for contralateral controls. 
 
Biceps Femoris Revascularization 
 Defect site revascularization was found to be significantly higher in both injured 
groups compared to the uninjured contralateral control (Figure 23). The autograft-treated 
groups had a significantly higher vascular volume at 2 and 4 weeks post-injury compared 
to the empty defect group. Representative images show the autograft-treated group had 
more smaller vessels and slightly thicker large vessels compared to the empty group.  
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Figure 23: Defect Revascularization 2 and 4 weeks post-injury.The revascularization 
of the defect site in the biceps femoris was determined by micro-CT angiography at 2 and 
4 weeks post-injury. The vascular volume was significantly higher in the autograft-
treated group compared to the empty defect group at both 2 and 4 weeks post-injury. All 
injured groups at all time points had a significantly higher vascular volume compared to 
the uninjured contralateral controls. Representative images of defect vasculature are 
shown with heat maps showing vessel diameter. *p<0.05 compared to empty and control. 




 H&E and Masson's trichrome stained sections showed very different healing 
responses by the empty defect and autograft-treated defect. In the empty defect, a thin 
connective tissue was left within the defect space with no myofibers present at the center 
of the defect at 2 weeks post-injury (Figure 24A-D & Figure 25A-D). This minimal 
regeneration in the empty defect group persisted through to 4 weeks post-injury, in which 
the tissue at the center of the defect consisted of vascularized fibrotic tissue (Figure 26 A-
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D & Figure 27 A-D). At  6 weeks post-injury, the empty defect group was infiltrated by 
fatty tissue (Figure 28A-D), and at 8 weeks post-injury, the defect area was thin with 
sparse areas of myofibers (Figure 29A-D). On the other hand, the autograft-treated group 
had thick tissue at the defect site, with distinct connective tissue deposition around the 
autograft site at 2-weeks post-injury (Figure 24 E-H & Figure 25 E-H). By 4 weeks post-
injury, the autograft-treated group had very little fibrosis and was mostly populated by 
myofibers (Figure 26 E-H & Figure 27 E-H). At 6 weeks post-injury, the representative 
autograft-treated section had some fatty infiltrate (Figure 28 E-H), though by 8 weeks, 
there was no sign of muscle injury in the autograft-treated muscle (Figure 29 E-H). 
  
 
Figure 24: H&E Histology at 2 weeks post-injury. Cross-sections of the entire biceps 
femoris show a thin defect space in the empty defect group (A) and a thick defect area in 
the autograft-treated group (E). Panels B, C, and D are enlarged images that correspond 
to the colored blocks in Panel A. Panels F, G, and H are enlarged images that correspond 





Figure 25: Masson's Trichrome Histology at 2 weeks post-injury. Blue staining shows 
connective tissue (i.e. fibrosis, collagen) while red staining shows muscle cells. A 
representative muscle from the empty defect group showed mostly connective tissue 
filling the defect space (A). Panels B, C, and D are enlarged images that correspond to 
the colored blocks in Panel A. The autograft-treated group showed connective tissue 
surrounding the autograft (E). Panels F, G, and H are enlarged images that correspond to 





Figure 26: H&E Histology at 4 weeks post-injury. The empty defect group showed 
very little muscle regeneration, with a thin tissue lacking in muscle cells in the center of 
the defect (A). Panels B, C, and D are enlarged images that correspond to the colored 
blocks in Panel A. The autograft-treated group showed predominantly regenerated 
muscle at 4 weeks post-injury (E). Panels F, G, and H are enlarged images that 
correspond to the colored blocks in Panel E. Red-dotted lines show approximate location 
of the defect space. 
 
 
Figure 27: Masson's Trichrome Histology at 4 weeks post-injury. Only a thin 
connective tissue stretched across the defect in the empty defect group, with no signs of 
muscle fibers in the center  (A). Panels B, C, and D are enlarged images that correspond 
to the colored blocks in Panel A. The autograft-treated group showed very little fibrosis 
and connective tissue at 4 weeks post-injury (E). Panels F, G, and H are enlarged images 
that correspond to the colored blocks in Panel E. Red-dotted lines show approximate 




Figure 28: H&E Histology of Biceps Femoris at 6 weeks post-injury. The middle of 
the empty defect at 6 week post-injury was thin with some fatty infiltrate  (A). Panels B, 
C, and D are enlarged images that correspond to the colored blocks in Panel A. The 
autograft-treated group showed very little fibrosis, with a little bit of fatty infiltrate. (E). 
Panels F, G, and H are enlarged images that correspond to the colored blocks in Panel E. 




Figure 29: H&E Histology of Biceps Femoris at 8 weeks post-injury. The empty 
defect group had mostly connective and fatty tissue in the center of the defect except for a 
small area of myofibers in the center  (A). Panels B, C, and D are enlarged images that 
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correspond to the colored blocks in Panel A. The autograft-treated group had no signs of 
injury at 8 weeks post-injury (E). Panels F, G, and H are enlarged images that correspond 
to the colored blocks in Panel E. Red-dotted lines show approximate location of the 
defect space. 
5.5 Discussion 
 We have developed the first volumetric muscle loss model in the rat biceps 
femoris. In this model, the empty defect resulted in a thin connective tissue filling the 
defect space up to 8 weeks post-injury, serving as a good negative control for muscle 
regeneration. An autograft-treated defect resulted in thick tissue at the defect site with 
myofibers and very little fibrosis, serving as a good positive control for muscle 
regeneration based on histology. Additionally, this model has the added benefits of ease 
of access to the muscle defect site and the ability to test thinner constructs, as this defect, 
though full-thickness, is within a 1-5mm thick muscle. We present this model as a good 
test bed for tissue engineering strategies focused on muscle regeneration. 
 This empty VML defect is unique in that it has a distinct lack of muscle 
regeneration in the center of the defect. Many VML models involve damage to only half 
a muscle or a full-thickness defect in one muscle in a muscle group. In both cases, the 
muscle defect is in close contact to other muscles that can contribute cells or factors 
directly to the defect site. In this biceps femoris defect, on the other hand, the defect itself 
is a full-thickness defect in the muscle with no closely linked muscles surrounding it. 
Because of this, the thickness of the tissue at the center of the empty defect was 
consistent and was a good indication of muscle regeneration or lack thereof.  
 This is the first VML model in which a positive control of muscle regeneration is 
presented, with a large difference in healing response between the negative and positive 
controls. This positive control treatment is reminiscent of the clinical gold standard 
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treatment of VML; however, there are distinct differences between this autograft 
treatment presented here and clinical treatments. In this positive control, the defect was 
sutured directly into the defect site with relatively aligned myofibers. This represents the 
ideal case for an autograft treatment and is obviously not possible in traumatic VML 
injuries in humans. Clinically, a large muscle defect would be treated with coverage of 
the area with a local or free muscle flap with different alignment and fiber density from 
the injured muscle [14]. Vascular reconstruction typically accompanies this muscle flap 
therapy to maintain perfusion in the flap. This type of microsurgical capability would be 
very difficult to achieve in a rodent model and was not performed in this study. 
Additionally, muscle flaps are used to cover the defect site, not to necessarily replace the 
empty defect site with tissue, and are limited in availability and restricted in applicability. 
The autograft treatment was specifically sutured into the empty space left by the defect 
and meant to directly replace the cells and structural proteins within the defect space, 
minimizing the distance stem cells would need to traverse to reach the injured area. 
Though the autograft treatment was similar to the muscle flaps used for human VML, the 
differences in the application of the muscle tissue between these two treatments suggest 
that the mechanisms by which they aid in muscle regeneration may differ as well. 
 It was observed in this study that despite the lack of vascular reconstruction to re-
connect the defect autograft tissue to the surrounding muscle, the autograft treatment still 
induced a vascular response that is greater than that of an empty defect. Clinically, it is 
well known that vascularization plays a role in maintaining muscle flap viability, as 
demonstrated by the movement towards using perforator-based flaps to maintain 
perfusion within flaps [189-191]. Preclinical studies have also shown the importance of 
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vascularization for the integration and successful implantation of graft materials [86, 87]. 
The high vascularity seen in the autograft-treated group  may have increased the 
likelihood of the autograft survival within the hamstrings defect. While this study did not 
delve into specific mechanisms by which vascularization may play a role in muscle 
regeneration, this difference in vascular response between and empty and autograft 
groups may have implications on how much tissue can regenerate and maintain viability 
within the defect space. In addition to maintaining the viability of the graft and defect 
area, the higher vascularization in the autograft-treated group may increase nutrient and 
waste transport, allow access to the defect site for circulating cells, and facilitate graft 
innervation [11]. Studies that deliver a vascular supply to the defect space may help 
determine if and how the increased vascularization may aid in muscle regeneration in this 
model. 
 In contrast to the difference in vasculature in the two groups, the muscle function 
was similar in both groups at 2 and 4 weeks post-injury. This was a surprising result 
given the stark differences in tissue appearance as well as the histological differences 
between the two tissues at each time point. While the autograft-treated defect appeared to 
be regenerated by 4 weeks based on histology images, there is still a large difference 
between the function of this tissue from the contralateral uninjured control. More 
importantly, while the empty defect appeared to have very little tissue at the defect area 
with no signs of regenerating myofibers at the center of the defect, hamstrings 
stimulations still generated comparable force to the autograft-treated group. One possible 
explanation for this is the effect of the defect on the physiological cross-sectional area 
(PCSA) of the stimulated muscles. The PCSA is closely related to the maximum muscle 
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tetanic force, and the PCSA can be used to accurately estimate the maximum tension a 
muscle can create [192]. The tibial branch of the sciatic nerve stimulates the biceps 
femoris and the semimembranosus, both of which would affect the readings in the force 
measurements. Though the defect volume and mass may be large in the biceps femoris 
defect, the cross-sectional area of the defect space is actually relatively small due to the 
thinness of the biceps femoris. Combined with the semimembranosus PCSA, the 
reduction in the PCSA by the defect may not be a large enough one to detect in functional 
force measurements. Moreover, the semimembranosus muscle may act as both a flexor 
and extensor in different conditions, which could potentially complicate the force 
readings [193]. 
 The hamstrings force measurements were vastly different from the quadriceps 
force measurements, in which the 8-mm full thickness defect resulted in a drastic 
reduction of muscle force. The uninjured quadriceps muscle produced a force about twice 
the maximal force produced by the hamstrings muscle. This is because of the anatomical 
differences between these muscles. The quadriceps muscles have large PCSAs and 
shorter fibers, allowing for the generation of greater forces. The hamstrings muscles, on 
the other hand, have intermediate PCSAs and longer fibers, allowing for larger 
excursions [194, 195]. Thus, while both the hamstrings and quadriceps muscle force 
measurements have a comparable amount of variability, the quadriceps model has a large 
enough range to allow for the detection of force differences between treatments. The 
hamstrings stimulations, on the other hand, would require a much larger sample size to 
find a significant difference between the negative and positive controls for muscle 
regeneration. 
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 In order to fully characterize the healing of the muscle defect, this study made use 
of biochemically analyzing enzyme activity and protein content from the tissue within the 
injured area to determine the degree of muscle regeneration at the defect site. Creatine 
kinase (CK) is an enzyme that catalyzes the reaction in which adenosine triphosphate 
(ATP) is used to convert creatine into phosphocreatine. This enzyme is found in highly 
metabolic tissues, especially skeletal muscle. CK has been traditionally measured in 
serum as a sign of myocardial infarction or muscular dystrophy [196, 197]. However, it 
has been used to characterize muscle regeneration in a minced muscle model in the rat 
tibialis muscle [198]. Although there is an initial decrease in CK activity within the first 
week of surgery, the activity increases as regeneration occurs through the next five 
weeks. While our study did not include early readings that would be required to see the 
initial decrease, CK activity was seen to increase slowly over time in the autograft-treated 
group, as expected of healing muscles after injury. The CK activity for the empty defect 
group rose slightly up to 6 weeks and decreased slightly at 8 weeks. Notably, the empty 
defect group and the autograft treated group did not have significantly different CK 
activity at 2, 4, 6, or 8 weeks post-injury. This is in agreement with our muscle function 
data in which the two groups also did not differ in maximal tetanic torque at 2 and 4 
weeks post-injury. 
 On the other hand, citrate synthase activity, which is an indication of the 
metabolic activity of the tissue, showed a different result, with the autograft-treated group 
improving to the level of uninjured controls by 4 weeks post-injury. Citrate synthase (CS) 
is a protein within the citric acid cycle that is necessary for cell metabolism and is present 
in all cells. However, tissues with higher metabolic activity will have a higher citrate 
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synthase activity. This CS activity matches the muscle histology much more closely than 
the CK activity, which may be due to the amount of tissue within the defect area. Even 
though both are indicative of muscle bioenergetics, studies have shown that the 
phosphocreatine utilization in skeletal muscle, which is usually catalyzed by creatine 
kinase, is still present in CK-deficient mice [199]. This suggests that muscle can still have 
a relatively high metabolic activity through the phosphocreatine system even without CK. 
This could help explain the differences between CS and CK activity in the autograft-
treated group; while CK activity was lower in the autograft-treated group, the muscle 
metabolic activity may still be high, accounting for the high CS activity. 
  In summary, this work established a new VML model in the biceps femoris of the 
rat that shows stark differences in tissue make-up histologically. While this model is 
limited in its ability to measure differences in muscle function in vivo across the different 
treatment groups, histology can easily be used to determine myofiber or fibrosis 
formation within the defect area. With the disparity in appearance between the negative 
(empty defect) and positive (autograft treatment) controls for muscle regeneration, the 
muscle regeneration of a treatment can be determined by comparing its thickness and 
cellular make-up with the two controls. Additionally, by comparing the negative and 
positive controls, insights into the differing healing responses may be elucidated. In this 
study, we found that revascularization of the defect site was different between the two 
groups, indicating that this may be one of the reasons behind the dissimilar regenerative 
responses. Further work is needed to fully determine the effect of revascularization on the 
healing of the biceps femoris defect, and this work will be outlined in part 2 of this 
chapter. 
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CHAPTER 6  Aim 2: Treatment of the Biceps Femoris VML Model 
with Microvessels 
6.1 Abstract 
 Large skeletal muscle injuries, such as volumetric muscle loss, result in a large 
defect space devoid of vasculature and cells. Vascularization is thought to play a crucial 
role in muscle regeneration in maintaining graft viability and eventual integration. 
Microvascular constructs have been shown to form vascular networks in vitro that can be 
facilitated by co-culture with myoblasts. This study aimed to evaluate the ability of these 
microvascular constructs, with or without myoblasts, to induce early revascularization of 
the defect space and to regenerate muscle. When grown in vitro, the microvessels co-
cultured with myoblasts resulted in faster sprouting of vessels and fuller networks than 
microvessels alone. When implanted, the two groups resulted in similar vascular 
volumes, though the microvessels with myoblasts group had a significantly higher 
vascular volume compared to an empty defect. Despite the increased vascular volume, 
both groups resulted in very little tissue in the defect space at 8 weeks post-injury. At 2 
and 4 weeks post-injury, the defect spaces in both the microvessels and microvessels + 
myoblasts groups were partially occupied with fat. While vascularization may play a role 
in muscle regeneration, the findings of this study suggest that other factors that influence 
muscle regeneration may have a larger effect than vascularization alone. 
6.2 Introduction 
 The majority of extremity injuries are penetrating soft-tissue wounds involving 
extensive damage to the muscle, also known as volumetric muscle loss (VML). In VML 
injuries, a large section of muscle is damaged and debrided, resulting in a large volume of 
space devoid of vasculature and stem cells. The gold standard for VML injuries is 
coverage of the damaged area with local vascularized muscle flaps; however, these flaps 
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tend to be thin and are not always readily available . With a large VML, it would be 
difficult to find a sufficient amount of viable, vascularized muscle near the defect to serve 
as a local muscle flap. Additionally, a muscle flap is only a coverage strategy; there is 
currently no means of replacing injured muscle with a functional unit that can maintain or 
restore normal function [30]. 
 In a large defect like VML, vascularization is of great importance. Intact skeletal 
muscle is highly vascularized, with capillary to muscle fiber ratios of around 1.5 [200, 
201]. Studies have shown that delayed angiogenesis and VEGF production impairs 
skeletal muscle regeneration after cardiotoxin damage [202]. For skeletal muscle to be 
regenerated, a vascular source must be present early in the healing stages in order to 
provide nutrients, cells, and guidance to the center of the defect site. In trying to develop 
tissue engineering strategies towards repairing VML, a major challenge that arises is the 
issue of transport to the center of the scaffold, where the lack of vascularization and 
nutrient/waste transport will likely lead to necrosis and poor survival of delivered cells or 
tissues [11]. Recent research into vascularized muscle constructs highlights the benefits 
of early vascularization for survival and eventual functional integration of the graft to 
skeletal muscle [86, 87].  
 One promising strategy of creating vascular networks in vitro that are readily 
implantable involves microvascular constructs (MVC) in which intact microvessel 
segments are isolated and suspended in collagen type I gel. Adipose-derived microvessels 
(or microvascular fragments) can be grown in a collagen gel in vitro, and within 7-12 
days of culture, the freshly isolated microvessels grow into vascular networks within the 
collagen [203]. When implanted into a mouse subcutaneous model, these constructs have 
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integrated with the tissue and produced viable perfusion-capable blood vessels within a 
week of implantation [204]. Freshly isolated microvascular fragments have been 
transplanted into a VML in the TA of a rat and were shown to increase perfusion in the 
defect site over an empty and cellular control [205]. Though freshly isolated fragments 
have the advantages of immediate transplantation and maintenance of tissue phenotype 
with no time in culture, there may be advantages in growing the microvascular networks 
in vitro as well. Studies have shown that pre-existing microvascular networks facilitate 
revascularization due to inosculation of host vessels to the preformed vascular network 
and the network's angiogenic effect on the surrounding tissue [206]. Thus, there may be a 
benefit of implanting microvessels that are grown in vitro to form networks that can then 
inosculate in vivo. 
 While microvascular constructs hold potential in regenerative medicine, its effects 
could be compounded by the addition of satellite cells. Satellite cells, also known as 
myoblasts when cultured in vitro, are adult muscle precursor cells that reside adjacent to 
skeletal muscle fibers [207]. Rhoads et al. showed that microvascular constructs (i.e. 
microvascular fragments in collagen gel) cultured over a rat myoblast monolayer resulted 
in greater sprout numbers and lengths than a fibroblast monolayer control after 5 days in 
culture [208]. In the same study, by culturing microvessels in media pre-conditioned by 
myoblasts, it was found that the effect that the myoblasts had on the microvascular 
fragments was due to a paracrine effect. Additionally, by adding VEGF receptors that 
directly competed for and blocked VEGF activity, the myoblast-mediated angiogenic 
effects were reduced, suggesting that VEGF may play a large role in the growth of the 
microvessels.  
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 Not only would the addition of myoblasts be beneficial to the growth and 
networking of microvascular fragments, the myoblasts themselves could play a role in 
muscle regeneration. In fact, recent studies have shown that Pax-7+ satellite cells are 
crucial for muscle regeneration after a cardiotoxin injury. Conditional depletion of Pax-
7+ satellite cells in a transgenic model resulted in failure to regenerate muscle, which 
were replaced with inflammatory cells and adipocytes [209, 210]. This reduced muscle 
regeneration was rescued after transplantation of Pax-7+ satellite cells. Satellite cell 
implantation for Duchenne muscular dystrophy resulted in fusion of the implanted cells 
with host fibers. However, the attempt at translating this treatment failed due to poor 
survival and migration of donor cells after transplantation [85]. Implantation of the 
myoblasts with the rapidly inosculated microvascular networks could also benefit the 
myoblasts by aiding in the survival and migration, especially when used as a therapy for a 
large defect like VML. 
 While microvascular fragments have been implanted subcutaneously as well as in 
a VML model with success with inosculation with host vessels, it is unclear if 
vascularization is indeed a road block for effective muscle regeneration. Additionally, 
microvascular constructs with myoblasts may increase the vascular response as well as 
provide vital muscle stem cells to the defect area but have yet to be tested for its 
regenerative potential in large muscle injuries. Thus, our objective was to determine the 
effects of a pre-formed microvascular construct with myoblasts on the revascularization 
and muscle regeneration of a VML defect. We hypothesized that treatment of the VML 
defect with these constructs will yield a higher revascularization in the muscle defect at 




 Myoblasts were isolated from GFP-transgenic Sprague Dawley rats. The soleus 
muscle was carefully isolated from each leg, weighed, and placed in a small volume of 
sterile PBS. The tissue was washed in sterile PBS and placed into 0.2% collagenase XI 
(6mL for every 2 muscles). The tissue was minced manually using tow sterile razor 
blades for 5 minutes and transferred into a 15mL conical tube. The tube was incubated in 
a 37°C water bath and incubated for 60 minutes, mixing once halfway through the 
incubation. Collagenase was then removed, and the homogenate was incubated in 6mL/2 
muscles of dispase (2.4U/mL) at  37°C for 45 minutes. The dispase was then removed, 
and the cells were resuspended in growth medium (F10, 20% FBS, 1% 
penicillin/streptavidin, and 2.5ng/mL bFGF). The cells were then passed through a 
100µm strainer (Steriflip, Millipore) and pre-plated for 30minutes to obtain a myoblast-
enriched population. 
Microvessel Isolation 
 Epididymal fat was isolated from Sprague-Dawley retired breeder rats. The fat 
was minced and digested with collagenase, after which vessels smaller than 500 microns 
and larger than 20 microns were isolated through filters. The microvessels were then 
suspended in a collagen gel (3mg/mL, 150,000 microvessels/mL + 10
6
 myoblasts/mL) 
around a polycaprolactone nanofiber mesh and cultured in vitro in serum-free media for 4 
days prior to implantation (Figure 30C & D). 
Surgical Procedure 
 Unilateral biceps femoris defect surgeries were performed on 13-week-old female 
Sprague-Dawley rats. A plastic spatula was inserted next to the medial aspect of the 
 103 
biceps femoris, providing a hard surface on which a 12-mm diameter biopsy punch was 
applied to the muscle’s lateral aspect to create the full-thickness circular defect (Figure 
30B). The defect was left empty (negative healing control), treated with an autograft 
(gold standard control), treated with a microvessel construct (microvessels group), or 
treated with a microvessel construct with myoblasts (microvessels + myoblasts group).  
µCT Angiography 
 At 2 weeks post-injury, contrast agent-enhanced micro-CT angiography was 
performed terminally on animals from the microvessels and the microvessels + myoblasts 
groups (n=5-6).  The technique has been previously described in detail [153-155]. 
Briefly, 0.9% salt solution (physiological saline) containing 0.4% papaverine 
hydrochloride (Sigma-Aldrich) was perfused through the vasculature to clear the blood 
vessels. The vasculature was then perfusion fixed with 10% neutral buffered formalin, 
rinsed with physiological saline, and injected with lead chromate-based radioopaque 
contrast agent (2 parts microfil MV-22: 1 part diluent, Flow Tech). Samples were stored 
at 4°C overnight to allow for polymerization of the contrast agent. The biceps femoris 
was excised, and the defect region (marked with sutures) was isolated. For contralateral 
control legs, a 12-mm biopsy punch was used to remove a similarly-sized piece of 
uninjured muscle. 
 Excised samples were further fixed for 48 hours then stored in PBS. Samples 
were scanned in the micro-CT (vivaCT 40, Scanco Medical) at 21µm voxel size. All 
scans were performed with an applied electroc potential of 55 kVp and a current of 109 
µA. The VOI consisted of a cylindrical volume 14.7mm in diameter that spanned the full 
thickness of the biceps femoris. A global threshold was applied for segmentation of 
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vasculature, and a Gaussian low-pass filter was used to suppress noise (σ = 0.8, support = 
1). 
Muscle Homogenization 
 At 2, 4, 6, and 8 weeks, animals were euthanized (n=6 per time point per group), 
and the defect area was harvested using a 12-mm biopsy punch. This defect area tissue 
was measured to obtain a wet weight, flash-frozen in liquid nitrogen, and stored at -80°C 
until homogenization. 
 For homogenization, tissues were removed from -80°C, cut with a razor blade 
into small pieces, then hand-homogenized with a tissue grinder (Duall
TM
 tissue grinders, 
Kimble-Chase Kontes). Samples were homogenized in 100mM potassium phosphate 
buffer (pH 7.4) at a ratio of 400µL of buffer for every 50mg of tissue. The homogenate 
was then separated into 5 equal volumes for analysis of creatine kinase activity, citrate 
synthase activity, and quantification of myosin/actin, triglycerides (fat), and 
hydroxyproline (collagen) content. Homogenates were frozen and stored at -80°C. 
Citrate Synthase Activity 
 Muscle homogenates were freeze-thawed 3 times and diluted (1:7) in 100mM Tris 
buffer (pH 8.0) prior to running the assay. 5.18µL of the diluted sample was added to the 
143.59 µL of 100mM Tris buffer, 20.5 µL 1.0mM 5,5'=dithio-bis(2-nitrobenzoic acid) 
(DTNB) in 100mM Tris buffer, and 10.25 µL 3mM acetyl CoA in 100mM Tris buffer. 
The assay reaction was started by adding 20.5 µL of 5mM oxaloacetic acid in 100mM 
Tris buffer. Solutions were warmed up to 30°C prior to the assay, and the assay was 
carried out at 30°C. The spectrophotometer (BioTek PowerWave XS) was programmed 
to delay for 2 minutes prior to running a kinetic program to take OD readings at 412nm 
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every 15 seconds for 3 minutes. The citrate synthase (CS) activity was calculated using 
the following equation: 
 
where ΔA/min is the change in absorbance, Vrxn is the volume of the assay reaction 





is the light path length (0.552cm for 0.2mL in a 96-well plate), Vsample is the volume of 
the sample used in the assay, Vbuffer is the volume of homogenizing buffer, wtmuscle is the 
weight of the homogenized muscle in g, and δ is the density of muscle (1.06g/mL). 
MHC/Actin Quantification 
 Samples were centrifuged at 5,000 x g for 15 minutes, and the supernatant was 
removed. The pellets were resuspended in 400µL of 100mM potassium chloride and 
20mM imidazole (pH 7.0). 10µg of the sample was run in a NuPAGE 4-12% Bis-Tris 
precast gel (Life Technologies), and the gels were dyed in a Coomassie Blue solution for 
1 hour. Gels were destained overnight and imaged with Bio-Rad Gel Doc XR. 
Histology 
 Transverse muscle sections taken approximately from the middle of the muscle 
defect were stained with H&E for morphological analysis. 
6.4 Results 
In vitro growth of microvessels 
 Microvascular constructs grown with myoblasts resulted in expedited sprouting of 
vessels at day 2 and denser networks with more branches of vessels at day 5 in culture 
(Figure 30A).  
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Figure 30: Microvessel Culture, Construct, and Surgery. (A) Microvessels grown in 
vitro with or without myoblasts. At days 2 and 5 in culture, the microvessels + myoblasts 
group showed more robust and faster growth than microvessels alone. (B) A 12-mm 
defect was created in the biceps femoris. (C) The microvessels were gelled around a 
nanofiber mesh. (D) The mesh was placed with microvessels face down into the defect 
and sutured. 
 
Early Revascularization of Muscle Defect with Microvessels 
 At 2 weeks post-injury, the vascular volume in the defect area of the microvessels 
and microvessels + myoblasts groups were significantly higher than the contralateral 
control. When compared to the vascular volumes of the empty and autograft-treated 
groups from the previous hamstrings characterization study, the microvessels + 
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myoblasts group had a significantly higher vascular volume compared to the empty 
defect group. Representative images of the vasculature from each group shows that all 
groups have comparably sized vasculature. The microvessels and microvessels + 
myoblasts group seemed to have more smaller vasculature that contributed to their 
vascular volumes. 
 
Figure 31: Vascular Volume in Microvessel-Treated Biceps Femoris. At 2 weeks 
post-injury, all injured groups had a higher vascular volume compared to the contralateral 
uninjured control. The microvessels + myoblasts group had a higher vascular volume 
than the empty defect group. Representative images of the vasculature in each group 
show that the microvascular groups have comparable vascular volume to the autograft 
group. Vessels colors represent vessel thicknesses. n=5-8 for injured groups, n=24 for 
contralateral controls. 
 
4-week microvessel histology 
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 At 4 weeks post-injury, both the microvessel and microvessels + myoblasts group 
had regenerating fibers close to the defect site (Figure 32 B,H) as well as fat deposits 
(Figure 32 C, G). While the microvessels only group exhibited areas of fibrotic tissue 
(Figure 32D), the microvessels + myoblasts group had a small island of muscle in the 
center of the defect (Figure 32G). 
 
Figure 32: Histology of Microvessel and Microvessels+Myoblasts groups at 4 weeks 
Post-Injury. (A) Transverse H&E stained section of microvessels-treated biceps femoris 
4 weeks after Injury. (B), (C), and (D) are 10x zoomed-in images with locations shown 
by colored squares in (A). (E) Transverse H&E stained section of microvessels + 
myoblasts-treated biceps femoris 4 weeks after injury. (F), (G), and (H) are 10x zoomed-
in images, with locations shown by colored squares in (E). Blue scale bars: 1000µm. 
Black scale bars: 100µm. 
 
8-week CS Activity 
 While citrate synthase activity was significantly lower in the empty defect 
compared to the contralateral uninjured controls at 8 weeks post-injury, the autograft, 
microvessels, and microvessels + myoblasts groups had relatively similar citrate synthase 
activity as the control (Figure 33).  
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Figure 33: Citrate Synthase Activity 8 weeks post-injury. Citrate synthase activity, 
expressed as units (mmol/min) per gram muscle wet mass, was significantly lower in the 
empty defect group compared to the uninjured contralateral control. n=6 for empty, n=27 
for controls, p<0.05. 
 
8-week histology 
 By 8 weeks post-injury, both the microvessels group and the microvessels + 
myoblasts group resulted in thin fibrous tissue within the center of the defect, with some 
fatty infiltration (Figure 33). The defect area was occupied either only with the mesh or 
with the mesh and some fibrotic tissue.   
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Figure 34: Histology of Microvessel and Microvessels+Myoblasts groups at 8 weeks 
Post-Injury. (A) Transverse H&E stained section of microvessels-treated biceps femoris 
8 weeks after Injury. (B), (C), and (D) are 10x zoomed-in images with locations shown 
by colored squares in (A). (E) Transverse H&E stained section of microvessels + 
myoblasts-treated biceps femoris 8 weeks after injury. (F), (G), and (H) are 10x zoomed-
in images with locations shown by colored squares in (E). Blue scale bar: 2000µm. Black 
scale bar: 100 µm. 
6.5 Discussion 
 We tested the ability of microvascular constructs with or without myoblasts for 
their abilities to quickly re-vascularize a large empty defect in the muscle and to 
regenerate the muscle. As was hypothesized, the microvascular constructs with myoblasts 
had a higher vascular volume compared to the empty defect group, indicating that this 
construct facilitated re-vascularization of the VML defect. However, contrary to our 
hypothesis, both the microvascular constructs alone and with added myoblasts resulted in 
very little muscle regenerated in the center of the defect space at 8 weeks post-injury. 
 According to previous research, the addition of myoblasts to microvascular 
constructs aid in the formation of vascular networks through a paracrine effect in vitro 
[208]. Thus, we expected the microvessels + myoblasts group to result in a higher re-
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vascularization in the biceps femoris defect compared to the microvessels group. While 
we did see an effect of the myoblast addition in culture in vitro, analysis of the implanted 
vascular network 2 weeks post-injury showed no significant difference between the 
microvessels group and the microvessels + myoblasts group. The reason for this may be 
due to the time point at which the vascular volume was taken. We decided on 
determining vascular volume at 2 weeks in order to give the vasculature enough time to 
inosculate but prior to its complete remodeling within the body. According to literature, 
perfusion of microvessels within implanted constructs increased through day 28 [211].  
From the same study, microvessels that were implanted subcutaneously still showed an 
irregular morphology at day 14, and by day 28, the vessels had remodeled to a typical, 
smooth vascular tree with larger diameter vessels This data indicated that analyzing the 
vasculature at an intermediate time point such as day 14 would be ideal for determining 
implant vascularization though the microvessels may be in the process of remodeling at 
day 14. 
 Despite no differences between the microvessels versus the microvessels + 
myoblasts group in early revascularization, both groups had vasculatures within the 
defect area that were more similar to the autograft treated group compared to the empty 
defect group. However, even with the early vasculature, neither the microvessels nor the 
microvessels + myoblasts groups had muscle myofibers within the defect space by 8 
weeks after injury. These data suggest that the role of vasculature in tissue regeneration 
in this model was overpowered by other factors within the regenerative process. 
 Deposits of fat that were apparent in the defect space at 2 and 4 weeks post-injury 
in the microvessels and microvessels + myoblasts treated groups, which seemed to be 
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remodeled away to leave a thinner tissue at week 8 post-injury. Though mesenchymal 
progenitors isolated from skeletal muscle and satellite cells have been shown to be 
capable of differentiating down the adipogenic pathway given the right conditions [212-
214], there is no sign within literature that microvessels would induce such fat formation 
[204, 215]. Fat deposition is associated with muscle disorders and incomplete muscle 
regeneration [48, 49]. Increased fat accumulation that impairs muscle regeneration are 
typically dispersed between muscle fibers or fibrotic tissue [216, 217]. In our study, the 
adipocytes formed a large continuous portion of the tissue cross-section rather than 
intermuscularly, as has been seen in the untreated empty biceps femoris defect 
previously.  More studies are needed to determine the mechanism by which the fat was 
created at the defect site and how it may influence muscle regeneration. 
 Despite very little muscle regeneration at the center of the defect, the 
microvessels and microvessels + myoblasts groups showed slight improvements in citrate 
synthase activity compared to the empty defect group. Citrate synthase exists in most 
cells as it is the enzyme that catalyzes the first step in the citric acid cycle.  It is 
commonly used as a metabolic marker to assess oxidative capacity and can be used to 
determine skeletal muscle oxidative capacity [218, 219]. However, because it is 
ubiquitous to all cells, differences in citrate synthase activity only characterizes the 
metabolic activity of the tissues involved. Thus, even though the microvessels and 
microvessels + myoblasts groups had similar creatine kinase activities compared to the 
control and autograft-treated groups at 8 weeks, this is not necessarily an indication of 
muscle regeneration. Creatine kinase, on the other hand,  is an enzyme that is more 
specific to skeletal muscle and is also linked to the energy usage of the tissue [198]. The 
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creatine kinase activity was slightly higher, though not significant, in the microvessels 
and microvessels + myoblasts treated groups compared to the empty defect. This 
indicates that there may be some differences in the amount of myofibers or myofiber 
activity within the defect area. These differences were likely at the edges of the defect 
rather than in the center, as the histology clearly showed no or few myofibers in the 
center of the defect in any group other than the autograft-treated group. 
 It is important to note that certain controls were not included in this study because 
they do not contribute greatly to the objective of this study, which was to determine the 
effects of early revascularization on muscle regeneration. Controls that include just the 
collagen alone or myoblasts delivered without microvessels were not crucial for this 
study because both of these groups have been shown to not improve vascularization [205, 
220]. Additionally, delivery of myoblasts alone have been shown to be futile due to the 
lack of graft viability without surrounding vasculature, particularly in a large empty 
defect [11].  While microvessels with a non-myoblast cell would have been an interesting 
control if the study focused mainly on the differences between the microvessels and 
microvessels + myoblasts group, in vitro studies have already shown that these constructs 
grown with fibroblasts do not induce the same vascular response as constructs grown 
with myoblasts [208]. 
 Several limitations exist in the testing of microvascular constructs in the biceps 
femoris model. First, the microvessels and myoblasts are both derived from Sprague-
Dawley rats and implanted into Sprague-Dawley rats, which are not purely inbred. Due to 
this allogeneic nature of the implants, there may be a concern with rejection of the tissue 
or cells, which would affect its ability to regenerate muscle or promote revascularization. 
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There are no signs of immune rejection in histology at 14 days, and CD-4 staining for T-
cells indicated no differences between the autograft and microvessel-treated groups, 
suggesting that there was no chronic rejection (data not shown). Acute or hyperacute 
rejection may still occur and would be difficult to determine in this model although 
proper perfusion and histology support the lack of complete immune rejection. Second, 
the myoblasts used in this study were isolated from a GFP transgenic rat, which could 
have implications on its functionality. From our in vitro co-cultures of myoblasts with 
microvessels, no differences were apparent between myoblasts isolated from wild-type 
Sprague-Dawley rats compared to myoblasts isolated from GFP-transgenic Sprague-
Dawley rats. Though minor differences may exist between GFP- and non-GFP- 
myoblasts, these differences did not deter the paracrine effects of myoblasts on 
microvessel growth. Third, the micro-CT angiography performed in this study was 
limited by a resolution of 21µm voxels, which did not allow for the detection of smaller 
vessels in the capillary range which are prominent in muscles. Additionally, the contrast 
agent is perfused through the vasculature with applied pressure and is not indicative of 
the natural perfusion of the body. Though laser doppler perfusion imaging was 
considered as potential indicator of perfusion, the nanofiber mesh in the microvessel 
constructs block the laser and prevent accurate measurements. 
 In this study, we have evaluated the effects of microvascular constructs with or 
without myoblasts on the revascularization and muscle regeneration of the biceps femoris 
muscle after a VML. While the microvascular construct with myoblasts did induce higher 
revascularization compared to an empty defect, the microvessels with or without 
myoblasts did not result in the recovery of myofibers within the defect space. Instead, the 
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defect space was occupied with fat cells within 14 days post-injury, and by 8 weeks post-
injury, the defect area was occupied by a thin fibrous tissue. More studies are needed to 
determine the exact effects of the microvessels on the surrounding skeletal muscle, 
though current data suggest the recovery of vascular supply in the defect space did not 
induce a large regenerative effect. 
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CHAPTER 7  Aim 3: Effects of Microvascular Constructs on the 
Healing of Composite Muscle & Bone Injuries 
7.1   Abstract 
 Large extremity injuries, such as open fractures in which both muscle and bone 
tissue are damaged, remain a challenge in the clinic. Gold standard treatment involves 
coverage of the bony defect with vascularized muscle flaps; however, large composite 
injuries leave scarce tissue viable to use for coverage. Vascular supply in these muscle 
flaps has been shown to be crucial in the healing process. In this study, we test if we can 
substitute tissues that provide vascular supply with pre-formed microvascular constructs. 
We implanted these constructs into a composite segmental bone defect and volumetric 
muscle loss model in two distinct locations: around the bone, similar to a periosteal 
substitute, or within the muscle defect, similar to a muscle flap substitute. We find that 
the microvascular constructs placed around the bone defect resulted in higher 
revascularization at day 7 post-injury, but this treatment deterred bone formation when 
implanted with our rhBMP-2 hybrid delivery system. On the other hand, the 
microvascular constructs placed within the muscle defect as a flap substitute did not 
significantly facilitate revascularization at 7 days post-injury but did improve muscle and 
bone functional metrics. Taken together, microvascular constructs do have potential in 
tissue engineering strategies for composite extremity injuries, though vascularization may 
not play the only role in facilitating regeneration. 
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7.2   Introduction 
Open fractures, in which a large soft tissue injury is sustained with a bone fracture 
or defect, are associated with a high rate of complications, such as osteomyelitis, delayed 
or persistent non-union, and muscle flap loss [221]. Approximately 82% of all fractures 
in the military are open fractures [1]. In the civilian population, a large number of open 
fractures are caused by motor vehicle accidents and falls from large heights. Though the 
incidence rate of open long bone fractures is low and ranges from 11.5 to 21 per 100,000 
people per year, these type of injuries are associated with a high rate of complication of 
up to 32% from infection, implant failure, and delayed union [222, 223]. Additionally, 
fractures and open fractures are frequently components of polytrauma, in which patients 
suffer from injuries to multiple body regions [224]. Polytraumatic patients that suffer 
from additional extremity injuries experience pain, impaired functional abilities, and a 
decreased quality of life [225]. 
The clinical gold standard for treating open fractures uses muscular flaps to cover 
the bone, but this treatment can be complicated by flap necrosis or partial flap necrosis, 
which can result in delayed amputation [226]. In injuries involving a large loss of soft 
tissue, availability of muscle flaps for transfer may be limited, and functional donor site 
morbidity has been reported for the latissimus dorsi, a muscle commonly used for muscle 
flap treatment [227, 228]. Patients that elect to salvage open fractures in the lower limbs 
often experience pain and issues with motility years after the injury and sometimes do not 
regain normal function of their extremity despite higher chances of re-hospitalization, 
osteomyelitis, and repeat surgeries than patients that elect to amputate the limb [30, 102]. 
Even with treatment and limb salvage, patients have significant levels of disability that 
lead to similar long-term functional outcomes as amputated lower extremities [229]. 
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Despite limitations of availability and donor site morbidity for muscle flap treatments and 
the lack of full limb recovery, there are currently no tissue engineering strategies for 
composite injuries of bone and muscle. 
The sizeable injuries that our defect models involve present a harsh environment 
with challenged mass transfer of nutrients, which prevents efficient regeneration within 
the large defect. Clinically, an important consideration for musculocutaneous or muscle 
flaps is the vascularity of the flap [190, 191, 230]. Not only is the vascular supply crucial 
for the survival and viability of the muscle flap, these soft tissue flaps also serve as a 
source of vascular supply [35]. To this end, muscle is a preferred flap over 
fasciocutaneous tissue due to its greater vascularity, and this clinical observation was 
confirmed in a murine tibial fracture model [138]. The vascularization of intact 
periosteum also plays a large role in the healing of bone fracture, and the removal of 
periosteum during fracture healing delays or prevents bone union [231]. Vascularization 
is important in aiding mass transfer in both muscle and bone tissues, and insufficient 
vasculature has been implicated for delayed healing [140]. In our model of composite 
muscle and bone injury, as discussed in section 3.2, the addition of the muscle injury to a 
bone defect resulted in a delayed early revascularization of the leg, possibly due to cross-
talk between the muscle and the bone through vasculature [104]. These data suggest that 
a vascular therapy may be able to aid in regeneration of both the muscle and bone. 
Microvascular constructs made with adipose-derived microvessels comprise of 
randomly aligned microvessel networks that quickly integrate with tissues and result in 
perfusion-capable vasculature when implanted subcutaneously in a mouse and in a rat 
VML model [204, 205]. With the increased perfusion that the microvascular constructs 
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could provide, the defect region could be replenished of nutrients and possible growth 
factors as well as be more amenable for cell delivery, providing a greater likelihood for 
regeneration. Our previous work (Section 4.2) showed that the implantation of 
microvascular constructs with myoblasts, or muscle stem cells, into a biceps femoris 
VML resulted in a higher vascular volume compared to the empty VML defect, 
suggesting that the constructs inosculate in vivo and can increase vascularity in a muscle 
defect space. 
 Given the importance of vascularization in tissue regeneration and the lack of 
early revascularization in our composite model, a tissue engineering strategy that 
provides a vascular supply may have an influence on the regeneration of the muscle and 
bone. The objective of this study is to examine the regenerative and angiogenic 
potential of microvascular constructs on composite bone & muscle defects. We 
hypothesize that microvascular constructs implanted into composite injuries at the 
muscle-bone junction will aid in revascularization and regeneration of both tissues. In 
testing this hypothesis, we decided to implant preformed microvascular network 
constructs around the mesh surrounding the bone defect, mimicking a periosteal 
substitute, or preformed microvascular network constructs with myoblasts within the 
quadriceps defect, mimicking a vascularized muscle flap. 
7.3   Materials/Methods 
Myoblast Isolation 
 Myoblasts were isolated from GFP-transgenic Sprague Dawley rats. The soleus 
muscle was carefully isolated from each leg, weighed, and placed in a small volume of 
sterile PBS. The tissue was washed in sterile PBS and placed into 0.2% collagenase XI 
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(6mL for every 2 muscles). The tissue was minced manually using tow sterile razor 
blades for 5 minutes and transferred into a 15mL conical tube. The tube was incubated in 
a 37°C water bath and incubated for 60 minutes, mixing once halfway through the 
incubation. Collagenase was then removed, and the homogenate was incubated in 6mL/2 
muscles of dispase (2.4U/mL) at  37°C for 45 minutes. The dispase was then removed, 
and the cells were resuspended in growth medium (F10, 20% FBS, 1% 
penicillin/streptavidin, and 2.5ng/mL bFGF). The cells were then passed through a 
100µm strainer (Steriflip, Millipore) and pre-plated for 30minutes to obtain a myoblast-
enriched population. 
Microvessel Isolation 
 Epididymal fat was isolated from Sprague-Dawley retired breeder rats. The fat 
was minced and digested with collagenase, after which vessels smaller than 500 microns 
and larger than 20 microns were isolated through filters. The microvessels with or 
without myoblasts (15,000 vessels per mL with or without 10
6
 myoblasts per mL) were 
then suspended in a collagen gel (3mg/mL) around a polycaprolactone nanofiber mesh 
and cultured in vitro in serum-free media prior to implantation. 
Surgical Procedure for Creation of the Composite Defect 
 All procedures were approved by the Georgia Institute of Technology Institutional 
Animal Care and Use Committee (protocol #A09039 and #12075). Thirteen week old 
female Sprague-Dawley rats (Charles River Labs, Wilmington, MA) were used for this 
study. Unilateral bone defects were surgically created in the femora of rats, as previously 
described [10, 151, 152]. Briefly, an anterior incision was made along the length of the 
femur and the muscle was then separated using blunt dissection. A modular fixation plate 
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was affixed to the femur using miniature screws (JI Morris Co., Part No. P0090CE250). 
A full-thickness segmental defect, 8 mm in length, was created in the diaphysis using a 
miniature oscillating saw. A perforated nanofiber mesh tube made of polycaprolactone 
(PCL) was then placed over the native bone ends surrounding the defect, and 150 μl 
alginate hydrogel containing rhBMP-2 was then injected into the defect space [10]. Non-
treated controls were not used in this study as previous studies have demonstrated that in 
the absence of rhBMP-2, the defect contains very little bone formation [150, 152]. 
Muscle defects were created through the full thickness of the quadriceps down to the 
femur using an 8 mm diameter biopsy punch. The defect encompassed regions of the 
rectus femoris, vastus lateralis, vastus medialis, and vastus intermedius. The bone defect 
was made first, then, once the incised muscles had been closed with 4-0 suture, the 
muscle defect was created. Animals were given buprenorphine post-surgery to manage 
pain (0.03 mg/kg 3x daily for the first 48 hours, then 0.01 mg/kg 3x for the next 24 
hours). 
 For testing the microvascular constructs created around the nanofiber mesh to 
surround the bone defect, the collagen gel containing microvessels (150,000 vessels per 
mL) was solidified around the cylindrical nanofiber mesh and cultured in vitro for 10 
days prior to implantation (Figure 35). All bone defects were treated with 150 μl of RGD-
functionalized alginate and 2 µg of rhBMP-2 per defect. Half of the animals received a 
collagen/microvessel-coated nanofiber mesh (MV+ group) while the other half received a 
bare nanofiber mesh (MV- group). The muscle defect was untreated in this part of the 
study and left empty. A subset of animals (n=6) were euthanized at 1 week post-injury for 
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micro-CT angiography in order to analyze revascularization of the limb. Remaining 
animals underwent radiography and micro-CT at 4, 8, and 12 weeks (n=2-3). 
 
Figure 35: Microvascular Construct Surrounding a Nanofiber Mesh. Axial view (A) 
and side view (B) of the construct is shown. When grown in vitro for 8 days, microvessel 
fragments grow into networks (C). An axial view of the components of the microvessel 
construct is shown in the diagram (D). 
 
 To create the microvascular constructs for implantation into the quadriceps defect, 
microvessels and myoblasts were suspended in a collagen gel that was solidified around a 
flat polycaprolactone nanofiber mesh (Figure 36A, B, D). The nanofiber mesh was 
sutured on top of the quadriceps defect with the majority of the microvascular construct 
(collagen gel with microvessels and myoblasts) within the defect space (Figure 36C). All 
bone defects were treated with a perforated nanofiber mesh tube made of 
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polycaprolactone (PCL) placed over the native bone ends surrounding the defect, and 150 
μl alginate hydrogel containing 1µg rhBMP-2 was then injected into the defect space. 
Half of the animals received the microvascular construct within the quadriceps defect 
(MV+) while half of the animals received no treatment for the quadriceps defect (MV-). 
A subset of animals (n=6) were euthanized at 1 week post-injury for micro-CT 
angiography in order to analyze revascularization of the limb. Remaining animals 
underwent radiography and micro-CT at 4, 8, and 12 weeks (n=3-4). 
 
Figure 36: Microvascular Construct for Filling of Quadriceps Defect. Side view (A) 
and top view (B) of the construct is shown. The bulk of the microvascular construct was 
placed into the quadriceps defect space, and the nanofiber mesh was sutured around the 
defect (C). A side view of the components of the microvessel construct is shown in the 
diagram (D). 
 
Muscle Isometric Tetanic Torque Assessment 
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 Isometric tetanic torque production about the knee by the knee extensor muscles 
was measured at 12 weeks post-surgery using a custom built apparatus based on a 
previous design used for assessment of lower leg muscle function (Figure 9B) [113]. All 
measurements were made under isoflurane anesthesia during a terminal procedure 
immediately prior to euthanasia. A 2-cm long incision was made through the skin 
exposing the femoral triangle in the upper thigh. The posterior branch of the femoral 
nerve was carefully isolated and a nerve cuff was positioned surrounding that branch.  
The rat was then carefully secured to the platform of the apparatus. The animal was 
positioned so that the knee angle was at 90
o
 and the ankle was secured to a force 
transducer (Isometric Transducer Model No. 60-2996, Harvard Apparatus). The knee 
extensor muscles were stimulated using a stimulator (GRASS S11 Stimulator, Grass 
Technologies) and the nerve cuff implanted on the femoral nerve. Stimulator pulse 
duration, frequency, and train duration were set to 0.5 ms, 175 Hz, and 500 ms, 
respectively; these settings elicited maximal isometric tetanic torque as determined in a 
pilot study. Measurements of injured muscles were normalized to contralateral intact 
muscle for each animal. 
Faxitron X-Ray Analysis 
 Digital radiographs (Faxitron MX-20 Digital; Faxitron X-ray Corp.) of the defect 
region in the femur were performed at an exposure time of 15 s and a voltage of 25 kV. 
Animals received X-ray imaging at 2, 4, 8 and 12 weeks post-surgery. 
MicroCT Analysis 
 MicroCT scans (VivaCT 40, Scanco Medical) were performed at 38.0 μm voxel 
size at a voltage of 55 kVp and a current of 109 μA. Scans were taken at 4 and 12 weeks 
 125 
post-surgery. Bone tissue was segmented by application of a global threshold 
corresponding to 386 mg hydroxyapatite/cm
3
 (roughly 50% of the native cortical bone 
density), and a low-pass Gaussian filter (sigma = 1.2, support=1) was used to suppress 
noise. Samples were contoured and evaluated over 146 slices taken from a central region 
within the defect in order to normalize between samples without including cortical bone. 
Ex-vivo analysis over the entirety of the defect region was also performed and showed the 
same differences among the groups as the in vivo data at 12 weeks. 
Biomechanical Analysis 
 Animals were euthanized by CO2 inhalation 12 weeks post-surgery. This time 
point was chosen based on previous publications demonstrating that bone apposition 
reaches a plateau by this time [150]. Torsional testing was performed on extracted 
femurs. The femurs were cleaned of soft tissue and the ends potted in mounting blocks 
using Wood's metal (Alfa Aesar, Wood Hill, MA). After removal of the fixation plate, 
the specimens were tested (ELF 3200, Bose ElectroForce Systems Group, Minnetonka, 
MN) at a rotational rate of 3° per second. Maximum torque was measured at the failure 
point from the torque-rotation data. Torsional stiffness was calculated by fitting a straight 
line to the linear portion of the curve before failure.  
Histology 
 Histological analysis was performed at 12 weeks post-surgery on 
extracted quadriceps muscles and femurs. Samples were perfusion fixed then immersion 
fixed for 48 h at 4 °C with 10% neutral buffered formalin. Following paraffin processing, 
5 μm-thick cross-sections were cut and stained with hematoxylin and eosin (H&E) or 
Masson’s Trichrome (for muscle/fibrosis). Bright-field images were obtained with the 
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Axio Observer.Z1 microscope (Carl Zeiss, Thornwood, NY). Images were taken at 4x 
and 10x magnification using the AxioVision software (Carl Zeiss, Thornwood, NY). 
7.4   Results 
7.4.1 Microvascular Construct around the Bone Defect 
Early revascularization at 1 week post-injury 
 Early revascularization was analyzed at 7 days post-injury and showed a 
significant increase in vascular volume of the leg in the microvessel/myoblast-treated 
group compared to the MV- group (Figure 37A). Despite the increased vascularization, 
representative images of the axial view of the thigh show that few vessels were present 
near or around the bone defect where the microvessels were implanted in the MV+ group 
(Figure 37B). 
 
Figure 37: Early Revascularization of Thigh near the Defect Area after 
Microvascular Treatment around Mesh. CT angiography showed an increased 
normalized vascular volume in the thigh in the microvessels group (MV+) compared to 
the group without microvessels (MV-) (A). Representative images of the vasculature (B) 
showed that any increased vasculature in the MV+ group was not centered around the 





 At 8 and 12 weeks post-injury, micro-CT scans showed the MV- group had a 
significantly higher mineral volume compared to the MV+ group (Figure 3A). 
Representative radiographs supported the micro-CT data, showing a completely bridged 
defect in the MV- group and only a partially bridged defect in the MV+ group. 
 
Figure 38: Longitudinal Analysis of Bone Regeneration after Microvascular 
Treatment around Mesh. (A) micro-CT scans showed significantly decreased mineral 
volume in the microvessels group compared to the alginate only group at 8 weeks 
(*p<0.05, n=2-3). (B) Radiographs showed full bridging in the alginate only group and 
partial bridging in the microvessels group by 8 weeks. 
7.4.2 Microvascular Construct in the Quadriceps Defect 
Early revascularization at 1 week post-injury 
 CT angiography showed no difference in thigh vascular volume between the 
microvessel/myoblast-treated quadriceps group and the empty quadriceps defect group 
(Figure 39). Representative images of the microvessel/myoblast-treated (MV+) and 




Figure 39: Early Revascularization of Thigh near the Defect Area after 
Microvascular Treatment in the Quadriceps. (A) CT angiography at 1 week post-
injury showed no difference in thigh vascular volume in the microvessel/myoblast-treated 
and empty quadriceps defect groups. (B) Representative images of the 




 Longitudinal µCT quantification of mineral volume within the center of the bone 
defect showed no differences between the microvessel/myoblast-treated quadriceps group 
(MV+) and the empty quadriceps defect group (MV-) (Figure 40A). However, the 
mineral volume average was consistently higher in the MV+ group compared to MV-, as 
shown by representative radiographs at 2, 4, 8, and 12 weeks post-injury (Figure 40B).  
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Figure 40: Bone Mineral Volume and Radiograph Images after Microvascular 
Treatment in the Quadriceps. (A) No significant differences were found in bone 
mineral volume between the microvessel/myoblast treated group (MV+) and the empty 
quadriceps defect group (MV-), though the MV+ group consistently had a higher mineral 
volume average at all time points. Representative radiographs (B) show bone formation 
at 2, 4, 8, and 12 weeks post-injury. n=3 
 
 Mechanical testing of the regenerated bones showed very similar results to the 
bone mineral volume measurements. Though the MV+ group had higher averages for 
failure strength (Figure 41A) and torsional stiffness (Figure 41B), these differences were 
not significant. 
 
Figure 41: Bone Postmortem Biomechanical Properties after Microvascular 
Treatment in the Quadriceps. No significant differences were found in failure torque 
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(A) and torsional stiffness (B) between the microvessel/myoblast treated group (MV+) 
and the empty quadriceps defect group (MV-). n=3 
 
Muscle Regeneration 
 The contralateral uninjured control quadriceps muscles had a significantly higher 
muscle force and mass when compared to the microvessel/myoblast-treated quadriceps 
(MV+) group and the empty quadriceps defect (MV-) group at 12 weeks post-injury. The 
MV+ group had a significantly higher muscle mass compared to the MV- group, though 
muscle force between the two groups were not significantly different (Figure 42A, B). 
The MV+ group performed at about 30% of the contralateral control while the MV- 
group performed at around 10% of the contralateral control (Figure 42C). Similarly, the 
muscle mass in the MV+ group was 60% of the contralateral uninjured control while the 
muscle mass in the MV- group was 40% of the control (Figure 42D). Representative 
post-mortem images of the quadriceps muscles in both groups showed a noticeable 
difference in the size of the treated (MV+) versus untreated (MV-) quadriceps muscles 
(Figure 42E).  
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Figure 42: Muscle regeneration after Microvascular Treatment in the Quadriceps. 
Contralateral uninjured controls had significantly higher muscle force (A) and mass (B) 
compared to the microvessel/myoblast treated (MV+) and empty defect groups (MV-). 
The MV+ group had a significantly higher muscle mass compared to the MV- group. No 
significant differences were found in normalized muscle force (C) and muscle mass (D) 
between the microvessel/myoblast-treated quadriceps (MV+) and the empty quadriceps 
defect group (MV-). Representative postmortem images of the quadriceps muscles in 
both groups are shown (E). *p<0.05 compared to MV+ and MV-. #p<0.05 compared to 
MV-. n=3 for injured groups, n=6 for controls. 
7.5   Discussion 
 This work, to our knowledge, is the first to test microvascular construct treatment 
of composite bone and muscle defects. These microvascular constructs were first tested 
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for their regenerative potential positioned around the nanofiber mesh that is placed 
around the bone ends, enveloping the bone defect area in the place of the resected 
periosteum. The periosteum contributes greatly to bone repair, providing cellular, 
vascular, and structural support to the defect or fracture site [232-234]. The 
microvascular construct, though comprised of different cells and structure, can mimic a 
periosteal substitute, providing vasculature and cellular components for bone 
regeneration.  
 Microvessels are known to inosculate within a week when embedded 
subcutaneously in mice [204]. Our micro-CT angiography data suggest that our 
implanted microvascular networks surrounding the mesh did not fully inosculate, as there 
was a lack of vessels around the bone defect at day 7 even in the microvessel treated 
group. However, the microvessels did still have an overall effect on revascularization of 
the leg. It is likely that this increase in local vascularity, more so in the surrounding 
muscle than in the bone defect, could be a result of the paracrine effects of the implanted 
microvascular networks, influencing endogenous cell recruitment and angiogenesis. 
CT measurements of mineral volume suggest that the microvascular constructs 
around the mesh may actually impede rhBMP2-mediated bone regeneration rather than 
facilitating it. Three plausible mechanisms can be proposed to explain this seemingly 
paradoxical observation: 1) The presence of the collagen matrix around the defect may 
deter or alter the release kinetics of rhBMP-2, disturbing the beneficial chemotactic, 
proliferative, and morphogenetic effects of the rhBMP-2. 2) The increased local blood 
perfusion in the surrounding muscle through the inosculated or newly formed 
microvascular networks could facilitate the local clearance of rhBMP-2 from within or 
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nearby the bone defect site, thus decreasing its bioavailability at the defect site. 3) The 
microvessels around the mesh may take up and use the rhBMP-2, which is known to 
induce formation of mature vascular systems, to create an amplified secondary pro-
vascularization milieu, thus leaving insufficient quantities of rhBMP-2 to drive 
osteogenesis [235]. Further studies into the release of rhBMP-2 from the microvessel-
impregnated construct will allow more insights into the proposed mechanisms. Thus, 
while we have shown a positive effect on early vascularization of the limb with the 
microvascular constructs, our hypothesis that this vascularization may aid tissue 
regeneration was rejected, possibly due to altering rhBMP-2 release kinetics in vivo. 
We next tested an alternative method of incorporating microvascular networks 
that minimizes interference with rhBMP-2 release in this model by incorporating the 
microvascular construct within the quadriceps volumetric muscle loss injury. Clinically, 
muscle flaps are often used to cover bony injuries and defects, contributing cells, 
cytokines, growth factors, and a vascular supply for bone regeneration [35]. Additionally, 
studies have shown that intact muscle is more effective at promoting bone repair than 
injured muscle, suggesting that muscle regeneration within a composite defect may 
contribute to bone regeneration [8, 9]. 
Contrary to our hypothesis, the microvascular + myoblast constructs implanted 
into the quadriceps defect space did not result in an increased vascular volume at day 7 
post-injury. Though networks were formed in vitro with the co-culture of microvessels 
and myoblasts in the collagen gel, these networks were not detected in the micro-CT 
angiography used to analyze vasculature at early time points. While it may be possible 
that the vascular networks are not inosculating, previous work (in Section 4.2) implanting 
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the microvessel/myoblast constructs into muscle defects resulted in an increased vascular 
volume, suggesting that these constructs do inosculate when implanted into damaged 
muscle. Limitations of the micro-CT angiography technique may also mask any 
differences in vascular volume with or without treatment. In this particular model, the 
vessels near and around the bone and quadriceps defects tend to be leaky, most likely due 
to a large amount of vasculature damage from creating the defects. Due to this, the 
contrast agent may escape the vasculature during perfusions at early time points, causing 
artifacts that artificially alter the vascular volume data. However, differences in 
vasculature are best seen in early time points, particularly within the first week of injury. 
For these reasons, we performed our micro-CT angiography at day 7. Though vascular 
volume in the composite defect was catching up to the bone defect only group by day 7 in 
our previous study, thereby making it difficult to detect differences between treated or 
untreated composite defect (in Chapter 3.2), day 3 micro-CT angiography tends to result 
in artifacts substantial enough to affect the vascular volume readings. 
It is also possible that the implanted microvascular construct may have trouble 
surviving in the harsh environments around the defect site. As mentioned earlier, the 
microvascular constructs around the mesh may not have fully inosculated, suggesting that 
graft survival may be challenging. The large bone and muscle defects tend to result in 
large hematomas or edemas, as previously seen via MRI scans of the leg [176], which 
may act as a barrier to inosculation of the microvessels to the surrounding host 
vasculature. Additionally, it has been that in this segmental bone defect model at day 7, 
CD68-positive macrophages were present along with polymorphonuclear cells, indicating 
a large inflammatory response to the defect [236]. These inflammatory cells are likely to 
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be releasing cytokines, though the exact composition of this mixture is currently 
unknown within our bone defect. The presence of inflammatory cells and signals may 
create an environment that is not conducive for survival of all the microvascular 
fragments in the construct. 
Despite the similar early revascularization between the microvessel/myoblast 
treated (MV+) and untreated (MV-) quadriceps groups, the MV+ group resulted in higher 
mineral volume averages, bone mechanical properties, muscle mass and function 
averages. None of these differences are significant, possibly due to the small sample size 
in the pilot study (n=3, post hoc power analysis showed a power of 0.45 at 12 weeks). 
However, these results are encouraging and suggest that the MV+ group is having a 
therapeutic effect on both the muscle and bone tissues. Though early vascular volumes 
were significantly increased in the MV+ group, there may be vascular or paracrine effects 
provided by the microvessels or myoblasts that could induce an endogenous response at 
the defect site. Also, the microvessels and myoblasts were delivered in a space-filling 
collagen gel, which may act as a conduit for endogenous cells to migrate into the defect 
space. Though this study did not have a collagen-only control, other studies have shown 
that collagen-only constructs do not induce increased vasculature or healing in the defect 
area, suggesting that the collagen by itself would not have resulted in such a large 
regenerative response [205]. The myoblasts within the constructs may also be 
contributing directly to muscle or bone regeneration by differentiating into myofibers that 
can fuse with endogenous cells or into osteoblasts that can aid in mineralizing bone. 
Further studies and histology at early time points will be needed to confirm whether the 
myoblasts are contributing to bone regeneration directly or if the contribution is through 
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regenerating the muscle and thus providing enough vascularization or cells in the muscle 
bed to facilitate bone regeneration. 
In the attempt to facilitate regeneration of two different tissues, it is important to 
note that these two tissues may send contrasting signals to the graft that may deter the 
regeneration of the other tissue. For this study, rhBMP-2 was delivered in an alginate 
hydrogel within the bone defect to improve bone mineralization and healing, as has been 
shown in previous studies [10]. However, rhBMP-2 has an osteogenic effect on satellite 
cells and has been shown to suppress myogenic differentiation and deter the myoblasts 
from myotube formation [237, 238]. In this study, rhBMP-2 was delivered at a very low 
dose (1µg per defect), which may have been beneficial for determining the myogenic 
potential of the microvessel/myoblast constructs. 
 Large, multi-trauma injuries are challenging to heal in the clinic and often result 
in complications or functional deficits in the affected limbs. Our study analyzes the 
treatment of a very challenging composite injury with a vascular approach surrounding 
the bone, acting like a periosteum substitute, or within the muscle defect, similar to a 
muscle flap substitute. While this vascular approach can aid in counteracting the delayed 
revascularization in the defect space depending on the treated location, regeneration of 
the bone and muscle tissues did not seem to be wholly dependent on the revascularization 
of the defect. These results have implications on delivering biological components 
concurrently with the clinically available BMP2 used for bone fusion and repair of multi-
tissue traumatic wounds to the extremities. 
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CHAPTER 8  SUMMARY AND FUTURE DIRECTIONS  
8.1   Overall Summary 
 Traumatic wounds to the extremities pose a serious challenge in the clinic. While 
recent advancements in reconstructive surgery have aided in reducing the number of 
complications in treating these traumatic wounds, large functional deficits still exist years 
after treatment, resulting in lowered quality of life and debilitating disabilities that 
sometimes prevent patients from returning to their original professions. In 2008, the 
Armed Forces Institute of Regenerative Medicine (AFIRM) was created as a federally-
funded institution within the Department of Defense to direct the investigations of 
clinical therapies for military medical needs. One of the areas of research that benefit the 
therapy of injured soldiers is limb reconstruction, regeneration, and transplantation. With 
the increasing use of body armor and the rise in use of improvised explosive devices 
(IEDs) in recent US conflicts, military injuries are progressively dominated by traumatic 
injuries to the extremities with large defects within the muscle and bone. In a recent study 
by Cross et al. evaluating the records of wounded service members that were deemed 
unfit to continue serving, 76% of the injured had an orthopedic diagnosis that was the 
primary unfitting condition, indicating that orthopedic-related injuries often lead to 
disabilities that have a significant impact on the patient's well-being [239]. These data 
highlighting the high incidence of disability and lack of functional recovery underscore 
the importance of developing tissue engineering strategies to focus on improving 
functional outcomes. 
 Despite the need for therapeutic alternatives to the current clinical treatments, few 
therapies exist that can aid in healing such large complex injuries, and even fewer are 
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robust enough to be translated into the clinic. Additionally, while much research has been 
conducted in the field of tissue engineering/regenerative medicine (TE/RM) on single 
tissue injuries, very little research has delved into the complicated task of regenerating 
multiple tissues simultaneously, as would be necessary in traumatic extremity injuries. 
Thus, the main objective of this project is to examine the regenerative potential of 
engineered matrix constructs and stem cells on composite bone & muscle defects. The 
central hypothesis was that stem cells delivered on engineered matrix constructs into the 
muscle defect will aid in muscle regeneration and promote bone healing, ultimately 
resulting in superior functional limb recovery. 
 This dissertation first focused on the development and characterization of 
preclinical models that reproduce the challenging injuries seen in the clinic (Aim 1, 
Chapter 3.1 & 3.2). Our lab has previously developed a critically-sized segmental bone 
defect in the femur of a rat, which has been shown to heal to intact bone strength when 
treated with 5µg of rh-BMP-2 in a hybrid delivery system consisting of a macroporous 
cylindrical nanofiber mesh made of polycaprolactone and RGD-functionalized alginate 
that can be injected into the lumen of the mesh [10]. In this dissertation, we created a 
model of volumetric muscle loss (VML) in the quadriceps muscles of the rat, injuring all 
four muscles in the quadriceps (Aim 1, Chapter 3.1). Muscle autografts were tested in 
this model and were found to be insufficient for functional healing of the quadriceps 
defect, similar to clinical outcomes for VML injuries. We then combined this VML 
model with the segmental bone defect to create a composite injury model in which a large 
section of bone and muscle are resected to reproduce the injuries associated with severely 
injured limbs (Aim 1, Chapter 3.2). We demonstrated that this new preclinical model 
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recapitulated features of the compounded functional deficits that are commonly observed 
in polytraumatic injuries clinically. Additionally, further characterization of this 
composite defect model revealed a possible role of early revascularization in the healing 
of the bone defect. Thus, with this aim, we presented two new platforms on which to test 
tissue engineering strategies as well as biological models to study the interplay between 
the healing of muscle and bone tissues. 
 From the first aim of this dissertation, it was found that the quadriceps VML 
model was difficult to heal, even with autograft treatment. While this was beneficial in 
emulating the injury characteristics of a clinical VML wound, the challenging nature of 
the wound, due to the injury of multiple muscles and the possible injury of blood vessels 
and nerves, could preclude regeneration from tissue engineering constructs not designed 
to fix so many types of tissues. Thus, we developed a simplified VML model within the 
biceps femoris of the rat whereby one single planar muscle was injured with less damage 
to vasculature or nerves (Aim 2, Chapter 4,1). This model included both a negative 
control for regeneration (empty defect) that exhibited little to no regeneration of muscle 
fibers at the center of the defect as well as a positive control for regeneration (autograft), 
in which an autograft sutured in the center of the defect resulted in healthy muscle tissue 
after 4 to 8 weeks post-injury. From this model, we further investigated into possible 
differences between the negative and positive controls for regeneration and found a 
distinct difference in the revascularization of the defect site. While both the empty defect 
and autograft-treated defect muscles had a higher vascular volume than uninjured 
contralateral control muscles, the autograft-treated defect muscles had a significantly 
higher vascular volume than the empty defect. 
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 We further investigated the effect of revascularization of the VML defect site by 
implanting a preformed microvascular network within the biceps femoris defect (Aim 2, 
Chapter 4.2). While this microvascular network quickly inosculated with host vasculature 
and resulted in an elevated vascular volume compared to the empty defect and uninjured 
control, the effects of the vascularization on muscle regeneration were harder to discern. 
The microvascular treatment resulted in the formation of a large amount of fatty tissue in 
the defect space within the first month of recovery that eventually remodeled away to 
leave thin, fibrous tissue in the center of the defect space. Thus, while we were successful 
in inducing an increased vascular response at early time points after injury, the 
vasculature was not sufficient to promote muscle regeneration. 
 As mentioned in Aim 1, characterization of the composite injury model in which 
both muscle and bone were damaged showed a difference in early revascularization of 
the leg in the composite injury that may have led to attenuated bone formation. Thus, we 
developed two vascular constructs that could be used to substitute two important tissues 
that are crucial in the healing of traumatic limb injuries (Aim 3, Chapter 5). First, a 
microvascular construct was developed around the nanofiber mesh, surrounding the bone 
defect area, similar to a periosteum substitute. Second, a microvascular construct was 
developed to sit within the quadriceps defect, similar to a vascularized muscle flap that is 
commonly used to treat open fractures in the clinic. While the microvascular construct 
placed around the bone defect area resulted in an increase in vascular volume at day 7 
post-injury, the construct seemingly deterred bone regeneration and resulted in less 
mineral volume than the untreated composite defect. This is most likely due to the effects 
that this microvascular construct around the bone had on the release kinetics of BMP-2, 
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suggesting that the BMP-2 in this case had a larger effect on bone regeneration than the 
microvascular construct itself. In contrast, the microvascular construct that acted as a 
vascularized muscle flap did not result in an increase in early revascularization, but it did 
increase the averages of mineral volume, bone function, and muscle function, though not 
by a statistically significant amount within the pilot study (n=3). These results suggested 
that while these microvascular networks could provide faster revascularization to the 
defect areas, the vascular networks alone may not be enough to aid in tissue regeneration. 
 Overall, this dissertation presented multiple preclinical platforms for testing tissue 
engineering strategies as well as models that can be used to gain insights on the healing 
of VML and composite VML/bone defects. From some of these insights gained on the 
vascularization of the defect sites, a vascular treatment strategy was tested within these 
platforms and shown to have varying results in the treatment of complex multi-tissue 
injuries. 
8.2   Development and Characterization of Preclinical Models that Reproduce 
Traumatic Limb Injuries 
 In the attempt to develop and design tissue engineering strategies that can aid in 
regenerating musculoskeletal injuries, preclinical models must first be developed to test 
these therapies. While few volumetric muscle loss models existed at the start of this 
dissertation work, the field has quickly expanded in the last five years, with more than a 
dozen articles published in developing and treating VML models. In the majority of the 
developed VML models, the size of the defects have been relatively small, with the 
removal of 50-100mg of muscle in rat models. Our quadriceps VML model, in contrast, 
involves the removal of 250-400mg of muscle, resulting in a very large defect in a very 
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large muscle. Likewise, our muscle function data showed a larger loss in function than 
any other VML models that currently exist. Additionally, we analyzed the regenerative 
potential of administering an autograft within the defect, expecting the muscle to heal 
with the treatment as has been previously shown  [41]. Instead, we found that the graft 
did not result in functional recovery of the muscle, emphasizing the severity of the 
muscle defect that we have created. 
 These results highlight the importance of defect size. In muscles of relatively 
small size, such as a mouse extensor digitorum longus muscle, the entire muscle can be 
removed, minced, and replaced within the muscle bed and regenerate within 4 months 
[41]. In contrast, our muscle treated with a minced autograft showed very little 
regeneration, with a reduced cross-sectional area and only half the strength of the 
uninjured contralateral control. It is well known that animals of smaller size, such as 
rodents, have a much quicker healing response to relatively large injuries. Thus, when 
therapies move from a rodent model to a larger animal model, few therapies demonstrate 
the same regenerative response in the larger animal. Likewise, this study showed that the 
size of the muscle defect matters. While smaller sized defects could possibly heal with an 
autograft treatment, a larger sized defect may not have the same regenerative response. 
This presents a very interesting scientific question: if a certain therapeutic induces a 
regenerative response in a small VML, would the same therapeutic induce the same 
response in a larger VML? It would be very beneficial and cost-efficient if a therapeutic 
can be tested within larger defects within rodent models before moving on to testing in 
large animal models. 
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 Our characterization of the quadriceps VML model showed the formation of a 
hematoma and/or edema as visualized by MRI. This is a normal response that provides a 
biological matrix with which the body can start healing, and it is an important 
consideration in investigating the regeneration of different tissues. While a hematoma 
may be beneficial in fracture healing and bone regeneration [240], edemas and 
hematomas may cause swelling and compartment syndrome in muscle injuries, which 
results in pain and possible ischemia if not treated [241]. Thus, while hematomas may 
bring inflammatory cells, cytokines, and growth factors to the site that may aid in tissue 
regeneration, an excessive amount of hematoma/edema that results in massive swelling 
may occlude perfusion of blood, cells, and nutrients to and from the injury site. 
 While the literature in the VML field has expanded dramatically in the last few 
years, few models exist that include simultaneous bone and muscle injuries. Of the few 
that exist, none have been used to test new therapeutics for regenerating the tissues. 
Instead, the models are used to gain insights into crosstalk between muscle and bone 
healing. The main purpose of developing our model was to determine the effects of 
treating the defects in an effort to improve treatment strategies in traumatic limb injuries 
in which functional recovery is often poor. Thus, we focused on developing functional 
outcome analyses such as maximal tetanic force testing to determine muscle function and 
torsional tests to determine bone function. 
 Our composite injury model supported observations that have been made in the 
clinic; the addition of a muscle injury to a bone injury deters bone regeneration, thus 
validating the model. The muscle is considered a "secondary periosteum" and provides 
cellular, molecular, and structural support to bone healing. The periosteum is regarded as 
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an important factor in fracture healing, and periosteal stripping significantly decreases 
blood flow to fractures and thus impairs fracture healing [242]. In our model, with the 
removal of both the periosteum and the "secondary periosteum," a large amount of 
vascular supply and cells are resected, leaving a large avascular void that the body must 
fill. From histology, the quadriceps muscle seemed to collapse on itself and shrunk in 
cross-sectional area, thereby affecting its function that is closely related to the muscle 
structure. This may be the body's response to the reduced vasculature and its way of 
protecting the tissue from necrosis. Without a nearby vascular supply, bone healing was 
likely reduced, thereby partially causing the attenuation of rhBMP-2-mediated bone 
regeneration in our model. 
 In further characterizing the composite model, we discovered an important insight 
that was crucial in determining our treatment strategy for aim 3. The composite injury 
revascularization occurred slower than the bone injury alone. Though this difference was 
mainly evident within the first week of injury, the vascular profile and maturity within 
the bone defect were different at 2 weeks post-injury. These data supported the idea that 
vascularization plays a pivotal role in tissue regeneration [11]. Size, again, may play a 
role in this difference in revascularization. While the bone defect resulted in a void which 
must be filled through vascularization to avoid necrosis in the center of that void, the 
addition of the muscle defect doubled the volume of that void, thereby delaying the 
vascularization into the empty spaces. We further explored the effects of vascularization 
on tissue regeneration by developing and testing a vascular treatment in the composite 
model in the third aim. 
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8.3   Pursuit of a Critically-Sized VML Model 
 Because the field of volumetric muscle loss injuries is still relatively new, no set 
standard exists to define the exact size or severity of a VML injury. VML defect sizes in 
the rat range from 50 to 300mg in mass. In contrast, the bone regeneration field has a set 
standard for a critically-sized defect, in which any defect equal or greater than critical 
size would lead to capping of the bone ends and very little regeneration within the defect 
space. This allows for some standardization of the size of defects, which as mentioned 
before, plays a large role in the degree of tissue regeneration that may occur after injury. 
Likewise, a muscle defect should be deemed "critically-sized" if the center of the defect 
shows no signs of regeneration, with a "capping" of muscle at the edges of the defect. 
 No published VML model has exhibited this type of capped healing. On the other 
hand, our biceps femoris defect model gives a glimpse of what a "critical size" in the 
volumetric muscle loss field might look like. In the empty defect group, the biceps 
femoris VML resulted in minimal regeneration, with no evidence of myofibers present in 
the center of the defect even after 8 weeks post-injury. This, in part, is due to the fact that 
this injury is a full-thickness defect with no connected nearby muscles to contribute to its 
healing. Though we decided to use a 12-mm biopsy punch to create this biceps femoris 
defect in order to match the defect mass of the quadriceps defect, this 12-mm punch may 
be larger than needed to create a "critically sized" muscle defect. It would be useful for 
the field if various sizes of muscle defects were tested in order to define such a "critical 
size" so that various treatments can be tested and compared in different VML models. 
Since the biceps femoris model already exhibits signs of a "critically-sized" defect, a 
logical progression would be to test different sized biopsy punches to create varying 
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VML sizes in the biceps femoris to determine if there is a size at which the muscle can 
heal. 
 The reason for defining a "critical size" for a defect is again due to the fact that 
size considerations play a big role in the healing and regeneration of tissues. Not only 
does the size of the defect affect the amount of material and cells that need to encompass 
the created empty space to heal it, size also affects mass transfer properties and the 
amount of vascularity needed to provide nutrients to the tissue formed within the defect. 
The same therapeutic that may be able to regenerate one VML defect may not be able to 
regenerate a different sized defect. As mentioned before and confirmed by the differences 
in regeneration with minced autograft treatments of different VML models, testing 
treatments in different sizes of defects may give some insights to whether or not a 
treatment could work in a large animal model or in humans. 
 Though the biceps femoris VML model seems to present a suitable "critical size" 
defect based on histology, the lack of muscle functional data may preclude its use in 
testing therapeutics. While in vivo measurements of biceps femoris function have been 
plagued by large variability that occluded differences between the negative and positive 
controls for muscle regeneration, an ex vivo method in which a strip of muscle from the 
center of the defect site could possibly allow for functional readings that support the 
histological data. However, developing an ex vivo method is a big challenge. Because ex 
vivo testing would be conducted on a smaller sub-section of the muscle, small differences 
in the isolation of the tissue for functional testing could lead to large variability in the 
data. It would be difficult to standardize the exact number of myofibers isolated for the 
testing, which may contribute to the variability of the functional ex vivo data. The exact 
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location from which the muscle strip is taken from may also have a large influence on the 
functionality. Despite these challenges and possible increased variability in 
measurements, the testing of ex vivo muscle strips from the defect site should result in a 
larger difference between the positive and negative controls, since all myofibers not 
included within the defect could be excluded from the reading. Thus, for the biceps 
femoris model, further research and work could result in the development of a functional 
assay of the regenerated muscle (or lack thereof) at the defect site. 
8.4   Challenges in the Use of Microvascular Constructs for Regeneration of 
Musculoskeletal Tissues 
 This dissertation demonstrated proof of concept that microvascular constructs, 
with or without myoblasts, are able to affect tissue regeneration in large extremity 
injuries. However, when these microvascular constructs were tested in three distinct ways 
in two different models (the biceps femoris VML and the composite model with a 
quadriceps VML combined with segmental bone defect), three different healing 
responses occurred. This section outlines a series of challenges that must be overcome 
before microvascular constructs can be a viable treatment in the healing and regeneration 
of musculoskeletal defects. 
 Microvascular constructs are comprised of viable tissues that are isolated from 
various animals and pooled into groups to minimize animal to animal variability. This 
variability presents various problems, as different animals may contribute different 
tissues that can have different potentials in grafting and regeneration. As mentioned in 
Aims 2 and 3, the microvascular constructs resulted in varying degrees of 
revascularization and muscle regeneration. While some of this may be due to the location 
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at which the microvascular constructs are implanted, some of these differences in host 
response may be due to the variability of the microvessels themselves. The microvessel 
isolation protocol, though optimized through repeated isolations and trials with different 
collagenase lots, mincing time, and digestion time, may need to be re-optimized if the 
characteristics of the isolated tissues vary. Thorough studies into plausible sources of 
variability may provide insight into the system that could allow for better control of the 
variability within the microvessel isolation and growth. 
 Possible causes for this variability may include age and gender. Age has been 
shown to influence vascularization in fracture healing, and it may very well have an 
effect on microvessel growth in vitro and inosculation in vivo [243]. A thorough study on 
the effects of age on the proliferation and networking of microvessels may help to isolate 
a possible cause of the variable effectiveness of the microvessels. Though we isolated 
microvessels from adipose tissue from male rats, this tissue could also be isolated from 
female rats as well, which may could influence the growth and characteristics of the 
microvessels. Estrogen is known to influence smooth muscle cells and endothelial cells in 
vasculature and can regulate vascular cell growth and migration, at least in humans [244-
246]. Thus, the gender of the animal from which microvessels are isolated may also 
affect their growth and networking in vitro. Other relevant causes for microvessel 
isolation variability may include human variability in the mincing and digesting of the 
microvessels. However, these aspects of the isolation process could be standardized 
through the use of machines, thereby minimizing the variability in human actions. 
 In this dissertation, the microvascular constructs were grown for the same amount 
of time in vitro prior to implantation into the animal. However, if different batches of 
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microvessels grow at different rates, this may not be the ideal way of standardizing the 
implanted constructs. For example, it was necessary to reduce the microvascular growth 
time in vitro when completing experiments involving both microvessel-only constructs 
and microvessel + myoblasts constructs because the addition of myoblasts sped up the 
growth and subsequent contraction of the constructs. A superior method of standardizing 
the vascular networks implanted in vivo would be to quantify the vascular networks in 
vitro and to implant constructs with similar connectivity and growth. However, this 
method would be impractical and was not explored within the purview of this 
dissertation.  
 Within the composite injury model, rhBMP-2 was delivered in the bone defect to 
aid in bone regeneration. However, this may have adverse effects on the microvessels 
and/or myoblasts that are delivered nearby, as BMP-2 may cause myoblasts to 
differentiate down the osteoblastic lineage or prevent myotube formation [237, 238]. 
Additionally, microvessels themselves could influence the mechanism by which rhBMP-
2 is inducing bone regeneration in vivo. Further research into the interplay between 
rhBMP-2 and microvessels could help explain the differences in healing responses seen 
when implanting the microvessels around the bone defect or in the muscle defect.  
 Because microvascular constructs provide a vascular therapy and thus necessitates 
analysis of the revascularization of the defect, the analysis method and timing greatly 
influences the chances of identifying the effects of the vascular therapy on 
vascularization. While micro-CT angiography is advantageous in that it allows for a 
method of quantifying and imaging vasculature, it has various limitations. The resolution 
for the micro-CT angiography method is determined by the resolution of the micro-CT 
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scan, which is linked to the sample size. We scanned whole rat legs in these studies, 
necessitating the use of a 37µm voxel size. However, if the tissue could be dissected into 
smaller parts and scanned, a higher resolution could be achieved. The resolution of the 
vasculature also depends on the contrast agent's ability to pervade into the vasculature. 
We used microfil contrast agent, which has a certain viscosity that may prevent its ability 
to flow into capillaries and small arterioles. It would be possible to perfuse the 
vasculature with barium sulfate, which may allow for a higher resolution of vasculature 
to be scanned [247]. In micro-CT angiography, the microfil contrast agent is perfused by 
forcing the contrast agent through the vasculature by pressure, which may result in 
artifacts in the scan if the pressure caused the microfil to escape leaky vessels in the 
healing defect. Additionally, because the contrast agent is delivered post-mortem through 
pressure perfusion, blood flow is not taken into account. A possible way to analyze actual 
perfusion within the body may be to inject fluorescent microspheres into a live animal 
and examine the locations of the microspheres via histology [248]. 
 While the translation of microvascular treatment for healing of defects may have 
potential, large barriers exist that need to be surpassed to allow for the possibility of using 
microvessels in the clinic. Human microvessels have not yet been successfully grown in 
vitro, and their ability to form networks or inosculate in vivo have not yet been evaluated. 
Microvascular treatment clinically would most likely be autologous; however, it is 
unknown whether microvessels isolated from an ailing trauma patient with possible 
systemic pro-inflammatory responses to the trauma may have the same therapeutic 
potential as microvessels isolated from a healthy person. Additionally, the issues in 
variability of microvessels faced in preclinical testing, such as differing optimizations of 
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protocols for isolating microvessels, will also apply to isolating microvessels for clinical 
use. Clearly, much more research and work  must be done before microvascular treatment 
can even be considered for clinical use. 
8.5   Final Conclusions 
 In conclusion, three models of extremity trauma (VML in quadriceps, VML in 
biceps femoris, and composite injury with segmental bone defect and VML) were 
developed and characterized. The models allow for quantitative measurements of 
functional outcomes in the affected tissues, making them excellent platforms for the 
screening of different therapeutics for functional recovery. From the characterization of 
these models, vascularization was found to play a role in the regeneration of the different 
tissues. Vascular therapy, in the form of microvascular constructs, was tested in the VML 
in biceps femoris and composite defect models and was found to have the ability to 
facilitate revascularization, though the regenerative potential was variable. Microvascular 
construct treatment of the quadriceps VML in the composite defect did influence bone 
regeneration, supporting the overall hypothesis that the treatment of muscle with 
engineered matrix constructs with stem cells could promote bone healing. 
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APPENDIX 
A.1. Microvessel Isolation Protocol 
A.1.1. Solutions (keep all solutions on ice or in fridge) 
1x PBS (Ca and Mg free, Sigma Aldrich) 
4x DMEM (GIBCO, with HEPES and NaHCO3) 
1x DMEM (low glucose, with pyruvate) 
BSA (Sigma Aldrich) 
FBS (10% in 1x DMEM, used as culture media) 
Petri dish (non-TC treated) 
0.1% BSA PBS (cation free) – sterile filtered 
1N NaOH – syringe filtered in 50mL conical 
1N HCl – syringe filtered in 50mL conical 
Collagenase Type I (Clostridial collagenase, Worthington Biochemicals) 
A.1.2. Preparation of Collagenase 
 Test lots of collagenase with empirical microvascular yield and quality 
assessment of in-vitro culture testing. Buy in bulk the selected lot (4-5grams). 
 Total volume of digestion solution is about 1.5 times the fat volume in mL. 
 Measure out lyophilized collagenase: 2 times the fat volume in mg. 
 Measure out DNAse: 1.5 times the fat volume in mg. 
 Add 1.5 times the fat volume (in mL) of 0.1% BSA-PBS to the collagenase and 
DNAse. 
 Mix and sterile filter. Prepare right before use. Add to fat at room temperature. 
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A.1.3. Fat Isolation 
 Materials needed: 
o Large gauze (3 per animal) – sterile 
o Straight hemostats – sterile 
o Large scissors – sterile 
o Small scissors – sterile 
o Forceps – sterile 
o 20mL 0.1% BSA/PBS in 50mL conical (per 2 rats) – sterile 
o Male rats – retired breeders (as heavy/old as possible) 
 After anesthetizing the animal with isoflurane, lay the animal down in the supine 
position. Put pressure on the middle of abdomen area with 2 fingers and swipe 
down to move testes. Wipe animal well with alcohol gauze in the pelvic area. 
 Grip the animal with hemostats on the skin directly at the base of the penis. 
 Cut the skin below the hemostat to expose the testes. Make 2 cuts from the first 
cut towards each hip. This should expose the testes. 
 Carefully place sterile gauze distal to the cuts. Touch only corners/edges of the 
gauze, fold the gauze in half, and place the gauze over the skin next to the 
incision. 
 Using the forceps to grip the outer muscle layer of the testes and make a cut with 
the smaller scissors to expose the testicles. Gently draw out the epididymal fat and 
vessels (laying it over the sterile gauze to preserve sterility), and harvest the fat 
only without severing the large testicular vessels or the epididymal head/tail. 
Place the fat into the BSA/PBS. 
 Expose the animal’s thorax and induce a hemo-pneumothorax to euthanize the 
animal. 
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A.1.4. Microvessel Isolation from Fat 
 From the BSA-PBS conical tube containing the fat, estimate fat volume and 
calculate the appropriate collagenase, DNAse, and BSA-PBS amounts for the 
digestion solution. Prepare this prior to mincing the fat. Sterile-filter solution 
before use. 
 Manually mince the fat pads for about 6 minutes to get a homogenous mix that 
can be drawn up into a 10mL pipette. 
 Add the digestion solution to the minced adipose tissue and manually stir with the 
pipette tip to create a homogenous mix. Transfer to a small Erlenmeyer flask (50-
125mL) with a small Teflon stir bar.  Digest in a 37°C water bath with agitation 
(6 minutes, manually shaking the flask to create turbulence). 
 Stop the digestion by adding serum containing cold media to the digestion 
solution (at least 1:1 volume). 
 Transfer the digestion solution into 50mL conical tubes and spin in a clinical 
centrifuge at 4000 rpm for 5 minutes. 
 Aspirate the supernatant and wash the pellet in further BSA-PBS. Break the pellet 
and re-suspend it in the new wash buffer. Transfer the solution to 15mL tubes. 
Spin at 3000rpm for 4 minutes. 
 Repeat the previous wash step again and spin down at 3000rpm for 3 minutes. 
 Aspirate supernatant and resuspend pellet in BSA-PBS. Filter through a 500μm 
nylon membrane. Wash the membrane with 5mL BSA-PBS. Discard the 
membrane and retain the flow-through. 
  Filter the flow-through through a 20μm filter, and collect the microvessel 
fragments retained on this mesh. Wash the mesh with 40-50mL of BSA-PBS and 
collect the solution (10mL at a time in a petri dish). Count a representative 
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volume (3 drops of 20μL) from a well-mixed suspension (use wide-bore 200μL 
tips). 
 Pellet the microvessel fragments (3000rpm for 4 minutes), re-suspend the pellet in 
about 50μL of BSA-PBS using a wide-bore pipette tip. 
A.1.5. Suspending Microvessels in a Collagen Gel 
 KEEP ALL SOLUTIONS ON ICE --- collagen solution at this concentration will 
gel and polymerize at room temperature. 
 The final concentration of collagen should be 3mg/mL in 1x DMEM. 
 Make about 1-2mL more collagen than needed due to losses in preparation. 
 Use about 8-12 mg/mL stock collagen I (Fisher Scientific, high-concentration 
collagen) and 4x DMEM. Dilute to the right concentration with deionized sterile 
water. 
 Fragment density is 20,000 fragments per mL of collagen solution. 
 Check pH by color before adding fragments. Purple is too basic, orange/yellow is 
too acidic. Add 1N NaOH or 1N HCl to adjust the pH. 
 Mix collagen, 4x DMEM, and sterile water to make the collagen solution --- keep 
on ice! Use frozen pipette tips if possible. 
 Mix the microvessels in ~50μL BSA-PBS well before adding the appropriate 
collagen solution amount to the tube containing the microvessels. Mix this 
solution a few times with a frozen pipette tip. 
 Transfer the collagen/microvessel solution to the culture chamber and place in 
incubator. Allow for 30-45minutes for polymerization. 
 Add media to the culture chamber after polymerization. Change media on day 3 
and every other day thereafter. 
 Angiogenic sprouts should be visible by day 3, and a microvessel network should 
be visible by day 7. 
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A.2. Myoblast Isolation Protocol 
A.2.1. Solutions for Myoblast Isolation & Culture 
 Primary myoblast growth medium: F10, 20% FBS, 1% pen/strep, bFGF 
 bFGF (Promega G-5071, 25μg powder) – dissolve in 1mL sterile 1% BSA-PBS. 
Aliquot into 50μL and store at -20°C. Use at 2μL bFGF per 10mL growth media. 
Don’t freeze thaw. 
 Differentiation medium: DMEM, 2% horse serum, 1% pen/strep. 
 0.2% Collagenase XI (Sigma C9407) – prepare lyophilized powder (100mg) in 
50mL PBS, aliquot in 5mL, store at -20°C. Don’t freeze-thaw. Use at this 
concentration. 
 Dispase II (Stem Cell Technologies, 5U/mL, 100mL solution) – Dilute 1:2 to get 
2.5U/mL. Aliquot 5-10mL and store at -20°C. Don’t freeze-thaw. 
 Collagen – Make to final concentration of .08mg/mL (dilute in .1N acetic acid). 
USE ONLY COLLAGEN-COATED FLASKS FOR MYOBLAST 
EXPANSION. To collagen-coat, add excess collagen solution into flask, incubate 
at 37°C overnight, and remove excess collagen. Can re-use this solution. Allow 
flask to dry in incubator, and rinse with PBS before use. 
A.2.2. Isolation of Soleus Muscle 
 Soleus muscle has the highest density of satellite cells, though any other muscles 
can be isolated for the isolation of myoblasts. 
 Remove skin from lower half of the leg. 
 Separate the hamstrings on the posterior side. 
 Remove hamstrings muscles to reveal the gastrocnemius. 
 Insert the tips of a small pair of forceps at the ankle under the gastrocnemius. 
Blunt dissect and cut. 
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 Lift the gastrocnemius muscle, and the soleus muscle is underneath (large white 
tendon). 
 Weigh the soleus muscles in a sterile container prior to transferring to a petri dish 
containing sterile PBS. 
A.2.3. Mechanical and Enzymatic Dissociation of the Muscle 
 Wash the tissue by transferring (with a sterile forceps) into a 100mm dish 
containing sterile PBS. Repeat this 2x. 
 Remove the connective/fat tissue from the muscle with sterile instruments and re-
weigh. 
 Add 0.2% collagenase XI (Sigma C9407, 100mg in 50mL PBS, aliquot and store 
at -20°C) --- use 5mL per 2 rat soleus muscles. 
 Mince the tissue using two sterile razor blades for 5 minutes (sterilize razor blades 
by wiping with alcohol pads). 
 Use a wide bore pipette tip (break of end of 5mL pipette) to transfer the contents 
into a 15mL sterile conical tube. 
 Rinse the dish with an additional 5mL of 0.2% collagenase and transfer into 
conical tube (final enzyme solution volume = 10mL per 2 muscles). 
 Place tube into a 37°C water bath and incubate for 2x30minutes. Triturate every 
30 minutes by pipetting up and down (wide-bore pipette if necessary). 
 Spin down cells (1400g for 4 minutes; 2800rpm for 15mL conical in the Guldberg 
cell culture room centrifuge) and aspirate off the collagenase. 
 Add 3mL/animal of dispase II (Stem Cell Technologies, 5U/mL diluted 1:2 to get 
2.5U/mL) and incubate at 37°C for 45 minutes. Triturate mixture after the 45 
minute incubation. 
 Spin down cells at 1400g for 4 minutes and aspirate off the dispase. 
 Resuspend cells in 10mL prewarmed growth media. 
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 Pass resuspended cells through a vacuum 100μm strainer (Steriflip, Millipore). 
 Spin down cells for 4 minutes at 1400g. 
 Remove supernatant and resuspend in growth media with bFGF. 
 Pass the resuspended extract through a 23G needle with a 10mL syringe (pull in 
extract and dispense extract). Dispense directly into appropriate dish for plating. 
 You can also preplate the cells --- transfer cells onto uncoated dish, incubate at 
37°C for 30 minutes, then transfer supernatant to a collagen coated dish. 
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